Oligodendrocyte Population Dynamics and Plasticity Probed by Genetic Manipulation in Mice by Iannarelli, P
  
 
 
Oligodendrocyte Population Dynamics and 
Plasticity Probed by Genetic Manipulation in Mice 
 
 
By 
 
Palma Iannarelli 
 
 
The Wolfson Institute for Biomedical Research, 
University College London 
 
 
A thesis submitted to the University College London in part fulfilment of the 
degree of Doctor of Philosophy 
 
 
January 2014 
 
 
 
! 2!
 
Declaration 
 
I, Palma Iannarelli, confirm that the work presented in this thesis is my own. 
Where information has been derived from other sources, I confirm that this has 
been indicated in the Thesis. 
 
 
 
Signed. 
!
!
!
!
!
!
!
!
!
!
!
!
! 3!
!
Abstract 
During embryonic development, oliogdendrocyte precursor cells (OLPs) originate 
in the ventral region of the neural tube, and from this area proliferate and migrate 
throughout the entire CNS. Work from several labs has shown dorsal regions of 
the neural tube can also be an additional source of OLPs. Ventrally and dorsally-
derived OLPs are thought to be specified differently, since morphogenic signals 
that are known to specify ventral OLPs are absent in the dorsal regions of the 
CNS. However, the question remains whether oligodendrocyte (OLs) with 
different developmental origins are functionally equivalent or not. If there are 
different specialized subtypes of OLPs and OLs, this might need to be taken into 
consideration when designing therapies for demyelinating diseases based on 
transplantation of pure OLPs from various sources. 
To address the question, I specifically ablated particular OL lineage cells with 
different developmental origins using a Cre/loxP system and Diphtheria toxin A 
chain (DTA). A transgenic mouse line was generated that carried DTA under the 
transcriptional control of Sox10, which is expressed in all OLPs regardless of 
their developmental origin. Upstream of the DTA open reading frame were 
sequences encoding the enhanced green fluorescent protein (EGFP) allowing 
expression of the toxin only after the floxed EGFP was excised. In order to 
selectively eliminate OLPs from ventral or dorsal origin, the Sox10-DTA mouse 
line was crossed with a line that expresses Cre recombinase selectively in dorsal 
or ventral regions of the developing telencephalon.  
I found that when either dorsal or ventral-derived OLPs were ablated with DTA, 
neighbouring OLP populations moved in to replace the missing cells. When 
ventrally-derived OLPs were ablated there was a slight delay in the accumulation 
of OLPs and in the onset of myelination. Even when all telencephalic-derived 
OLPs, both ventral and dorsal, were ablated, populations from more posterior 
brain regions made up for the loss. This work strongly suggests that OLPs, in the 
developing telencephalon, from dorsal and ventral origins are functionally 
equivalent. 
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Chapter 1 
 
 
Introduction 
 
 
1.1 Embryonic Development of the Central Nervous System 
 
“What is perhaps the most intriguing question of all is whether the brain is 
powerful enough to solve the problem of its own creation.” Gregor Eichele (1992) 
 
One of developmental neurobiology’s deepest enigmas is how the nervous system 
forms from a few all–purpose cells into a complex organ. For over a century, it 
has seemed a completely hopeless quest to understand how the entire nervous 
system is constructed and operated. However, recent rapid advances in molecular 
biology, genetics, cell biology and biochemistry have led a spectacular increase in 
the understanding of this fascinating phenomenon. The fruit fly, Drosophila 
melanogaster, has been at the heart of many studies contributing to our 
understanding of the nervous system (NS). Even though flies bear little 
resemblance to humans, they do share many of the cellular and molecular 
mechanisms of their development and behaviour with vertebrates including 
mammals. Therefore, fundamental insights learned from the fruit fly have helped 
direct research in more complex organisms, including mice and humans. The 
central nervous system (CNS) is one of the most important organs of an animal – 
it serves as a body command centre. It controls basic life functions such as 
breathing and digestion; it spreads messages throughout the body including the 
internal organs and skin. It is responsible for thought, intellect, memory, 
movement and sensation. Its formation is one of the most fascinating and 
complicated processes in biology; one of the earliest systems to begin its 
formation and the last to be completed. 
 
1.1.1 Initial development of the neural tube 
 
Many rounds of cell division turn a single fertilized egg into a hollow ball of cells, 
called the blastula. In the mouse, this is reached at about 72 hours after 
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fertilization. Formation of the multilayered body plan, known as gastrulation, 
begins at embryonic day 6.5 (E6.5) when cells of the blastula redistribute 
themselves into three distinct “germ layers”:  outer ectoderm, inner endoderm and 
interstitial mesoderm. These germ layers eventually give rise to all tissues of the 
body. In mammals, gastrulation is marked by the formation of the primitive streak 
– a thickening of cells at the posterior end of the embryo. These cells move out to 
form a rod-like structure that extends from the tail toward the centre of the 
embryo where it ends in a spot called the primitive node (the anterior tip of the 
streak). Epiblast cells, which are ectoderm–derived cells, migrate through the 
streak and spread downward and laterally to form the mesoderm and endoderm. In 
vertebrates, the ectoderm forms the epidermis and nervous system. 
 
The development of the NS begins when the dorsal mesoderm of the gastrula 
induces, via chemical signals, the overlying ectoderm to become the neural plate – 
a sheet of elongated epithelial cells. The region of ectoderm that receives these 
signals will become the NS and the rest of the ectoderm will become epidermis. 
Next, the lateral edges of the neural plate begins to thicken and move upward, 
forming the neural folds, which eventually fuse at the dorsal midline to complete 
the conversion of the sheet to a tube. This newly formed tube will serve as the 
source of the entire CNS. The region of the embryo that lies between the newly 
formed neural tube and the surface ectoderm is composed of the neural crest stem 
cells (NCSC) which will give rise to the peripheral nervous system (PNS) and 
other descendents (e.g., pigment cells, facial skeleton). The process by which a 
neural tube is formed is called neurulation (Figure 1.1). This exquisitely 
coordinated multi-step process has distinct signalling factor requirements at each 
step to change shape and movement of cells.  
 
After neural tube closure, the anterior end or cephalic portion (prospective head 
region) undergoes a series of swellings, constrictions, and flexures to form three 
distinct, but connected rounded cavities called primary brain vesicles: (1) the 
prosencephalon; (2) the mesencephalon; and (3) the rhombencephalon. During 
subsequent development, the first and third vesicles divide once more forming a 
total of five secondary vesicles: (1) telencephalon; (2) diencephalon; (3) 
mesencephalon; (4) metencephalon; and (5) myelencephalon. The telencephalon 
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and diencephalon make up the forebrain. The mesencephalon becomes the 
midbrain; and the metencephalon and myelcephalon make up the hindbrain 
(Figure 1.2). The generation of secondary vesicles is controlled by an anterior-
posterior patterning system. The complete set of molecular players is still not fully 
known.  
 
 
 
 
 
 
 
Figure 1.1 Formation of the vertebrate neural tube. Transverse sections through 
the center of the embryo. (A) Shaping of the neural plate. (B) Invagination of the 
neural plate to form the neural groove. (C) Closure of the neural groove to form 
the neural tube. The neural tube runs along the anterior-posterior axis of the 
embryo and will generate the future brain and spinal cord.  Figure taken from Gos 
et al., (2002). 
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Figure 1.2 Divisions of the vertebrate CNS. This figure shows the anatomic 
landmarks in an embryonic CNS. The CNS is divided into two main parts: brain 
and spinal cord. The brain itself is subdivided into three main parts: forebrain, 
midbrain and hindbrain. Forebrain (green) is further subdivided into the 
telencephalon (tel) and diencephalon (di). The midbrain region (yellow) is not 
divided; however, the hindbrain (red) is subdivided into the metencephalon (1) 
and myelencephalon (2-7). 1-7 represent rhombomeric segmentation. The retina, 
not shown in this figure, is also part of the CNS. The retina originates as 
outgrowths of the developing brain but keeps its connections with the brain 
through the optic nerve. Taken from Chizhikov and Millen (2005). 
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Early in development, the walls of the neural tube consist of rapidly proliferating, 
morphologically homogeneous cells, called neuroepithelial (NE) cells. These cells 
are multipotential; i.e., they have the ability to generate all the cell types found in 
the CNS (that is neurons, astrocytes and oligodendrocytes) depending on the 
signals they receive. NE cells in the embryonic spinal cord, for example, are 
instructed to differentiate towards specific lineages through the action main 
opposing gradients of two major morphogenic signals, Sonic hedgehog (Shh) and 
bone morphogenetic protein (BMP). These morphogens induce expression of 
different transcription factors in a concentration-dependent way: the transcription 
factors are then responsible for the longitudinal organization of the neural tube. 
Particular combinations of transcription factors are necessary for the specification 
of any region along the dorsal-ventral (D-V) or anterior-posterior (A-P) axes of 
the neural tube.  
 
1.2 Neuroglial cells in the CNS 
 
In the central nervous system, it is usually neurons that get all the attention. Glial 
cells traditionally have been regarded as being the boring, passive, supporting 
players for neurons. Even Rudolf Virchow, the German pathologist who first 
described glial cells in 1846, gave a low-opinionated view of these cells. He 
described these cells as ‘the substance which lies between the proper nervous 
parts, holds them together and gives the whole its form’. He called them 
“neuroglia”; a name that literally means “nerve glue” in Latin. Research over the 
last couple of decades has shown that glia play more dynamic roles than 
previously thought and are vital to the health of the CNS. Evidence is now starting 
to accumulate that neurons and glia depend on each other for survival and that the 
functional architecture of the brain and spinal cord depend on this intimate 
neuron-glia relationship. 
 
There are two major glial cell types in the CNS: macroglia and microglia. 
Microglia are considered the immune cells of the CNS. They are thought to arise 
from mesodermal tissue. In contrast to microglia, macroglia are derived from the 
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NE cells of the neural tube. Macroglia are the most abundant glial cells in the 
CNS; they consist of two cell types: astrocytes and oligodendrocytes (OLs).  
 
Astrocytes, the most numerous glial cells, are star-shaped as their name implies. 
Astrocytes are multifunctional cells that are actively involved in a number of 
processes in the CNS. They have long processes that extend to the surfaces of 
blood vessels to control the flow of nutrients, including oxygen, to neurons. 
During embryonic development, they act as guides for developing neurons to 
reach their target cells. They regulate extracellular ion homeostasis and recycle 
excitatory neurotransmitters such as glutamate. They can also become phagocytic 
following CNS injury. Microglia, the smallest of glial cells, are the first immune 
responders in the CNS to any kind of damage or injury.  They protect the CNS 
from invading pathogens. Under pathological conditions, such as stroke, 
neurodegenerative disease, tumour invasion, chemical or physical trauma, these 
cells become activated and move rapidly toward the site of injury and act as 
scavengers to remove damaged and dead cells and other debris from the area. 
Oligodendrocytes are the cells responsible for producing a fatty protein called 
myelin. Myelin provides insulation and facilitates saltatory (jumping) conduction 
of action potentials. Each OL can supply myelin for several axons and each axon 
can be supplied by several OLs. Oligodendrocytes have been reported to be 
involved in synaptogenesis, indicating that these cells are more versatile than 
previously thought (Bergles et a, 2000). This has led scientists to re-evaluate their 
role in the adult CNS. 
 
1.2.1 Oligodendrocyte development 
 
Markers for oligodendrogenesis studies 
Oligodendrocytes are the cells responsible for synthesizing and maintaining the 
protein-rich lipid membranes called myelin, which ensheaths axons in the CNS.  
The main function of myelin is to allow the efficient conduction of action 
potentials along the axon; and to prevent electrical cross-talk between axons. 
Impulses are severely slowed or stopped altogether in demyelinated axons. 
Another important role of myelin is to provide physical support for axons and 
perhaps provide neuroprotection.  
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The progression of an oligodendrocyte precursor cell (OLP) to a mature OL and 
its morphological and some of its biochemical diversity is illustrated in Figure 1.3. 
The availability of molecular markers for the various stages of OL development 
has made it possible to identify and locate these cells by light microscopy.  
 
Oligodendrocyte precursor cells go through three main stages in the process of 
maturing and producing myelin: 1) in mice the oligodendrocyte progenitor stage 
is characterized by the expression of Olig1 and Olig2, Sox10, PDGFRα, and NG2; 
2) the immature OL stage is denoted by expression of O4 and GalC; 3) the 
terminally mature OL stage is identified by the expression of integral myelin 
proteins such as myelin basic protein (MBP) and proteolipid protein (PLP). Each 
main stage of lineage development displays not only a unique molecular profile 
but also a different morphology. OLPs take on a bipolar morphology while the 
immature OLs have a complex multipolar morphology and mature OLs have 
multiple primary, secondary and tertiary branches extending toward axons and 
forming myelin sheaths. 
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Figure 1.3 This diagram illustrates the main stages in OL development and some 
of the lineage markers that are expressed at various stages of lineage progression. 
The OL lineage arise from multipotent NE cells in the ventricular zone (VZ).   
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1.2.2 Factors that control oligodendrocyte development 
 
Olig1 and Olig2 
Transcription factors are usually useful early markers of lineage determination. 
Expression of the basic helix-loop-helix (bHLH) transcription factors Olig1 and 
Olig2 precedes all other markers known so far in the OL lineage, such as Sox10, 
PDGFRα, and O4 (Lu et al., 2000). Both Olig1 and Olig2 are expressed 
throughout development into adulthood. Both Olig genes are also expressed in 
early progenitors in the pMN domain of the spinal cord, which sequentially 
generates motor neurons followed by oligodendrocytes (Lu et al., 2000; Zhou et 
al., 2000). The combined expression of Olig2 and Neurogenin-1 and -2 (Ngn1, 
Ngn2) are thought to generate motor neurons. Once the specification of motor 
neurons is complete, the expression of Neurogenins is down-regulated, which 
coincides with the generation of OLPs (Sun et al, 2001). Sun et al. found that 
Ngn1 can inhibit the expression of glial-specific genes by regulating the 
availability of the transcriptional coactivator CBP/p300 for gliogenesis. The story 
of the switch from motor neuron production to the generation of OLPs is not that 
simple, however. For example, mice lacking both Ngn1 and Ngn2 do not have 
premature, or an increased rate of, oligodendrocyte production (Rowitch, 2004). 
 
Olig2 is required for both motor neuron and oligodendrocyte specification in the 
spinal cord (Lu et al., 2002; Takebayashi et al., 2002; Zhou and Anderson, 2002). 
Mice lacking Olig2 or both Olig genes lack motor neurons and oligodendrocytes, 
therefore, die at birth through asphixiation. Mice lacking only the Olig1 gene are 
born healthy but have a slight delay in OL maturation (Lu et al., 2002). However, 
normal amounts of OLs and myelin are generated by P30. This indicates that the 
function of Olig1 is redundant during development. However, Arnett et al. have 
demonstrated that Olig1 function is required during myelin repair (Arnett et al., 
2004). Olig1 protein, in mice, is found predominantly in the nucleus of OLs and 
OLPs during development; however, two weeks after birth and throughout 
adulthood, this protein is almost found completely in the cytoplasm.  Moreover, 
Arnett et el. (2004) showed that during remyelination Olig1 protein shifts from 
the cytoplasm to the nucleus in OLPs. They have shown in mice that nuclear 
Olig1 was present in active demyelinated lesions induced by cuprizone, ethiduim 
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bromide, or lysolecithin. Nuclear Olig1 was also present at the edges of human 
multiple sclerosis (MS) lesions. They also showed remyelination is extremely 
inefficient in Olig1-null mutants compared to wild-type mice. Thus, Olig1 may 
have a role in OL differentiation in adult mice and, therefore, remyelination in 
white matter injury. 
 
SoxE proteins 
Sox proteins are transcriptional regulators with a sequence-specific DNA-binding 
domain typical of the high mobility group (HMG) superfamily. They function by 
pairing up with other transcription factors to perform vital functions during 
development (Wegner, 1999). Sox proteins are subdivided into groups based on 
the HMG box amino acid sequence. To date, the Sox10 gene family is divided 
into eight subgroups, A-H (Wegner and Stolt, 2005). Oligodendrocytes express 
various Sox proteins during development, such as Sox4-6, Sox8-11, and Sox17 
(Kuhlbrodt et al., 1998; Stolt et al., 2002; Stolt et al., 2003; Stolt et al., 2004; Stolt 
et al., 2006; Sohn et al., 2006; Potzner et al., 2007). Group E Sox proteins (Sox8-
10) are particularly important in OL development (Stolt et al., 2003; Stolt et al., 
2004; Wegner and Stolt, 2005).  
 
Sox10 expression starts about one day after Olig1 and Olig2 expression and about 
a day earlier than PDGFRα in the OL lineage of the spinal cord. Its expression is 
maintained throughout the life of an OL. Zhou et al. have shown that ectopic 
expression of Olig2 can induce the expression of Sox10 in vivo (Zhou et al., 
2000). This suggests that Sox10 may be a direct target or may just simply function 
downstream of Olig2 in the CNS. Mice that lack both copies of the Sox10 gene 
have a normal number and distribution of OLPs but lack terminally differentiated 
OLs, therefore fail to express myelin proteins. Experiments by Stolt et al. (2002) 
suggested that Sox10 is capable of directly influencing the transcription of myelin 
genes (e.g. MBP) by binding directly to multiple sites within the MBP promoter. 
Very recently, studies done in the Richardson laboratory have shown that Sox10 
can physically interact with both Olig1 and Olig2 in mice (only Olig1 in fish), and 
that the Olig1/Sox10 complex can activate MBP transcription in vivo (Li et al., 
2007). 
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Similar to Sox10, Sox8 expression begins very early in OL development and is 
maintained during and after differentiation (Stolt et al., 2004). Like Sox10, Sox8 
protein is capable of binding to myelin genes such as MBP and PLP.  Stolt et al. 
addressed the role of Sox8 in OL development by creating a Sox8-deficient mouse 
line. Unlike Sox10-deficient mice, these mutant mice have a normal lifespan and 
did not exhibit any overt phenotype. The number and distribution of OLPs in the 
spinal cord was comparable with the wild-type littermates. The only difference 
detected was a slight transient delay of terminal differentiation lasting 
approximately one week. Thus, terminal differentiation is influenced by Sox8 but 
not entirely dependent on it, unlike Sox10 which is absolutely required for 
terminal differentiation. This might indicate that Sox8 is a weaker transcriptional 
activator than Sox10, since Sox8 is capable of binding to the same myelin gene 
promoters (Stolt et al., 2004).  
 
OL specification in the spinal cord is strongly influenced by Sox9. Like Sox8, 
Sox9 expression is detected in the spinal cord prior to the onset of gliogenesis. 
When OLPs first appear in the pMN domain of the ventral spinal cord they 
express all three of the SoxE proteins. However, unlike Sox8 and Sox10, Sox9 
expression is down-regulated at the onset of terminal differentiation (Stolt et al., 
2003). Stolt et al. addressed the role of Sox9 in OL development by generating a 
Sox9 mutant mouse. Their study found that when Sox9 was removed in a tissue-
specific manner and at the time of specification, there was a large reduction in the 
number of OLPs generated early on; however, OLP numbers recovered by the end 
of embryogenesis (Stolt et al., 2003). 
 
Recent work from the Wegner laboratory has shown that Sox9 and Sox10 have an 
effect on the survival and migration of OLPs in the spinal cord (Finzsch et al., 
2008). They uncovered these novel functions of SoxE proteins by generating mice 
that were deficient in both Sox9 and Sox10. Sox9 and Sox10 were detected in a 
tissue-specific manner after OLP specification (under the action of Sox10-Cre). 
Finzsch et al. showed that normal numbers of OLPs were generated; however, 
these OLPs migrated in an abnormal pattern and approximately half of these cells 
died via apoptosis by E15.5. Moreover, the remaining OLPs that did survive did 
not express PDGFRα. These remaining OLPs did, however, express other 
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oligodendroglial markers such as Olig2, NG2, and O4. They also showed by 
chromatin immunoprecipitation that Sox9 can bind to a 5’ flanking region of the 
PDGFRα gene. These results suggest that Sox9 may directly activate PDGFRα. 
However this cannot be the whole story because recent work in the Richardson 
lab has mapped OLP-specific regulatory elements of the PDGFRα gene to the 
3’side of the gene (Flores-Garcia, unpublished). 
 
Platelet Derived Growth Factor Receptor Alpha (PDGFRα) 
Growth factors are freely diffusible proteins that regulate the functions of cells, 
such as proliferation, migration, and differentiation, by binding to receptors found 
on the surface of target cells. The PDGF family consists of four ligands: PDGF-A, 
-B, -C, and –D, which signals through two PDGF receptors (PDGFRα and β). 
PDGFRα can be activated by either PDGF-A, –B, or –C ligand, whereas PDGFRβ 
can be activated by the PDGF-B or –D ligand (LaRochelle et al., 2001; Li et al., 
2000; Bergsten et al., 2001). Platelet Derived Growth Factor A and one of its 
receptors, PDGFRα, play an important role in proliferation of OLs. Immature 
OLPs express PDGFRα and respond to PDGF-A ligand secreted by neuronal cell 
bodies (Fruttiger et al., 2000). When OLPs begin to differentiate they lose their 
PDGFRα and acquire other OL makers such as O4 (Hall et al., 1996; Butt et al., 
1997). The Richardson laboratory and other groups have shown that PDGF-A is 
mitogenic for predifferentiated OLPs in vitro and in vivo (Noble et al., 1988; Raff 
et al., 1998; Richardson et al., 1988; Calver et al., 1998). When PDGFRα-positive 
OLPs are cultured in vitro with PDGF-A, they divide and continue to divide 
without differentiating. However, when PDGF-A is removed from the medium, 
OLPs stop dividing and differentiate into OLs. Mice lacking PDGF-A have a 
major reduction in the number of OLPs and OLs, suffer from tremors, and die 
within the first few weeks of life (Fruttiger et al., 1999). OLP cells are specified in 
these mutant mice, but do not proliferate as normal. In contrast, mice 
overexpressing PDGF-A exhibit an increase in OLP numbers (Calver et al., 1998). 
However, these extra, ectopic cells are eliminated via apoptosis so that the final 
number of OLs is normal. This demonstrates that PDGF-A acts as a potent 
mitogen for OLP cells and is usually rate-limiting for OLP proliferation, but that 
OLs depend on other factors for survival. Data from OLP cell cultures, PDGF-A 
overexpressing and PDGFRα-null mice have also shown that the proliferative 
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effect of PDGF-A on OLPs is dose dependent (van Heyningen et al., 2001). 
Basically, as long as PDGF-A ligand is present, OLPs will continue to divide until 
all the ligand is used up, at which point OLP division slows down and stops, 
allowing OL differentiation to follow.  
 
1.2.3 Developmental origin of oligodendroctyes 
 
The developmental origin of OLs had been debated for over a decade. It is now 23 
years since the first published study reported the developmental origins of these 
cells (Warf et al., 1991).   Prior to this study, it was generally believed that 
oligodendrocytes were derived mainly from radial glial cells or derived from the 
ventricular layer along the entire length of the neural tube (Choi, 1985). Warf et 
al. reported, despite the fact that OLs are distributed throughout the spinal cord, 
OLP are generated exclusively in the ventral part of the spinal cord.  Other studies 
in the 1990s revealed the same thing: OLs arise in the ventral regions of the neural 
tube, from which they spread laterally and dorsally to populate the entire neural 
tube (Noll and Miller, 1993; Pringle and Richardson, 1993; Yu et al., 1994; Timsit 
et al., 1995; Troussee et al., 1995).  However, there were several groups that did 
not support this view (Cameron-Curry and Le Douarin, 1995; Spassky et al., 
1998). For example, Cameron-Curry and Le Douarin used surgically constructed 
quail-chick chimeras to determine the origin of OLs. They first ablated a 
particular region of the neural tube in a chick embryo and then transplanted this 
region with an equivalent region from a stage-matched quail embryo (and vice 
versa). OLs were identified by species-specific labelling. This study revealed that 
OLs are generated from both the dorsal and ventral halves of the neural tube. 
While in another study that was theoretically similar, the opposite result had been 
obtained (Pringle et al., 1998). Pringle et al. revealed that OLs are generated only 
from the ventral neural tube and argued that the dorsal neural tube only generates 
astrocytes. How can two similar studies give opposite results? According to 
Richardson, one likely cause of the researchers’ opposite result is the criteria used 
to define a dorsal graft differed between the two studies (Richardson et al., 2006). 
Cameron-Curry and Le Douarin included dosal ependymal cells – cells that form 
the lining of central canal of the spinal cord - as part of the dorsal neural tube, 
whereas Pringle et al. excluded these cells from the dorsal grafts. It is now thought 
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that the ependymal layer is actually derived from ventral progenitor domains, such 
as p2, pMN, and p3 (Fu et al., 2003; Fogarty et al., 2005). However, this was not 
known at the time of the quail-chick studies and therefore the idea of single versus 
multiple OL origins had been a subject of much debate for many years. In vitro 
assays using primary embryonic spinal cord cells have further suggested that OLs 
can be derived from both the ventral and dorsal regions of the spinal cord (Rao et 
al., 1998; Liu et al., 2003). These in vitro assays contained a group of cells, called 
glial-restricted precursors (GRPs), which have the potential to differentiate into 
OLs and astrocytes but not neurons. These bipotential cells have really never been 
detected in vivo at times when OLs and astrocytes are being generated, but have 
been generated in vitro from different parts of the spinal cord – dorsal and ventral 
regions. Currently, GRPs are thought to arise as an artifact due to in vitro 
conditions or these precursor cells have a greater developmental competence in 
vitro because conditions can be easily made to coax these cells into OLs or 
astrocytes. Recently, publications from three independent research groups 
reported that the dorsal region of the spinal cord does in fact generate OLs (Cai et 
al., 2005; Vallstedt et al., 2005; Fogarty et al., 2005). Two of the research groups, 
Cai et  al. and Vallstedt et al., used mutant mouse models to show that OLs are 
specified in the dorsal spinal cord. Both groups examined Nkx6.1-/- and Nkx6.2-/- 
double-mutant mouse embryos, and Cai et al. also examined the Shh-/- mutant 
mouse line. In both mutant mouse models, ventrally-derived OLs are not 
generated; however, OLPs were generated in the dorsal region of the spinal cord. 
In addition, dorsal spinal cord explants from E11.5 wild-type mouse embryos also 
generate OLPs when grown in culture for a couple of days. This shows that 
dorsally-derived OLs  are not generated because there might be a re-specification 
of the dorsal neural tube or changes in the progenitor domains due to lack of 
Nkx6.1 and Nkx 6.2 or Shh genes, but are actually specified under normal 
conditions. Dorsally-derived OLs might have been missed in earlier studies 
because these OLs are generated later than the ventrally–derived OLs, so by the 
time they appear ventrally-derived OLs are already scattered throughout the spinal 
cord. On the other hand, Fogarty et al. (2005) used a Cre-loxP based in vivo fate 
mapping approach that allows irreversible cell marking to trace the fate of a 
specific dorsal progenitor domain to show that the dorsal spinal cord generates 
OLs. Moreover, they also showed the estimated contribution of dorsally-derived 
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OLs to the OL population of the mature spinal cord and their anatomical location. 
Together these publications have finally put the debate to rest; i.e., that of the 
spinal cord. 
 
The initial restricted localization of OLPs in the ventral region of the neural tube 
is not limited to the spinal cord but is also seen in the forebrain. In the forebrain, 
the earliest OLPs originate from the ventral neuroepithelium. For instance, in 
mice and rats, early OLP specific genes such as, Olig1, Sox10, and PDGFRα first 
appear in the anterior entopeduncular (AEP) area. These cells then migrate 
throughout the forebrain (including the cortex), and mature once they reach their 
final destination; i.e., the white matter tracts. There had been considerable debate 
over whether the forebrain has single or multiple origins. It has been debated for 
many years whether the dorsal forebrain can actually generate OLs. Olivier et al. 
(2001) used quail-chick chimeras to show that all telencephalic OLs are derived 
from the ventral telencephalon, specifically the AEP area. Nakahira et al. (2006) 
used in utero electroporation to insert plasmids containing Cre recombinase into 
the dorsal or ventral forebrain regions of EGFP reporter mouse embryos to show 
that OLPs in the dorsal forebrain originates from the ventral forebrain. In contrast, 
Ivanova et al. (2003) used in situ hybridisation to suggest that OLs are generated 
in two waves (or stages), the ventral telencephalon providing the first wave and a 
second wave occurring in the postnatal cortex. None of these studies, however, 
have directly showed that cortical OLs are generated in the dorsal telencephalon. 
Recent development in transgenic mouse models utilizing the Cre/LoxP system 
has provided a new a way to explore the embryonic origins of OLs and the 
journey these cells take. Kessaris et al. (2006) took advantage of this genetic 
approach that allows specific cells to be permanently labelled so that the 
distribution of these cells and all their progeny can be detected at subsequent 
stages. Their data provide direct evidence that dorsal forebrain neuroepithelial 
cells generate OLs in vivo. Moreover, they have shown that telencephalic OLs 
arise from three successive migratory waves of oligodendrogenesis. The first 
wave is generated in the ventral region of telencephalon (AEP; medial ganglionic 
eminence, MGE), the second wave is generated from more dorsal regions (lateral 
ganglionic eminences, LGE; caudal ganglionic eminences CGE), and the third 
wave begins around birth from the cortex. They also revealed that the first wave 
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of OLPs, that is AEP and MGE-derived OLPs, disappear in the brain after birth. 
The reason for the disappearance of these cells is obscure. 
 
The results from Kessaris et al. (2006) have closed more than a decade long 
period of conflicting opinions. There can no longer be the slightest doubt that 
multiple sites of OLs origins exist, whether in the spinal cord or brain. It becomes 
apparent that the next question is the role of region-specific OL populations in the 
CNS. Do these OL populations have related but more specialized activities? Do 
they have a crucial role or a permanent impact on the normal development of the 
CNS? It should be pointed out that evidence for morphological heterogeneity 
among OLs have been suggested and/or reported since 1928. Wilder Penfield and 
Pio del Rio-Hortega (1928) were the first to describe subtypes of OLs. They 
described the four distinct morphologies of myelinating OLs, types I-IV, that 
myelinate axons with different diameters. OLs myelinating large axons seem to 
differ from those myelinating small axons (Butt et al., 1995; Butt et al., 1998). 
Whether such difference is environmentally induced or origin-derived is unclear. 
Neural and astrocyte heterogeneity exists, perhaps regionally specialized OLs 
exists too. 
 
1.3 Artificial Chromosomes and cloning vectors 
Artificial chromosome-based cloning systems have become essential tools in 
cloning large DNA fragments. There are three types of artificial chromosomes 
commonly  used for this purpose: yeast artificial chromosomes (YACs), bacterial 
artificial chromosomes (BACs) and P-1 derived artificial chromosomes (PACs). 
The YAC was first developed and used in 1987 by David Burke. It is constructed 
using specific regions of yeast chromosomes, including the telomere (to protect 
linear DNA from degradation), the centromere (required for segregation of sister 
chromatids into each new daughter cell), and the replication origin sequences 
(which allows the DNA to be replicated).  Since its development, YACs have 
been used for the construction of physical genetic maps of many species and for 
the generation of transgenic mice.  However, there are some disadvantages with 
YACs, including chimerism and instability (prone to rearrangement), low 
transformation efficiency and low DNA yield. The method used to purify the 
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YAC vector is quite laborious because YAC DNA is structurally similar to the 
normal chromosomes of the yeast in which it is propagated. 
 
In order to overcome a few disadvantages of YACs, PAC and BAC vectors were 
developed. Both PAC and BAC vectors are used to clone large DNA fragments in 
Escherichia coli (E.coli) cells. BACs are derived from an F-factor plasmid and 
PACs are based on the bacteriophage P1 genome and also contain the F-factor in 
E.coli. BAC and PAC vectors are highly stable in the host, which is a major 
advantage over YACs. They can be easily transfected into E.coli by 
electroporation at efficiencies of up to 100 times greater than yeast. In addition, 
their DNA can be easily purified using standard plasmid miniprep protocols and 
can be easily manipulated since the DNA exists in the supercoiled circular form. 
(See Table 1.1 for feature comparison.) BACs and PACs were developed in 1992 
and 1994, respectively. Since then their usefulness has grown tremendously. The 
first BAC transgenic mouse was generated by Yang et al. (1997). The advantage 
of using these large genomic vectors over small plasmid or viral vectors in 
generating mouse lines is that these genomic vectors are large enough to contain 
all the regulatory elements required for authentic tissue/cell specific expression of 
a selected gene without requiring prior knowledge of the locations of the essential 
regulatory elements.  
 
Features YAC BAC/PAC 
Configuration Linear Circular 
Host Yeast Bacteria 
Copy# / Cell 1 1-2 
Cloning Capacity unlimited Up to 350 kb 
Transformation spheroplast Electroporation 
DNA Isolation PFGE Standard plasmid prep 
Insert Stability unstable stable 
 
Table 1.1 Differences between YAC and BAC/PAC cloning vectors. Table taken 
from AGI  Protocols. (PFGE – pulsed field gel electrophoresis) 
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1.4 Mouse models 
Mice have been used for scientific research for decades to elucidate biological 
processes and to determine the cause and progression of human diseases among 
other things. Many of the great advancements and medical breakthroughs of the 
past century would not have been possible without the use of mouse models. Even 
though humans do not closely resemble mice in physical form, we do share a lot 
of similar genes. Mice make good research subjects for a variety of reasons: they 
are genetically close to humans, they have a relatively short generation time, and 
they reproduce large litters. Most importantly, the genetics of mice is highly 
developed (e.g. the complete genome sequence is available) and they can be easily 
manipulated at a genetic level. 
 
There are two widely used methods to modify mice genetically: (1) pronuclear 
microinjection, and (2) embryonic stem (ES) cell method. One of the first 
techniques created to generate a transgenic animal was pronuclear microinjection 
(Gordon et al., 1980). In this method, cloned DNA is directly microinjected into 
the pronucleus of single-cell fertilised oocytes, which are then transferred to a 0.5-
day pseudopregnant recipient mouse. Offspring are screened for the presence of 
the transgene by Southern Blot and PCR analysis. The second method, embryonic 
stem cell, is used extensively to create transgenic mice. In this method, cloned 
DNA is introduced into ES cells by transfection or electroporation. Correctly 
targeted ES cells are then microinjected into 3.5-day old mouse blastocysts and 
reimplanted into 2.5-day pseudopregnant female mouse. Chimeric offspring 
carrying the cloned DNA are generally identified by observing the coat colour 
which is different for donor and host mouse strains. Chimeric mice are then mated 
to determine whether the transgene is transmitted to the germline, and, if so, to 
establish a transgenic line. 
 
Four transgenic mouse lines used in this Thesis were generated by pronuclear 
microinjection of PACs. The main advantages of pronuclear microinjection over 
ES cell method are 1) pronuclear microinjection is much less labour-intensive and 
quicker than the ES cell method, and 2) insertion of the PAC is not targeted and 
therefore does not inactivate the endogenous gene. There are, however, some 
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disadvantages in using pronuclear microinjection technique: 1) the exogenous 
DNA integration site cannot be predetermined therefore it may integrate into a 
critical site and disrupt an endogenous gene, and 2) it is possible that even the 
large PAC DNA fragment will not contain all regulatory elements required for 
authentic cell-type and temporal transcriptional control. Point 1) can be easily 
overcome by having several founders or independent lines.  
 
1.5 Cre/loxP recombinase system 
Cre/loxP system has been increasingly used in developmental biology. Cre 
recombinase, derived from the P1 bacteriophage, belongs to a family of site-
specific recombinases called the integrase family (Sternberg and Hamilton, 1981). 
Cre recombinase efficiently catalyses recombination between specific sites in a 
DNA molecule; these sites are known as loxP. Each loxP site consists of two 13-
base pair palindromic arms separated by an 8-base pair asymmetric spacer region. 
When two loxP sites are oriented in the same direction along a DNA strand, Cre 
recombinase action will result in the removal of DNA between the sites along 
with one of the loxP sites. When two loxP sites are oriented in the opposite 
direction, Cre recombinase action will result in the inversion of DNA between the 
sites (Figure 1.4). The Cre/loxP system is relatively simple because it does not 
need additional enzymes for Cre to work, the loxP target sites are small and easy 
to synthesize, and Cre is a very stable protein.  
 
Over the past decade, a large number of different Cre-expressing mouse lines 
have been generated. Cre-expressing mouse lines have been used to analyse the 
function of genes in vivo, for fate-mapping studies and cell ablation experiments. 
The use of the Cre/loxP system in mice requires two lines of mice; one mouse line 
carrying a loxP-flanked (“floxed”) sequence and the other mouse line expressing 
Cre recombinase in selected cells or tissues. These two mouse lines are crossed to 
produce mice that carry both transgenes. As a result, Cre recombinase will 
activate the expression of a transgene or eliminate an endogenous gene depending 
on what the loxP sites flank. This recombination event is permanent for both 
recombined cells and all their progeny, and will only occur in cells that express 
Cre. 
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Figure 1.4 Diagram of Cre-mediated recombination of a targeted gene flanked by 
loxP sites.  When two loxP sites are orientated in opposite directions, the floxed 
target gene will be inverted. When two loxP sites are orientated in the same 
direction, the floxed target gene will be excised. Red boxes are loxP sites.  
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1.6 The aims of the project 
 
Controversy regarding the sources of OLs in the forebrain and spinal cord has 
been resolved by studies from Dr. Richardson’s laboratory using the Cre-loxP in 
vivo fate-mapping technique (Fogarty et al., 2005; Kessaris et al., 2006). This 
technique allows cells arising from a given region to be permanently labelled or 
“tagged” so that they and all their progeny can be followed throughout 
development. This strategy has been the best approach to solve the origin of OLs 
because the patterning of the neuroepithelium remains unaltered. Data from Dr. 
Richardson’s laboratory and others revealed that there are multiple origins of OLs 
derived from the ventral and dorsal regions of the neuroepithelium in the 
developing mouse telencephalon and spinal cord. This has raised the question of 
whether or not functionally specialized OL subtypes exist in the CNS. The aim of 
this project was to determine the population dynamics of OLPs in the developing 
telencephalon when OL lineage cells with different developmental origins (e.g. 
dorsal versus ventral) are ablated. The first goal was to generate a transgenic 
mouse line that can specifically ablate OL lineage cells when crossed to a Cre 
line. To do this, a Sox10-lox-EGFP-STOP-lox-DTA mouse line was generated 
using PAC technology. A PAC library was first screened to identify PAC clones 
containing Sox10 genomic inserts. Sox10 was chosen since all OLs express this 
marker throughout their development. The chosen PAC insert was then targeted 
by homologous recombination to introduce a floxed EGFP followed by DTA 
(Diphtheria Toxin A chain). The modified PAC DNA was microinjected into the 
pronucleus of fertilised mouse oocytes in order to generate transgenic mice that 
expressed EGFP in OLPs and OLs; in addition, activate DTA in specific OLP 
lineages when crossed to various Cre-expressing mouse lines. DTA is activated in 
OLPs derived from a Cre-expressing region. This Cre-loxP recombination 
strategy was used to ablate specific OLs lineages in the forebrain. The in vivo 
function of OL lineage cells is ascertained by removing the lineage cells and 
observing the consequences. Chapter 3 describes the generation and 
characterisation of the Sox10-lox-EGFP-STOP-lox-DTA (or simply called Sox10-
DTA) mouse line. Chapter 4 reports the results of the ablation of OL lineage cells 
from different developmental origins. Chapter 5 summarises the findings of this 
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Thesis and relates the findings to prior and subsequent research, and suggests 
possible directions for future studies. 
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Chapter 2 
 
 
Materials and Methods 
 
 
 
2.1 PAC library screening 
For the isolation of mouse genomic clones containing the gene of interest, I 
screened a P1-derived bacterial artificial chromosome (PAC) library generated 
from DNA taken from the spleen of a 5-week-old 129S6/SvEvTac female mouse 
(RPCI-21). The library had been purchased from the UK HGMP Resource Centre. 
To construct the library, DNA was isolated from the spleen and partially digested 
with MboI. Fragments were then ligated into BamHI-cut pPAC4 vector, 
transformed into E.coli DH10B cells and gridded onto 22 x 22-cm nylon filters 
using an automatic colony gridding machine. Each filter contains 18,432 clones 
spotted twice or a total of 36,864 clones per filter. This library consisted of 7 
filters. Screening was performed in the same manner as described in section 
2.11.1. Briefly, several filters along with a piece of nylon mesh between each 
filter were rolled up with the colony side facing inwards and slid into a large glass 
rotisserie bottle containing hybridisation buffer. Filters were prehybridised at 
65oC with constant rotation for at least 2 hours. A denatured radioactive labelled 
probe was then added to the hybridisation buffer in the bottles and incubated at 
65oC overnight. The following day, filters were washed in trays, blotted on 
Whatman paper for a few seconds to remove excess solution, and immediately 
wrapped in plastic wrap. Filters were then exposed to X-ray films for 8-24 hours, 
depending on the strength of the hybridisation signals. Positive colonies were 
located and identified using a grid file available from C.H.O.R.I. 
(http://bacpac.chori.org). 
 
2.2 Purification and manipulation of plasmid DNA 
Isolation of plasmid DNA was based on the alkaline lysis method of Sambrook 
and Russell (2001). 
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2.2.1 Plasmid mini preparation for rapid analysis 
On the day before preparation, an inoculation of a single colony representing the 
appropriate bacterial strain was grown in 3 ml of LB broth containing the 
appropriate antibiotic at 37oC overnight (16 hours) while shaking. 1.5 ml of this 
bacterial culture was placed in a sterile eppendorf tube and centrifuged for 1 
minute at maximum speed (13200 rpm) to pellet the cells. The supernatant was 
discarded and the pellet was resuspended in 100 µl of Solution I (50 mM glucose, 
25 mM Tris-HCl pH 8.0 and 10 mM EDTA pH 8.0) by vortexing. 200 µl of 
freshly-prepared solution II (1% w/v SDS and 0.2 N NaOH) was added. The tube 
was gently inverted several times to mix, and then incubated for 5 minutes at 
room temperature. 150 µl of Solution III (3 M potassium acetate and 11.5% w/v 
glacial acetic acid) were then added and again the tube was gently inverted several 
times. Protein and chromosomal DNA were precipitated by centrifuging the tube 
for 10 minutes at maximum speed. The supernatant was transferred to a fresh tube 
containing 900 µl of ethanol to precipitate the plasmid DNA. The tube was 
centrifuged for 10 minutes at maximum speed and the pellet was washed with 
70% ethanol, air dried at room temperature and resuspended in 40 µl  of TE buffer 
(5 mM Tris, pH 7.5, 0.5 mM EDTA, pH 8.0). 
 
2.2.2 Plasmid maxi and glycerol stock preparation 
On the day before preparation, an inoculation of 100 µl of the overnight culture 
from the plasmid mini preparation was placed in 50 ml of LB broth containing the 
same appropriate antibiotic and grown overnight at 37oC, shaking at 200-300 rpm. 
The next day, 850 µl was removed and placed in a labelled cyrovial tube 
containing 150 µl glycerol to make a glycerol stock to store at -80oC. The 
remaining culture was centrifuged at 3750 rpm for 10 minutes at 4oC to pellet the 
cells. The supernatant was decanted into a waste beaker and the pellet was 
resuspended in 4 ml of Solution I. Solution II was freshly prepared each time and 
8 ml of which were added. The tube was gently inverted several times to mix, and 
then incubated on ice for a maximum time of 5 minutes. 6 ml of Solution III were 
added to the lysed material. The tube was gently inverted several times to mix and 
then incubated on ice for 5 minutes. The mixture was then centrifuged at 3750 
rpm for 15 minutes at 4oC. The supernatant was transferred to a new tube. If the 
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supernatant was still cloudy, then the mixture was centrifuged again. The 
supernatant was collected in a fresh tube by filtering through two sheets of 
autoclaved muslin cloth in order to remove the white precipitate. This procedure 
was repeated if the supernatant was still cloudy after filtering through the muslin 
cloth. 17 ml of isopropanol were added. This mixture was incubated for 15 
minutes at room temperature to precipitate the DNA, and centrifuged for 15 
minutes at 3750 rpm at 4oC. The supernatant was discarded and the pellet was 
resuspended in 2 ml TE and 2.5 ml 4.4M LiCl, which was maintained on ice for 1 
hour to precipitate residual RNA. After centrifugation at 3750 rpm for 15 minutes 
at 4oC, the supernatant was transferred to a new tube and 9 ml of 100% ethanol 
was added to precipitate the DNA. The tube was once again centrifuged at 3750 
rpm for 15 minutes at 4oC, the supernatant gently removed, and the pellet rinsed 
with 70% ethanol prior to its resuspension in 400 µl of TE buffer. The solution 
was then transferred to a new 1.5 ml eppendorf tube containing 5 µl of 4 mg/ml 
DNase-Free RNase (Qiagen), and incubated at 37oC for 15 minutes. 10 µl of 20% 
SDS were then added to the tube to inactivate the RNase and the tube was then 
heated at 70oC for 10 minutes. 415 µl of phenol-chloroform were added to the 
mixture, vortexed, and centrifuged at 13200 rpm for 5 minutes at room 
temperature. The supernatant was transferred to a fresh tube containing 400 µl of 
chloroform:IAA (24:1). The mixture was vortexed, centrifuged at 13200 rpm for 5 
minutes at room temperature. The supernatant was transferred to a fresh tube. To 
this, two volumes of 100% ethanol and 0.1 volumes of 3 M Sodium acetate was 
added. The mixture was vortexed and spun for 10 minutes at 13200 rpm at room 
temperature. Finally, the DNA pellet was air dried and resuspended in 200 µl TE 
buffer.    
 
2.2.3 Preparation of PAC DNA 
It was very important to avoid significant PAC DNA breakage during sample 
preparation and handling. Some amount of shearing is unavoidable; however, it 
must be kept to a minimum in order to achieve good results. Since PACs replicate 
at low copy number in E.coli (one or two copies), the yield of DNA is limited, 
therefore, large culture volumes are needed to obtain sufficient PAC DNA. High 
purity PAC DNA was prepared using a modification of the standard alkaline lysis 
method with an overnight 5 ml pre-culture and an overnight 400 ml main culture. 
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400 ml of LB broth containing 15 µg/ml Kanamycin were inoculated with 500 µl 
of transformed EL250 cell pre-culture and grown overnight at 32oC with 
continuous shaking at 200 – 300 rpm. The cell culture was transferred into 8 x 50 
ml Falcon tubes (cat no. 227261, CellStar) and centrifuged for 10 minutes at 3750 
rpm at 4oC. The supernatant was decanted into a waste beaker and the pellets were 
resuspended each in 8 ml of solution P1 plus RNase A (50 mM Tris-HCl pH 8.0, 
10 mM EDTA pH 8.0, 100 µg/ml RNase A) by pipetting up and down. The lysis 
buffer, P2 (0.2 N NaOH, 1% SDS), was each time freshly prepared and 8 ml of 
which were added to each falcon tube. The tubes were gently inverted several 
times to mix, and then incubated at room temperature for a maximum time of 5 
minutes. 8 ml of P3 (3 M potassium acetate, 11.5% w/v glacial acetic acid) were 
added to each tube and gently inverted until the suspension was completely white. 
The tubes were maintained on ice for 1 hour before centrifuging at 3750 rpm for 
15 minutes at 4oC. The supernatant was collected in a fresh tube by filtering 
through two sheets of autoclaved muslin cloth in order to remove the white 
precipitate. This procedure was repeated if the supernatant was still cloudy after 
filtering through the muslin cloth. 24 ml of ice cold-isopropanol were added to 
each tube and mixed gently. The tubes were incubated for 15 minutes at room 
temperature to precipitate the DNA, and centrifuged for 15 minutes at 3750 rpm at 
4oC. The supernatants were discarded and the pellets were each resuspended in 
250 µl TE. The resuspended pellets were all pooled into 4 x 1.5 ml eppendorf 
tubes using wide bore tips to prevent DNA shearing.  These four 1.5 ml eppendorf 
tubes were given a short pulse spin at 13200 rpm to remove any undissolved white 
precipitate. The clear supernatants were transferred to 4 clean 1.5 ml eppendorf 
tubes and 500 µl of phenol-chloroform were added to each tube. The tubes were 
gently inverted several times and centrifuged for 5 minutes at 13200 rpm. This 
phenol-chlorofom extraction step was repeated once more. To remove any 
remaining phenol, the upper phase was removed and placed in new eppendorf 
tubes and extracted with 500 µl of chloroform-isoamyl alcohol. After 
centrifugation at 13,200 rpm for 5 minutes, the upper aqueous phase from the four 
tubes were pooled into 1 x 2.0 ml microcentrifuge tube, mixed well and then split 
into 4 x 1.5 ml eppendorf tubes. 1 ml of ice cold 100% ethanol was added to each 
tube and the tubes were inverted several times. Two of these tubes were then 
stored at -20oC for future use and the remaining two tubes were spun for 10 
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minutes at 13200 rpm.  After centrifugation, the pellets were washed in 1 ml 70% 
ethanol and spun again for 3 minutes at 13,200 rpm. The DNA pellets were air 
dried and resuspended in 100 µl MilliQ water. The resuspended DNA solutions 
were pooled together using a wide bore pipette.  
 
The second method of purifying PAC DNA from E.coli was using the 
NucleoBond® BAC Maxi Kit (cat no. 635941, BD Biosciences). PAC DNA 
purification was carried out according to the manufacturer's instruction.  
 
2.3 DNA digestion and electrophoresis 
 
2.3.1 DNA digestion with restriction endonucleases 
Restriction digests of plasmid or genomic DNA were completed using the 
appropriate buffer, and 20-100 units of enzyme purchased from New England 
Biolabs. Samples were incubated at appropriate temperature for 1-2 hour(s), and 
the resulting digest was confirmed by agarose electrophoresis.  
 
2.3.2 Ligation of DNA fragments 
Ligation involves linking together of a fragment of DNA to a linearized vector. 
This can be accomplished by mixing linearized plasmids and DNA fragments 
together in the same tube, and then allowing them to "incubate" at room 
temperature for several hours. Through random associations, the sticky (cohesive) 
ends of the cut DNA molecules will anneal, and the addition of DNA ligase will 
catalyse the formation of a phosphodiester bond between adjacent nucleotides if 
one nucleotide contains a 5'-phophate group and the other nucleotide contains a 
3'-hydroxyl group. Typically, ligations performed with a 3:1 molar ratio of insert 
to vector results in the highest yield of correct transformants. Ligations were 
conducted in a 10 µl reaction containing 1 x ligation buffer (cat no. B0203S, 
NEB), linearised vector, compatible template and 1 µl or 400 U of T4 DNA ligase 
(cat no. M0202S, NEB). The mixtures were incubated at 16oC overnight. After the 
reaction was complete, 1 µl of the ligation reaction was used for the 
transformation of bacteria and the remaining volume was stored at -20oC. 
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2.3.3 Analysis of PAC DNA by Pulsed-Field Gel Electrophoresis (PFGE) 
PFGE, developed by Schwarz and Cantor (1984), is a powerful tool used to 
separate extremely large DNA fragments by size using an electric field to force 
the DNA fragments through the gel. PFGE differs from conventional gel 
electrophoresis by using two alternating electric fields. During conventional 
agarose gel electrophoresis, DNA larger than 15 Kb migrates with the same 
mobility regardless of size. In contrast, PFGE allows these large DNA fragments 
to be sized by periodically altering the direction of migrating DNA by altering the 
electric field in different two directions. With each change in the orientation of the 
electric field, DNA fragments have to align themselves with the direction of the 
electric current before they can begin to migrate. Smaller sized DNA fragments 
align themselves more quickly than the larger DNA fragments. Therefore, larger 
DNA will lag behind since they take longer to reorientate themselves to the new 
electric field, providing a separation from the smaller DNA. The frequency and 
the length of time with which the electric current alternates can be programmed. 
PFGE was carried out using a Bio-Rad contour-clamped homogeneous electric 
field (CHEF) DR-II system at 4oC in a 1% agarose gel in 0.5 x TBE running 
buffer (45 mM Tris-borate, 1 mM EDTA, pH8.0) for 12 hours at a voltage 
gradient of 6 V/cm with an initial switch time of 2.1 seconds and a final switch 
time of 10 seconds. A 2 mm plug of Pulse MarkerTM (Sigma, 0.1-200 Kb) was 
used as size standard. All Gels were stained with ethidium bromide and visualised 
under UV light. 
 
2.4 Amplification of PAC ends 
 
2.4.1 Inverse Polymerase Chain Reaction (iPCR)   
This protocol was initially described by Mizobuchi and Frohman (1993). In order 
to further characterise the region of the mouse genome contained in each PAC 
clone, the ends of the PAC clones were revealed and blasted against the mouse 
genome database (www.ensembl.org). This technique involves digesting the PAC 
DNA with a restriction enzyme which is known to cleave the PAC vector 
sequence and at an unknown site in the insert. To increase the odds of getting an 
amplifiable product, various enzymes were used per PAC end. The 5´-end of the 
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PAC was digested with PstI, PvuII and SmaI and the 3´-end was digested with 
PstI, SphI, and HindIII. All restriction enzymes were used singly in a 10 µl 
reaction mixture containing 3 µl PAC DNA, 1 µl enzyme (or 10-20 U/µl), 1 µl 
buffer, 1 µl bovine serum albumin (1:10 dilution), and 4 µl H20. The reaction was 
incubated overnight at 37oC. Digestion reactions were stopped by incubating them 
at 70oC for 10 minutes, followed by a precipitation step. The DNA pellets were 
resuspended in 10 µl of water. Then, the digested DNA fragments were 
encouraged to self-ligate (circularize) in a 20 µl reaction mixture containing 3 µl 
of the digested PAC DNA, 1µl (or 400 U) of T4 DNA ligase, 2 µl of ligase buffer 
and 14 µl water. The reaction mixture was incubated at 16oC overnight. The 
following day, 1 µl of the ligation mixture was added to a 25 µl reaction mixture 
for inverse PCR. DNA amplification conditions for both rounds were as follows: 
1 cycle at 95oC for 4 minutes; 34 cycles of 30 seconds at 95oC, 50 seconds at 51oC 
and 1.5 minutes at 72oC; 10 minutes at 72oC and then held at 4oC. The sequences 
of the primers are listed in Table 2.1. PCR primers used in the reaction are 
primers that are pointing away from the known sequences in order to amplify the 
flanking sequences. The outline of this protocol is shown in Figure 2.1. 
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Figure 2.1 Inverse PCR method. This technique involves digestion by a 
restriction enzyme of a preparation of DNA containing the known sequence and 
its flanking region. Digestion of this PAC with BamHI results in many fragments 
containing genomic and/or vector DNA. Next, individual restriction fragments are 
converted into circles by intramolecular ligation, and the circularized DNA is then 
used as a template in PCR.  The unknown sequence is amplified by two primers 
that bind specifically to the known sequence and point in opposite direction. The 
amplified PCR product was then used as a template for a second round of PCR 
using nested primers to ensure specificity. PCR products were purified, cloned 
into TOPO and sequenced.  
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Primer name Primer Sequence 
5’→ 3’ 
 
pPAC4 3’ F1  CGA CTC ACT ATA GGG AGA GG 
pPAC4 3’R1 GGC ATG ACT ATT GGC GCG CC 
pPAC4 3’F2  CGA GCT TGA CAT TGT AGG AC 
pPAC4 3’R2 CCT TGA GAG CCT TCA ACC CA 
pPAC4 5’F1 ACA GTT CTG ACT TTT ACG AC 
pPAC4 5’R1  TTG ACT AGT GGG TAG GCC TG 
pPAC4 5’F2 TAT TAC ACG CCA TGA TAT GC 
pPAC4 5’R2  TGA GTC GCT CCT CCT GCC AG 
 
Table 2.1 Primer sequences used for inverse PCR reactions. “F”, forward primer; 
“R”, reverse primer; “1”, first round PCR; “2”, second or nested PCR. 
 
 
 
The PCR products were visualized by electrophoresis. Fragments amplified 
during the initial inverse PCR were diluted 20 fold and a 1 µl aliquot was then 
used as a template for a second PCR round using nested primers. Nested primers 
are a second pair of primers that bind within the first PCR product and produce a 
second PCR product that will be shorter than the first one. The reasoning behind 
this strategy is that if the wrong fragment of DNA were amplified by mistake in 
the first PCR round, the probability is extremely low that it would be amplified a 
second time by a second pair of primers (all products non-specifically amplified in 
the first round will not be amplified in the second). The amplified products from 
round two were gel purified, cloned into TOPO (cat no. 45-0640, TOPO TA 
Cloning® Kit Dual Promoter pCR®II-Topo®Vector Invitrogen) and sequenced. 
The sequences obtained were blasted against a known mouse genomic database 
(ENSEMBL database of the Wellcome Trust Sanger Institute). 
 
2.4.2 DNA sequencing 
All DNA sequencing reactions were carried out by WIBR Scientific Support 
Services Group. Sequencing was performed on a Beckman Coulter CEQ 8000 
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Genetic Analysis System. In this thesis, sequencing was done on double stranded 
DNA from plasmids. To ensure good results, DNA was prepared by miniprep or 
maxiprep, rinsed in 70% ethanol and resuspended in MilliQ water. Quality and 
quantity of template was determined by agarose gel electrophoresis. 
 
2.5 Determination of DNA concentration 
DNA concentration was determined by using first a UV spectrophotometer and 
later by agarose gel electrophoresis. It was found that estimating DNA 
concentration by gel electrophoresis was a more reliable method. 
 
2.5.1 Photometric method 
The deuterium lamp was turned on 15 minutes before analysis to allow the lamp 
to heat up. Readings were taken at wavelengths of 260 nm (OD260) to measure 
DNA concentration, and 280 nm (OD280) to measure protein concentration. The 
ratio between the readings OD260/OD280 provides an estimation of sample purity. 
Pure preps of DNA have ratios (OD260/OD280) of 1.8 – 2.0. Protein contamination 
will decrease this value. DNA concentration was calculated on the basis that an 
OD of 1.0 at a wavelength of 260 corresponds to 50 µg/ml of double stranded 
DNA. Sterile distilled water was added to one quartz cuvette and placed in the 
spectrophotometer to determine the background absorbance (at OD260) for the 
sample. Then a separate quartz cuvette containing 1ul of DNA solution and 0.99 
ml of sterile water was placed in the spectrophotometer to obtain an absorbance 
reading. The following formula was used to calculate the concentration of a DNA 
sample: 
? µg of DNA in cuvette = OD260 x dilution factor x 50 µg DNA / 1 OD260 unit 
  
2.5.2 Agarose gel method  
For visual determination of DNA concentration, several volumes of DNA (e.g. 1, 
3, 5 µl) were resolved on a 1% agarose gel along with a DNA molecular weight 
marker of known size and concentration, such as HyperLadder I (cat no. BIO-
33026, Bioline). The amount of DNA was estimated by comparing the intensity of 
the DNA sample with standards of similar size and known concentration. 
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2.6 Extraction of DNA from agarose gels 
Following visualisation by agarose gel electrophoresis, the appropriate sized DNA 
fragment was excised from the gel (as close to the band as possible) using a clean 
scalpel and transferred to a clean microcentrifuge tube. One of two methods was 
used to recover DNA fragments from gel slices: Dialysis tubing or illustra GFXTM 
Extraction Kit (GE HealthCare). 
 
2.6.1 Dialysis tubing method 
Dialysis tubing (MWCO-12-14000 Daltons, Medicell International Ltd.) is 
pretreated by heating membranes (8-10 cm strips) at 90oC in 1 mM EDTA / 2% 
NaHCO3 for 10 minutes, boiling in H2O for 10 minutes, rinsing several times in 
H2O, and stored at 4oC in 50% ethanol. Immediately prior to use, the membranes 
are rinsed thoroughly in sterile H2O and then in sterile 1 × TAE buffer. For 
electroelution, the gel slice was placed lengthwise into the dialysis bag, with one 
end sealed with a dialysis clip, and sterile 1 × TAE buffer is added (just enough to 
cover gel slice). Air bubbles were carefully removed from the bag, and the other 
end was sealed with a dialysis clip. The sealed dialysis bag was submerged 
completely in the gel electrophoresis chamber such that the length of the gel slice 
is parallel to the electrodes and the side containing the gel slice is closest to the 
negative pole. Electroelution is carried out in 1 x TAE buffer at 130 V  for about 
30 minutes or until the DNA was eluted from the excised gel piece. The current 
caused the DNA to migrate out of the gel and trapped within the tubing. The 
assembly is removed carefully from the buffer chamber, blotted dry, one of the 
dialysis clips was removed, and the DNA is removed gently using a pippet tip. 
Eluted DNAs were then added to a fresh eppendorf tube containing equal volumes 
of phenol-chloroform, vortexed and centrifuged for 10 minutes at 1370 rpm. The 
supernatant was transferred to a fresh tube containing equal volumes of 
chloroform:IAA (24:1). The mixture was vortexed, centrifuged at 13200 rpm for 5 
minutes. The supernatant was transferred to a fresh tube. To this, two volumes of 
100% ethanol, 0.1 volumes of 3 M Sodium acetate, and 1 µl of glycogen (20 
mg/ml stock, cat no. 901393, Roche) were added. Glycogen is used to help 
increase recovery of nucleic acid from alcohol precipitation and also help to form 
a visible pellet. The mixture was vortexed and spun for 10 minutes at 13200 rpm 
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at room temperature. Finally, the DNA pellet was air dried and resuspended in 10-
20 µl clean distilled water (depending on size of pellet).  
 
2.6.2 Illustra GFXTM Extraction Kit  
Illustra GFXTM Extraction Kit (GE HealthCare) was carried out according to the 
manufacturer's instruction.  
 
2.7 Bacterial cloning 
 
2.7.1 Preparation of electrocompetent E.coli cells 
Electrocompetent cells were prepared similarly for the two E.coli strains used in 
this study: XL1-Blue and EL250. The XL1-Blue is tetracycline resistant strain 
which grows at an optimum temperature of 37oC; whereas, the EL250 strain did 
not have an antibiotic resistant gene. The EL250 strain was grown at 32oC in the 
absence of antibiotics. However, a negative control, consisting of just SOC 
medium in a vial, was placed at 32oC along side the vial containing the EL250 
strain to ensure that the Soc medium was not previously contaminated with 
unwanted bacteria. 
On the day before preparation, an inoculation of a single colony representing the 
appropriate bacterial strain was established in SOC medium and grown for at least 
12 hours at the appropriate temperature. The following day, 400 ml of fresh SOC 
medium was inoculated with 1% of the overnight preculture (4 ml). The culture 
was incubated at 37oC until the A600 was between 0.6-0.8 (3-4 hours). 16 x 50ml 
conical tubes were pre-cooled on ice and the 2 x 400 ml cultures were equally 
distributed into these and cooled for 15 minutes. Cells were then pelleted by 
centrifugation at 1500 x g for 15 minutes. All subsequent procedures were 
completed at 4oC with minimal agitation to the cells to preserve their viability. 
The supernatants were discarded and the pellets were resuspended in 25 ml cold 
sterile MilliQ water, then pooled into 8 x 50 ml tubes, and re-centrifuged at 1500 
x g for 15 minutes. The supernatants were discarded and the pellets were 
resuspended in 25 ml cold sterile MilliQ water, then pooled into 4 x 50 ml tubes, 
and centrifuged again as before. The cell pellets were then resuspended in 10 ml 
cold sterile MilliQ water, pooled into 1 x 50 ml tube and re-centrifuged. The 
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supernatant was removed and the pellet was resuspended in 10 ml of cold 10% 
glycerol and re-centrifuged. After the last centrifugation, the supernantant was 
carefully discarded and the pellet was resuspended in 250 µl 10% glycerol, 
aliquoted into 1.5 ml screw-cap cyro-tubes, shock frozen in liquid nitrogen and 
stored at -80oC.  
 
2.7.2 Targeted modification of PAC in EL250 E.coli cells  
The preparation was based on Yang et al. (1997), where 10 ml of LB medium was 
inoculated with 100 µl of EL250 E.coli containing the appropriate PAC clone and 
grown overnight at 32oC. The following day, 4.0 ml of the preculture was 
inoculated into a 50 ml LB main culture and grown at 32oC with shaking until the 
OD600 was between 0.5-0.8. Then 10 ml of the growing culture was transferred to 
into a 250 ml conical flask and placed at 42oC with shaking (200 revolutions/min) 
for a total time of 15 minutes. Immediately after the 15 minute induction, the flask 
was placed into an ice bath and mixed by hand for a minimum of 8 minutes, to 
ensure the temperature of the flask dropped as quickly as possible. The cells were 
transferred to a 50 ml conical and centrifuged at 5500 x g for 8 minutes at 4oC. All 
subsequent procedures were completed at 4oC with minimal agitation to the cells 
to preserve their viability. The pellet of cells were resuspended in 1 ml of ice-cold 
water and transferred to a cold 1.5 ml Eppendorf tube (which was placed on ice). 
Cell suspension was centrifuged using a benchtop centrifuge for 20 seconds at 
4oC. The tube was placed on ice, and the supernatant was aspirated. The process 
was repeated two more times. Finally, the cell pellet was resuspended in 50 µl of 
ice-cold water and transferred to a precooled electroporation cuvette (0.1-cm gap). 
Finally, the cell pellet was resuspended in 100 µL of ice-cold water. Next, 1–3 µl 
(100 ng) of the plasmid fragment was added to 50 µl of the competent cells and 
electroporated in a 0.1 cm cuvette using a BIO-RAD electroporator under the 
following condition (bacteria EC1 program): 1.75 kV, 25 µF with the pulse 
controller set at 200 Ω. Then 1.0 ml of LB medium was added immediately to the 
cuvette, which was then incubated at 32°C for 2 hours with shaking. Cells were 
spread on selective plates and incubated at 32°C overnight. 
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2.8 Generation of transgenic mice 
 
2.8.1 Purification of PAC DNA for pronuclear microinjection 
Highly purified DNA is essential for successful transgenic production. Debris 
within the DNA can easily clog the microinjection needle and/or interfere with 
integration of the DNA into the host genome. Large scale PAC DNA preparation 
was performed as described previously (see section 2.2.3). For the generation of 
linearized, full length PAC DNA for pronuclear microinjection, 100 µl of PAC 
DNA (maxi prep grade) was digested with the appropriate restriction enzyme in a 
300 µl reaction volume for 6-8 hours. 30 µl of sinking dye was added to the entire 
reaction before it was carefully loaded onto a 1% agarose gel using a cut P200 tip. 
The digested DNA was run on a PFGE next to ג-DNA standards to separate the 
insert from the PAC vector and sheared DNA. After the gel had run, the marker 
lanes plus a small part of the preparative lane on one side was stained with 
ethidium bromide (Fluka, Switzerland) for 30 minutes with very gently agitation 
at room temperature (Figure 2.2A). The central part of the gel containing most of 
the preparative slot remained unstained (as ethidium bromide is toxic to embryos). 
The stained gel was placed under UV-light to mark the precise location of the 
PAC fragment of interest by placing nicks on either side of the gel. The stained 
gel was then placed next to the unstained gel and the fragment of interest was cut 
out using the marked nicks and a ruler as a guide. The PAC vector was also cut 
out in the same manner and was used as a marker for the second gel run. The PAC 
insert and the PAC vector slices were rotated 90oC relative to their original 
directions of mobility and electrophoresed in a 4% low-melting-point agarose 
(NuSieve® GTG® Agarose) in 0.5 x TBE at 40 V for 11 hours to concentrate the 
PAC insert (Figure 2.2B). The PAC vector was then stained with ethidium 
bromide to determine the migration distance of the PAC insert into the 4% low-
melting-point agarose, so as not to stain the insert with ethidium bromide (Figure 
2.2C). The unstained PAC insert was excised, weighed and equilibrated with 
Tempa buffer (1 M Tris-HCl pH 7.5, 0.5 M EDTA pH 8.0, 5M NaCl) containing 
30 µM spermine (cat no. 85590, Fluka BioChemika) and 70 µM spermidine (cat 
no. S-0266, Sigma) for a minimum of 1.5 hours with gently agitation. The gel 
slice was then placed in a microcentrifuge tube, and the agarose was melted at 
68oC for 10 minutes and then immediately placed at 42oC for 5 minutes. While 
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the tube was at 42oC (to avoid immediate solidification of the gel), two units of β-
agarase (cat no. M0392L, New England Biolabs) per 100 µl of agarose were 
added and digested for 2 hours at 42oC. Once the agarose had been totally 
digested, the PAC insert was then equilibrated in microinjection buffer (1 M Tris-
HCl pH 7.5, 0.5 M EDTA pH 8.0, 5 M NaCl, filtered sterilized). This was done 
by carefully placing three small 0.025 µm dialysis filters (cat no. VSWP01300, 
Millipore) onto the surface of 3 ml of microinjection buffer in a 35 mm Petri dish. 
50 µl PAC insert was spotted onto the center of a dialysis filter with a cut off tip. 
Dialysis was allowed to proceed at room temperature for 1 hour without any 
shaking or movement. The PAC insert was carefully removed from the filters with 
a cut off tip and transferred into a sterile Eppendorf. This PAC insert stock was 
stored at 4oC until needed. It was used for microinjection for up to 3 weeks 
following purification 
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Figure 2.2 Recovering and concentrating intact PAC DNA from preparative 
pulsed field gels. (A) Once PFGE has ended, the outer track of the gel is stained 
with ethidium bromide and photographed under UV light in order to mark the 
positions of the PAC insert and vector backbone. The stained gel was placed next 
to the unstained gel and the fragments of interest were excised. (B) The PAC 
insert and vector backbone slices were rotated 90º relative to their original 
directions of mobility, embedded in 4% low-melting-point agarose and 
electrophoresed. (C) The gel was cut in half and the slice containing the vector 
backbone was stained with ethidium bromide. The position of the PAC insert was 
estimated based on the position of the vector. The PAC insert was excised from 
the 4% agarose gel. 
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2.8.2 Estimation of PAC DNA concentration for pronuclear microinjection 
To estimate the concentration of  purified PAC insert, several dilutions of the 
PAC were run on a PFGE gel next to defined amounts of  purified PAC insert that 
have given transgenic founders. The gel was stained with ethidium bromide and 
placed under UV light to determine the concentration needed for microinjection. 
The quality of the DNA is one of the most crucial factors for successful 
generation of transgenic mice. The concentration as well as the integrity of the 
purified PAC insert was checked by PFGE. The purified PAC insert was diluted 
to a final concentration of approximately 2 ng/µl with microinjection buffer 
containing 30 µM spermine and 70 µM spermidine just prior to injection. 
 
2.8.3 Mouse strain 
The most common strain combination for all mice used to generate transgenics in 
this thesis is C57BL6xCBA. F1 generation mice were purchased from a 
commercial supplier (Charles River Laboratories, UK), housed in the University 
College London (UCL) animal facility and were maintained on a 12 hour light-
dark cycle at a constant temperature and humidity. All animal experiments were 
carried out according to the UK Animal Act 1986 and approved by the UCL 
Animal Care Committee.  
 
2.8.4 Superovulation 
Hormones were used prior to mating to stimulate the release of greater number of 
eggs, to induce follicular development, and to control the expected time of 
ovulation. Donor female C57BL6xCBA F1 hybrid mice (4-5 weeks of age) were 
superovulated with an intraperitoneal (i.p.) injection of 5 i.u. serum gonadotrophin 
(Folligon, Intervet), followed 45 hours later by 5 i.u. human chorionic 
gonadotropin (Chorulon®, Inyervet). Gonadotropins were diluted in 0.9% sodium 
chloride (NaCl Injection B.P., Antigen Pharmaceuticals). Females were mated 
with C57BL6xCBA F1 hybrid males immediately after second injection. The next 
morning the females were examined for the presence of a copulation plug in the 
vagina.  
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2.8.5 Collection of fertilised egg 
Oviducts were harvested from donor females that had a copulation plug in the 
vagina. Oviducts were transferred in a 60 mm Petri dish containing 5 ml of M2 
medium (cat no. M7167, Sigma). The oviducts were gently opened using two 
pairs of forceps under a stero-microscope (Leica M26) to release the egg/cumulus 
cell bunch. The cell bunch was then transferred using a mouth-controlled hand-
made microcapillary pipette (cat no. A5177-5EA, Sigma) to a 35 mm Petri dish 
containing 3 ml of M2 medium and 0.1 mg/ml of hyaluronidase (cat no. H-4272, 
Sigma). To prepare microcapillary pipettes, 1.0 mm diameter thin walled glass 
tubings were pulled over a Bunsen flame and broken in the middle of constriction. 
Those with a 150-180 µm internal diameter were selected and polished lightly at 
the edge of a flame. Embryos were then incubated in the M2/hyaluronidase 
mixture for 10 minutes or until eggs were completely denuded of cumulus cells.  
After brief treatment with hyaluronidase, the naked embryos were washed once in 
M2 medium and once in prewarmed and equilibrated M16 medium (cat no. 
M7292, Sigma) to remove traces of hyaluronidase. Flushed embryos were 
transferred to a drop culture of M16 covered with mineral oil (cat no. M8410-
100ml, Sigma). The drop culture dish containing embryos was placed in an 
incubator set at 5% CO2 and 37oC (Heto-Holten CellHouse 170) until ready for 
microinjection. 
 
2.8.6 Pronucleus microinjection of PACs  
Microinjection workplace was set up on an antivibration table (supplied by Micro 
Instrument Ltd.). Pronuclear microinjection was performed under a Leica 
working-distance condenser (cat no. 506059, Leica, Germany).  Two 
micromanipulators were placed on each side of the microscope. The injector was 
attached to the right-hand-side micromanipulator (Eppendorf, FermtoJet®) and 
the holding pipette (cat no. 930-00-101-5, int. 15µm, Eppendorf AG) was 
assembled onto the left-hand-side micromanipulator (Eppendorf, CellTram 
Vario). The DNA solution was loaded into the drawn out glass injection pipette by 
capillary force via the blunt end of the pipette (TW100F-6 glass thin wall 
w/filament 1.0 mm 6”, World Precision Instruments). A flaming micropipette 
puller was used to generate all injection pipettes (Model P-97, Sutter Instruments 
Co.). Eggs to be injected were suspended in a drop of M2 medium on a clean, 
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siliconized glass depression slide which was placed on a microscope stage.  
Fertilized eggs which had two visible pronuclei were held in position by gentle 
suction with a holding pipette. The egg was “bounced” off and recaptured until it 
was in a suitable orientation. The egg was positioned so that the larger of the two 
pronuclei was located on the outer edge of the egg closest to the injection pipette. 
Under 40X magnification, the pronucleus to be injected was focused and the tip of 
the injection pipette was placed below the egg and brought into the same focal 
plane using the vertical control on the micromanipulator. The microinjection 
pipette was then gently pushed through the zona pellucida and into the nucleus 
whereby DNA is injected by a constant working pressure until the volume of the 
pronucleus approximately doubled; the tip was then slowly withdrawn. 50-70% of 
the eggs survived injection.  
 
2.8.7 Embryo transfer 
Mature CD-1 F1 females were placed with vasectomized CD-1 F1 males to 
induce pseudopregnancy the evening before the transfer. The fertilized eggs 
which survived microinjection were rinsed in M2 (since mineral oil may be 
somewhat toxic to the foster mother) and then transferred to the ampullae of half-
day pseudopregnant foster females. Females that have been plugged by a 
vasectomized male were anaesthetised with a solution containing 25% of fentanyl 
citrate/fluanisone (Hynorm, VetaPharma Ltd.) and 25% of midazolam (Hypnovel, 
Roche). The induction dose was administered intraperitoneally at a dose of 5 µl/g 
body weight. The left side of the lower back was shaved, swabbed with 70% 
ethanol, and a small incision was made with dissecting scissors to expose the 
ovary and/or fat pad which are visible through the body wall. The mouse was then 
placed on the stage of a dissection scope (Leica MZ75) and a small incision was 
made in the body wall just over the ovary. The fat pad (to which the ovary and 
uterus are attached) was then drawn through the incision using blunt forceps. A 
small clamp was attached to the fat pad to keep the ovary in position. The 
undamaged injected embryos were then loaded into a glass transfer pipette and the 
pipette was then inserted into the opening of the swollen oviduct and eggs were 
gently blown into the oviduct. The glass transfer pipette was prepared using 1.0 
mm diameter thin glass tubing (TW100-6 glass thin wall no filament 1.0 mm 6”, 
World Precision Instruments) pulled over a Bunsen flame and broken in the 
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middle of the constriction. Those with 120-150 µm internal diameters were 
selected and polished lightly at the edge of a flame.  The clamp was removed from 
the fat pad; and the fat pad, ovary, and oviducts were returned to the body cavity, 
which was then closed with two stitches (W8597, Ethicon). The skin was then 
closed with surgical staples. Mice were kept warm (32oC) until the effects of the 
anaesthetic had worn off and monitored to ensure that there were no post-
operative complications. Pups were born approximately 19-21 days after the 
transfer. 
 
2.9 Screening potential founder mice 
 
2.9.1 Tail biopsies and DNA extraction 
Potential transgenic pups were examined for the integration of the transgene into 
the genomic DNA. The procedure used for genotyping transgenic animals entails 
cutting off the distal portion of the animal’s tail (tip biopsy) under local anesthesia 
(Cryogenic® fine spray, Acorus Therapeutics Ltd.) with sterile sharp scissors. 
Tail biopsies are a rich source of genomic DNA. During all tail biopsies, the 
remaining tail tip was cauterized with silver nitrate (Silver Nitrate Pencil, 
Veterinary). Mouse tail-tip biopsies (1 mm) were placed in 1.5 ml centrifuge tubes 
containing 488 µl of extraction buffer (100 mM Tris pH 8.0, 5 mM EDTA, 0.2% 
SDS, 200 mM NaCl). 12 µl of 20 mg/ml stock of Proteinase K (cat no. P2308, 
Sigma) were added to the samples, and the samples were vortexed. The samples 
were then placed in a 55oC water bath overnight or until complete cell lysis 
occurred. 200 µl of 6M ammonium acetate were added to the samples, the 
samples were vortexed and then placed on ice for 15 minutes. The samples were 
then centrifuged at 13.2 rpm (or 16.1 rcf) for 15 minutes.  The supernatants, 
avoiding the cell debris, were transferred to new 1.5 ml centrifuge tubes. 500 µl of 
isopropanol were added to each sample, and the samples were vortexed 
immediately. DNA was then pelleted by centrifuging the samples at 13.2 rpm for 
10 minutes. The DNA pellets were washed once in 70 % ethanol, air dried for 5 
minutes, and then resuspended in 50 - 100 µl of MilliQ water. Samples were 
placed at 55oC for 10 minutes to aid dissolution of DNA. DNA was stored at 4oC 
until needed. 
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2.9.2 Polymerase Chain Reaction 
Genotyping is quite important for proper maintenance and use of the transgenic 
line. PCR consists of exponentially amplifying segments of DNA that lie between 
two regions of known sequences by multiple cycles of denaturation, annealing, 
and DNA synthesis (Mullis et al., 1987). Transgenic founders were rapidly 
screened by PCR using specific primers designed to detect the presence of the 
transgene. Primers were selected using the following key parameters:  
• Melting temperature between primer pair did not differ by more than 5oC 
• All primers contained a G or C base at the 3’-end 
• G/C content between 40-60% 
• length of approximately 20 nucleotides 
• no inverted repeat sequences greater than 3 bp in length 
 
The reagents were from Promega, UK. Amplifications were carried out in a 25 ul 
volume containing 2 µl of genomic DNA, 0.2 units of Taq DNA polymerase; 1 x 
reaction buffer, 1.5 µl of 25 mM Magnesium Chloride, 0.25 µl of DNA 
polymerisation mix (containing 20 mM each of dATP, dCTP, dGTP and dTTP, 
Amersham Biosciences) and 0.2 mM of forward and reverse primers (MWG). 
Amplifications were carried out using a Mastercycler gradient (Eppendorf). PCR 
parameters were as follows: denaturation at 95oC for 5 minutes, followed by 35 
cycles of denaturation for 30 seconds at 95oC, annealing for 50 seconds at the 
appropriate temperature (see Table 2.2), extension for 1.5 minutes at 72oC, and a 
final extension of 10 minutes at 72oC. The generation of a PCR product was 
confirmed after loading 25 ul (mixed with 2.5 ul of 10 x loading buffer: 15% 
Ficoll, 0.25% Xylene Cyanol, 0.25% Bromophenolblue in diluted water) onto a 
1% agarose gel containing EtBr (Sigma and Aldrich) and running at 120 V for 30 
minutes. Ethidium Bromide allows the products to be visualised by ultra-violet 
light using a transilluminator. The size of the product was inferred by the 
inclusion of a molecular weight marker, Bioline HyperLadder 1 (cat no. 
BIO33026), which has products ranging 200 bp to 10,000 bp.  
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Table.2.2 Genotyping was routinely performed by PCR using the appropriate 
primers. All primers were synthesised commercially (MWG AG Biotech). Most 
Sox10-DTA embryos and new born pups were screened under UV light for the 
presence of EGFP fluorescence. EGFP, indicating expression from the transgene, 
was seen in the inner ear and in the sensory fibres from the DRG in embryos, and 
in the salivary glands of postnatal pups. *Annealing temperature was decreased by 
1oC with every cycle to a touchdown annealing temperature of 56oC. 
 
 
 
 
 
 
Transgene 
  
Forward Primer 
5´ → 3´ 
Reverse Primer 
5´ → 3´ 
Expected 
Product 
Size, bp 
Annealing 
Temp 
OC 
Sox10-DTA GAAATCGTGTCAGGCGATCT GAGCTCAAGGATCAGAGTGTCCCACCCTGC 600 *56 
Nkx2.1-iCre TTGGCGCGCCTCTACCCCACCTCTGGC
CCTCC 
 
AGGTACAGGAGGTAGTCCCTC 900 62 
Gsh2-iCre TTGGCGCGCCTGTGAAGCGTTGGACAG
AGGCCC 
AGGTACAGGAGGTAGTCCCTC 600 62 
Emx1-iCre GAGGGACTACCTCCTGTACC GCCAAGGATGACTCTGGGCA 900 56 
Olig2-iCre GTGGAAGACGTGGCCGCC CCCAGCTATCAACTCGCGCCC 410 61 
Rosa26 wt AAAGTCGCTCTGAGT TGTTAT GGAGCGGGAGAAATGGATATG 550 59 
Rosa26 mutant AAAGTCGCTCTGAGT TGTTAT GCGAAGAGTTTGTCCTCAACC 250 C129 
1300 F154 
59 
Dbx1-iCre GAAACCTGGACTCTGAGACTGGG GAGAGAAATCGCTTCCTCC 700 66 
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2.10 Southern Blot Analysis  
 
2.10.1 Probe generation   
All probes were amplified by PCR and gel purified as previously detailed. 25 – 50 
ng of gel purified DNA template was labelled with 32P-dCTP (Amersham) using 
the RediprimeTM II Random Prime Labelling System (cat no. RPN1633, 
Amersham Pharmacia Biotech) exactly as described by the manufacturer. 
Unincorporated label was removed using Micro Bio-Spin chromatography 
columns (BioRad Laboratories, USA). The purified labelled probe was denatured 
at 95oC for 5 minutes and rapidly cooled on ice for 2 minutes. The probe was then 
added to the blocked membrane in buffer and incubated overnight to allow probe 
molecules to find their targets. 
 
2.10.2 Southern Blot 
Southern blot was described by Edward M. Southern (1975). 15 µg of genomic 
DNA prepared from mouse tail was digested with one or more appropriate 
restriction enzymes. The resulting fragments were separated according to size by 
0.8% agarose gel electrophoresis in 1 x TAE (0.04 M Tris, 0.001 M EDTA, 
0.35% glacial acetic acid) in the absence of EtBr. After electrophoresis was 
complete, the gel was stained with EtBr for approximately 15 minutes. After 
staining, the gel was rinsed with water and then photographed with a fluorescent 
ruler.  
For efficient transfer of large DNA fragments, the DNA was depurinated by 
submerging the gel in 0.25 M HCl for 30 minutes with constant gentle agitation. 
Depuriation step is optional; however, DNA fragments greater than 15 kb are 
difficult to transfer to the blotting membrane, so acid treatment makes the 
fragments smaller by taking out the purines. To separate double-stranded DNA 
into single-stranded DNA, denaturation was performed in 0.4 M NaOH and 1.5 M 
NaCl for 30 minutes with constant gentle agitation, followed by neutralisation in 
0.5 M Tris-HCl, 1.5 M NaCl and 1 mM EDTA with the pH adjusted to 7.5 for 30 
minutes, after which the gel was equilibrated in 10 x SSC (1.5 M NaCl, 0.15 M 
Sodium Citrate) for 5 minutes. All of the above steps were performed in room 
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temperature with constant gently shaking. Upward capillary transfer of the DNA 
was performed overnight onto a nylon membrane optimised for nucleic acid 
transfer (HybondTM-XL, Amersham Biosciences) using 10 x SSC. After 
completion of the capillary transfer, the DNA was UV crossed-linked to the 
membrane using a crosslinker (UV Stratalinker 1800, Stratagene,), with a UV 
dosage of 120 mJoules. 
Prehybrisation was carried out in sealed roller bottles in a hybridisation rotisserie 
oven (Hybaid Maxi-14, USA) for at least 1 hour using 100 µg/ml denatured 
sheared salmon sperm DNA (Eppendorf®) in MIB buffer (0.225 M NaCl, 15 mM 
NaH2PO4, 1.5 mM EDTA, 10% PEG 8000, 7% SDS). Sheared salmon sperm 
DNA is used as a blocking agent to reduce background. For all probes, 
hybridisation was carried out at 65oC overnight. After hybrids have formed 
between the probe and target, the membranes were washed once in 0.1% sodium 
dodecyl sulfate at 65°C for 15 minutes and once in 0.2 x standard saline citrate, 
0.1% sodium dodecyl sulfate at 65°C for 20 minutes in order to remove non-
specifically bound probe from the membrane. Excess wash was drained from the 
membrane, and the membrane was placed on a flat sheet of plastic wrap. The 
edges of the wrap were folded over the backside of the membrane to seal it. The 
membrane was then exposed to a high performance autoradiography film 
(Hyperfilm, Amersham Biosciences) and an intensifying screen at -80oC for 
varying lengths of time. All films were developed using an automatic film 
processor (X-Ograph Compact X2, UK). 
 
2.10.3 Reprobing a Southern Blot 
If a membrane was to be reused for hybridisation with a different probe, the old 
probe was stripped by incubating the membrane twice in boiling 0.1% SDS with 
gently agitation and allowing the solution to cool to room temperature. The 
stripped blot was rinsed twice in SSC and reautoradiographed on X-ray film to 
ensure the original probe has been completely removed. 
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2.11 Tissue staining 
 
2.11.1 Staging of embryos 
Female mice were placed with male mice. The presence of a copulation plug the 
morning after the females were caged with males indicated mating.  Fertilization 
was considered to have occurred at midnight. Therefore, midday at the date at 
which a copulatory plug was observed was designated E0.5. Plugged females 
were then separated from the males. Timed pregnant mice were sacrificed by CO2 
inhalation followed by cervical dislocation and whole embryos were removed. 
 
2.11.2 Tissue preparation for immunohistochemistry and in situ 
hybridisation 
Animals to be perfused were anaesthetised with an intraperitoneal injection of 
1:1:2 mixture of Hypnorm, Hypnovel and sterile water. Newborn mice were 
deeply anaesthetized by hypothermia. Animals were perfused via the left cardiac 
ventricle with PBS followed by 4% paraformaldehyde in 1 x PBS.  Brains and 
spinal cords of newborn and adult mice were rapidly dissected out and post-fixed 
by immersing the tissue in 4% PFA in 1 x PBS. The post-fixation time ranged 
from 30 minutes to overnight depending on the primary antibody that was to be 
used and age of tissue. There was no perfusion step when dealing with embryonic 
tissue; however, tissue was fixed by immersion of embryo in fixative. The brains 
of pups examined between P0 and P20 were embedded in 3% agarose and then 
vibratome-sectioned at 200 µm prior to post-fixation. All samples were 
cryoprotected overnight at 4oC in depc-treated 20% (w/v) sucrose in PBS, 
embedded in Tissue-Tek OCT compound (R.A. LAMB), frozen rapidly in 
menthanol precooled to its freezing point with dry ice, and stored at -80oC before 
sectioning. Sections were cut with a cryostat (Bright OTF5000) whose chamber 
temperature was set at approximately -20oC and specimen temperature at about -
15oC.  All sections were mounted on SuperFrost® Plus glass slides (cat no. 631-
0108, VWR International) and air-dried for at least 1 hour, and either stored at -
80oC or used immediately. 
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2.11.3 Immunohistochemistry 
After sections were air-dried, the slides were first immersed in 1x phosphate-
buffered saline (80 g NaCl, 2 g KCl, 26.8 g Na2HPO4-7H2O, 2.4 g KH2PO4 in 1 L 
H2O pH 7.4) containing 0.1% Triton X-100 for 5 minutes to remove excess 
Tissue-Tek OCT compound. Nonspecific binding sites were blocked by of 
incubating the slides with PBS containing 10% heat inactivated sheep serum and 
0.5% Triton X-100 for at least 1 hour at room temperature before applying the 
primary antibody. Sections were stained in a dark humidified chamber to prevent 
evaporation. All primary antibodies were incubated overnight at 4oC in the 
appropriate dilution. After primary antibody binding, sections were washed three 
times in PBS containing 0.1% Triton X-100 for 15 minutes each to remove 
unbound antibodies. Appropriate fluorescent secondary antibodies were applied 
for one hour at room temperature in PBS containing 10% sheep serum and 0.1% 
Triton X-100. All steps after the addition of the fluorescent secondary antibody 
were kept in the dark to prevent the breakdown of fluorochromes. After secondary 
antibody binding, sections were washed three times in PBS containing 0.1% 
Triton X-100.  Sections were then incubated with the nuclear marker, Hoechst 
(0.01 mg/ml, Sigma) in 1 x PBS containing 0.1% Triton X-100) for 5 minutes, 
followed by a 5 minute wash in PBS containing 0.1% Triton X-100. After 
staining, the sections were post-fixed in 4% PFA in PBS for 5 minutes and then 
washed for 5 minutes in PBS containing 0.1% Triton X-100. This final fixation 
step links all the antibodies in place thus preventing their dissociation. Sections 
were coverslipped with an antifade mounting medium (Dako Cytomatin 
Fluorescent or Citifluor AF1 by Agar). Mounted sections were kept at 4oC in a 
dark box.  
For double labelling experiments, the primary antibodies were applied together 
and revealed with different fluorescent secondary antibodies. Antibodies used in 
this thesis are summarized in Table 2.3. 
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Antibody  Host Dilution Source Catalogue 
no. 
GFP Rabbit 1:8000 Abcam AB290 
Sox10 Guinea 
Pig 
1:2000 Gift from M. 
Wegner 
N/A 
PDGFRα Rat 1:500 BD Biosciences 558774 
NeuN Mouse 1:400 Chemicon MAB377 
MNR2 Mouse 1:400 Sigma N/A 
Olig2 Rabbit 1:2000 Gift from C. Stiles N/A 
GFAP Mouse 1:400 Sigma G-3893 
APC (CC1) Mouse 1:400 Calbiochem OP80 
Brdu Mouse 1:10 Mab-BU20A BU20A 
Β-galactosidase Rabbit 1:1000 Abcam AB616-1 
Anti-Rabbit IgG, H+L 
Fluorescein conjugated 
Goat 1:200 Pierce 
Biotechnology 
31583 
Anti-Rabbit IgG, H+L 
Rhodamine conjugated 
Goat 1:200 Pierce 
Biotechnology 
31670 
Anti-Guinea Pig IgG, 
H+L 
Fluorescein conjugated 
 
Goat 1:200 Chemicon AP108F 
Anti-Guinea Pig IgG, 
H+L 
Rhodamine conjugated 
 
Goat 1:200 Chemicon AP108R 
Anti-Guinea Pig IgG, 
H+L 
Rhodamine conjugated 
 
Donkey 1:200 Chemicon AP193R 
Anti-Mouse IgG, H+L 
Fluorescein conjugated 
Goat 1:200 Pierce 
Biotechnology 
31569 
Anti-Mouse IgG, H+L 
Rhodamine conjugated 
Goat 1:200 Pierce 
Biotechnology 
31663 
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Table 2.3 Panel of antibodies used in this study. Table shows all the primary and 
secondary antibodies used for immunohistochemistry, their working dilutions, 
sources and catalogue numbers. 
 
2.11.4 In situ hybridisation  
This is a method of localising and detecting specific mRNA sequences in 
morphological preserved tissue sections by hybridizing the complementary strand 
of a nucleotide probe to the sequence of interest. RNase contamination is one of 
the biggest concerns when working with RNA since these enzymes are very stable 
and can degrade RNA very easily. In order to remove all sources of RNases, 
reagents were treated with 0.1% (v/v) Diethylene Pyrocarbonate (DEPC) for 
several hours before autoclaving. Labware was treated with 3% H2O2 for at least 
30 minutes and then rinsed in DEPC-treated water or baked at 200oC overnight 
before use. 
 
Template preparation 
DIG-labelled antisense RNA probes were transcribed from cDNA templates 
cloned into a vector (usually pBluescript II +). Briefly, 10µg of plasmid DNA was 
linearised, at the 5’–end with respect to the sense direction of the cDNA, for two 
hours using 100 units of the appropriate restriction enzyme in a total volume of 
100 µl. Following complete digestion, 5 µl of 10% SDS along with 1 µl of 
proteinase K (stock conc. 20 mg/ml) was added to the linearised plasmid and 
placed at 55oC for 15 minutes. The DNA was then subjected to two 
phenol/chloroform extractions to remove RNases and other proteins from the 
nucleic acid sample. The linearised plasmid was then recovered by ethanol 
precipitation, followed by a 70% ethanol rinse and resuspended in 50 µl of clean 
MilliQ water. DNA was quantified by running an aliquot (1 µl) along with a DNA 
ladder on a 1% agarose gel.  
 
Probe synthesis 
In vitro transcription requires a purified linear DNA template containing a 
promoter, ribonucleotide triphosphates, buffer system that includes DTT and 
magnesium ions, and an appropriate RNA polymerase. It is extremely important 
to ensure that all of the solutions used in RNA experiments are completely RNase 
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free. In vitro transcription was driven either by T3 or T7 RNA polymerase, 
depending on the orientation of the cDNA sequence relative to the promoter. A 
standard RNA transcription reaction mixture contained 1 µg of linear template, 5 
µl of 5 x transcription buffer (cat no. P11813, Promega), 7.5 µl of 100 mM DTT 
(Dithiothreitol, cat no. P117B, Promega), 2.5 µl of 10 x DIG-NTP mix (Dig 
labelling, cat no. 11277073910, Roche), 1 µl of RNAsin (RNase Inhibitor, cat no. 
N211A, 40 U/µl, Promega), 1 µl of T3 (cat no. P402A, 80 U/µl, Promega) or T7 
(cat no. P2077, 20 U/µl, Promega), and clean water adjusted to a total volume of 
25 µl. Transcription was carried out at 37oC for two hours. After the reaction was 
completed, 75 µl of DEPC treated water was added to the tube to bring the 
volume up to 100 µl. 5 µl of diluted probe was electrophoresed in a 1% agarose 
gel to check the size and integrity.  RNA probes were aliquoted and stored at -
80oC. 
 
Hybridisation procedure 
Sections were air-dried at room temperature for at least one hour before antisense 
probes diluted at 1/1000 in hybridisation buffer (50% formamide, 100 mg/ml 
dextran sulphate, 1 mg/ml tRNA, 1 x Denhardt’s, solution, (50 x stock, 1% Ficoll 
400, 1% polyvinylpyrrolidone, 1% bovine serum album), and 1 x salt solution (10 
x salt stock, 2 M NaCl, 50 mM EDTA, 100 mM Tris-HCl pH 7.5, 50 mM 
NaH2PO4-2H2O, 50 mM Na2HPO4, DEPC treated) were added. The probe was 
denatured at 70oC for 5 minutes, vortexed and pulse spinned before added to the 
slides and covered with glass coverslips (24 x 50 mm, borosilicate glass, VWR) 
that were previously baked overnight at 200oC (to render them RNase free). 
Hybridisation was carried out overnight in a humidified chamber at 65oC. The 
next day, slides were washed three times, each time for 30 minutes, at 65oC with 
washing buffer containing 1 x SSC, 50% formamide, and 0.1% Tween-20. 
Sections were then washed twice, each time for 30 minutes, at room temperature 
with 1 x MABT (5 x stock, 0.5 M maleic acid, 0.75 M NaCl, 1 M NaOH, 0.5% 
Tween-20). Sections were then blocked in blocking buffer (8 g blocking reagent, 
Roche cat no. 1-096-176, 100 ml 5 x MABT, 200 ml distilled H2O, heated to 65oC 
to dissolve than 80 ml of heat treated sheep serum added and finally made up to 
400 ml with distilled H2O) for 1 hour at room temperature. The sections were then 
incubated with an alkaline phosphatase-conjugated DIG antibody (Roche, 
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Germany) diluted 1:1500 in block, and placed in a humidified chamber overnight 
at 4oC. The next day, sections were washed five times, each time for 15 minutes, 
at room temperature with MIBT buffer and twice with staining buffer (0.1 M 
NaCl, 0.05 M MgCl2, 0.1 M Tris pH 9.5, 0.01% Tween-20). Bound probe was 
visualised by incubating the sections in a solution containing (20 ml staining 
buffer, 0.025 M MgCl2, 87 µl NBT (1 g 4-nitrobluetetrazoline chloride crystals 
dissolved in 7 ml dimethylformamide and 3 ml distilled H2O)  and 67 µl BCIP (1 
g 5-Bromo-4-chloro-3-indolyl-phosphate 4-toluidine salt dissolved in 20 ml 
dimethylformamide) and 20 ml 10% polyvinylalcohol solution). Once staining 
was complete, slides were rinsed in tap water for at least 30 minutes, than 
dehydrated through ascending concentrations of ethanol (60, 80, 95, and 100%) 
for 5 minutes each. Sections were cleared twice in pure xylene for 5-10 minutes 
each and then coverslipped with DePex mounting medium (BDH). Sections were 
viewed under light microscopy to detect the presence or absence of intracellular 
blue staining. 
 
2.11.5 LacZ staining 
Beta-gal staining allows identification of embryonic tissues/cells expressing lacZ 
marker protein by the development of a pigmented (blue) product in the presence 
of the chromogenic substrate 5-bromo-4-chloro-3-indoyl-β-d galactopyranoside 
(X-Gal, cat no. B9285, Sigma). 
 
Tissue preparation  
Briefly, mice were anesthetized with Hyporm/Hpovel until effect. Mice were then 
perfused with cold 1 x PBS followed by LacZ fixative via the left ventricle of the 
heart. Once perfusion was complete, the brain and spinal cords were isolated and 
immediately transferred to LacZ fixative containing 1% formaldehyde, 0.2% 
glutaraldehyde, 2 mM MgCl2, 5 mM EGTA (pH 8.0), in 1 x  PBS. Tissues were 
normally fixed for 30 mintues; however, whole embryos were fixed for 2 hours at 
RT. Fixation time is critical since over-fixation inhibits enzyme activity. After 
post-fixation, tissues were transferred into 20% (w/v) sucrose in 1 x PBS at 4oC 
overnight. The following day, tissues were embedded in OCT as described in 
section 2.11.2. 
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X-Gal staining and evaluation  
Sections were cut on a cryostat, collected on SuperFrost® glass slides, air-dried 
for one hour, and either stored at -80oC or used immediately. Sections were 
washed for several hours (or overnight) in LacZ wash buffer containing 2 mM 
MgCl2, 0.01% NaDOC, 0.02% Nonidet-P40 in 1 x PBS prior to staining. Sections 
were then transferred to an X-gal staining solution (which contained 1 ml of 
50mg/ml X-Gal dissolved in dimetylformamide, 82mg K3Fc (CN6), 105 mg K4Fe 
(CN6)3H20, diluted in ~ 49 ml wash buffer) covered from light and incubated at 
32o - 37oC until the desired staining intensity was achieved. After lacZ staining, 
sections were washed several times in distilled water for at least 30 minutes, fixed 
overnight in 4% PFA and then dehydrated through ascending concentrations of 
ethanol (60, 80, 95, and 100%) for 2 minutes each. Sections were cleared twice in 
pure xylene for 1 minute each and then coverslipped with DePex mounting 
medium (BDH). Sections were left in xylene for only a few minutes since it can 
affect the final LacZ stain. Sections were viewed under light microscopy to detect 
the presence or absence of intracellular blue staining. 
 
2.11.6 Sudan Black B staining  
Sudan Black is a fat soluble dye that is used to evaluate fatty tissue such as 
myelin. 0.7 g Sudan Black B (cat no. S0395, Sigma) was dissolved in 100 ml of 
70% ethanol. The mixture was stirred at room temperature for 1 hour and filtered 
through Whatman 3mm chromatography paper. This solution can be kept for 
prolonged periods. 
Sudan Black staining was performed on tissues that were fixed in 4% PFA 
overnight. Sections were rinsed twice in 70% EtOH for a few minutes. Sections 
were then placed in 0.7% Sudan Black solution in 70% ethanol for 10 minutes to 
2 hours (until the desired degree of intensity of staining is attained). Sections were 
rinsed in distilled water and coverslipped with an antifade mounting medium 
(Dako Cytomatin Fluorescent or Citifluor AF1 by Agar). Myelin takes on an 
intense black colour because of the dye. 
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2.11.7 Cell counts in micrographs 
Multiple small black squares, each with a specific surface area of were placed 
within the corpus callosum (CC), motor cortex (MC), or anterior commissure 
(AC) and the number of Sox10-postive or PLP-positive cells were counted for in 
each square and the average was taken. Results of cell counts are expressed per 
measured unit area of the CC, MC, or AC rather than counting the total number of 
cells in the CC, MC, or AC, to avoid bias that may result from the possibility of 
slightly different sized surface areas examined between mice and therefore 
making counting more accurate. These counts were made on a minimum of six 
sections per brain per each two animals per group. All data were presented as 
mean ± SD values for each group. Statistical analysis was performed with the 
Mann-Whitney nonparametric test, and statistical significance was accepted at p< 
0.05.  All statistical analysis was performed using SPSS statistical software. 
 
2.12 Microscope 
 
2.12.1 Light microscope 
Sections were analysed using a Zeiss microscope (Germany) equipped with a 
digital camera (Hamamatsu). Images were captured digitally on a Dell computer 
by using the SimplePCI imaging software. Figures were prepared using Adobe 
Photoshop 6.0 software. 
 
2.12.2 Laser confocal microscope 
Some stained sections were observed under a Leica TCS SP confocal microscope 
using Leica Confocal Software. Figures were prepared using Adobe Photoshop 
6.0 software. 
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Chapter 3 
 
 
Generation and Characterisation of Sox10-DTA 
Transgenic Mice 
 
 
 
3.1 Introduction to Sox10 
 
Sox proteins (Sry-related HMG box) are structurally related to the mammalian 
testis-determining factor, Sry, encoded by a gene on the mammalian Y 
chromosome (Laudet et al., 1993; Wright et al., 1993). To date, more than 20 
vertebrate Sox members have been identified, all of which contain a HMG (High 
Mobility Group) domain. This domain contains DNA-binding surfaces which 
allow sequence-specific DNA-binding. These proteins are sometimes referred to 
as architectural transcription factors since they are known to regulate gene 
transcription by binding to the minor groove of double-stranded DNA and 
inducing a large bend in the DNA helix. This binding action may recruit other 
transcription factors to form an active complex initiating the transcription of target 
genes (Werner et al., 1995). The Sox gene family can be subdivided into eight 
subgroups, A-H (Wegner, M., 2005). Members within each subgroup share 
approximately 80% amino acid identity within the HMG domain and are more 
closely related to members of the same subgroup than to other subgroups. The 
nomenclature of individual Sox genes is based on their order of discovery, starting 
with the archetype Sry, followed by Sox1, Sox2, Sox3, and so on. Human SOX 
proteins are denoted with capital letters and all other species are denoted with 
lowercase letters. 
 
Sox proteins play important roles in many different developmental processes such 
as sex determination, chondrogenesis, neurogenesis, formation of the eye lens and 
generation of B-cells (Wegner, M., 1999). Each Sox gene displays a unique 
temporal and spatial expression profile in vivo during development. However, 
there is a lot of cross-talk and functional redundancy which makes it very difficult 
to assign specific functions to individual genes. 
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The SoxE subgroup is one of the best characterized subgroups. This group 
includes Sox8, Sox9 and Sox10. Sox8 and Sox10 share a 93.7% amino acid 
sequence identity within the HMG box domain, whereas Sox8 and Sox9 share 
98.7% similarity (Schepers et al., 2000).  
 
Sox8 is expressed in the CNS, gonads, and craniofacial structures during 
embryonic mouse development (Schepers et al., 2000).  Knockout mice for Sox8 
develop normally and show no obviously altered developmental phenotype, this 
result suggests a redundancy in function among SoxE proteins (Sock et al., 2001; 
Stolt et al., 2004).  
 
Sox9 plays an essential role in chondrogenesis, in the early stages in mammalian 
sex determination, and in CNS gliogenesis. Mutations in the Sox9 gene result in 
severe bone abnormality, XY sex reversal, and defects in the specification of OLs 
and astrocytes (Chaboissier et al., 2004; Barrionuevo et al., 2006; Stolt et al., 
2003).  
 
Sox10 plays an important role in neural crest development. It is involved in the 
early development of neural crest derived tissues, such as melanocytes, enteric 
nervous system, and Schwann cells. It also has an important role in the 
development of OLs. Like most Sox proteins, Sox10 was first identified by RT-
PCR using degenerate oligonucleotide primers on total RNA from E11.5 mouse 
embryos. The PCR products were cloned and sequenced to reveal the novel gene 
(Wright et al., 1993). The mouse Sox10 gene is located on chromosome 15 and 
contains five exons and four introns. The size of the genomic sequence is about 10 
Kb in length and its mRNA transcript is about 3 kb (Pusch et al., 1998). The 
protein is made up of 466 amino acids with a molecular weight of approximately 
56 kDa (Pusch et al., 1998). 
 
In the spinal cord, Sox10 expression begins at E11.5 in a limited domain in the 
ventral part of the ventricular zone whose position is identical to the pMN 
domain. By E13.5, while some Sox10-positive cells remain in the ventricular 
zone, most cells have dispersed through the ventral half of the developing spinal 
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cord with a few cells in the dorsal region. By E16.5, Sox10-positive cells are 
found throughout the spinal cord (Pringle et al., 1993; Woodruff et al., 2001). Up 
until this point, Sox10-positive cells are found only in the grey matter of the 
spinal cord. At E18.5, Sox10-positive cells start to accumulate in the prospective 
white matter where they begin to terminally differentiate into mature OLs and 
express myelin-specific genes such as PLP, MBP and MAG (Stolt et al., 2002). 
This expression pattern of Sox10 is characteristic of OL lineage cells since 
comparative immunohistochemical analysis on adjacent sections or double 
immunolabeling with other known OL lineage markers such as PDGFRα and 
Olig2 reveal strongly overlapping expression patterns. During development, Olig2 
expression slightly precedes that of Sox10, whereas PDGFRα expression follows 
Sox10 by one day. Mature OLs lose their PDGFRα expression while Olig2 and 
Sox10 are expressed throughout the entire lineage. 
  
In the developing telencephalon, Sox10 expression begins slightly later than in the 
spinal cord. It begins approximately a day later at E12.5 in the ventral region from 
the medial ganglionic eminence (MGE) to the anterior entropeduncular (AEP) 
(Pringle et al., 1993; Woodruff et al., 2001; Tekki-Kessaris et al., 2001). As in the 
spinal cord, these cells express Olig2, Sox10 and PDGFRα, migrate extensively 
throughout the grey matter while proliferating, and enter terminal differentiation 
around birth. 
 
Genetic studies in mice have revealed the role of Sox10 in OL development. In 
Sox10-deficient mice, OLPs are specified and develop normally but myelin gene 
expression is nearly absent in these cells suggesting that maturation of OLs is 
dependent on Sox10 (Stolt et al., 2002). OLP specification is not affected, 
probably due to the presence of Sox9 protein since this protein is expressed before 
Sox10 in OLPs. As mentioned previously, loss of Sox9 protein leads to a severe 
decrease in the number of OLPs during embryonic development (Stolt et al., 
2003). In wild-type mice, Sox9 expression in OLPs ends just before these cells 
mature, therefore Sox10 protein is responsible for terminal differentiation of OLs. 
Loss of Sox9 and Sox10 gene function in OLPs after the specification event and 
before terminal differentiation revealed that these two genes are necessary for 
migration and survival of OLPs (Finzsch et al., 2008). Loss of both gene functions 
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lead to altered patterns of OLP migration, increase rate of apoptosis, decrease 
number in OLPs, and a reduction in the expression of PDGFRα, suggesting that 
these genes may regulate PDGF expression. 
 
Despite the importance of Sox10 in nervous system development, little is known 
about how the transcription of this gene is regulated and how it functions to 
regulate gene expression in OLs. What is known is that Sox10 binds directly to 
three sites on the myelin gene promoter of MBP (Stolt et al., 2002). All three sites 
are found in the proximal region of the MBP gene promoter, where site 1 is bound 
by two Sox10 molecules and sites 2 and 3 are bound by single Sox10 molecules. 
Various regions of the MBP promoter were used to drive a luciferase reporter 
gene in order to reveal the binding behaviour of Sox10 (Stolt et al., 2002). Sox8 
was found to bind the same target sites on the MBP promoter as Sox10, but at 
lower affinity. Therefore, Sox8 is thought to be a weaker transcriptional activator 
than Sox10 (Stolt et al., 2004). This may explain why Sox8-deficient mice lack a 
severe phenotype, whereas Sox10-deficient mice fail to generate mature or 
myelin-producing OLs.  More recently, work done in the Richardson laboratory 
has shown that Sox10 physically interacts with Olig1, and this Olig1-Sox10 
complex can activate MBP transcription in vivo (Li et al., 2007). Sox10 protein is 
also known to regulate Connexin32 and Connexin47 genes (Schlierf et al., 2006). 
Connexins are proteins involved in forming gap junctions - intercellular channels 
that allow ions and tiny molecules to move between adjacent cells. 
Oligodendrocytes are known to form gap junctions with neighbouring astrocytes 
(Schlierf et al., 2006). Mice lacking connexion-32 and -47 have thin or no myelin 
sheaths, show extensive OL cell death and axonal degeneration. These mice 
develop tremors, seizures and die around P51 (Menichella et al., 2003; Odermatt 
et al., 2003). 
 
Objective  
 
A transgenic mouse line was developed as a tool for studying OL population 
dynamics in the developing telencephalon and spinal cord. The transgene has the 
structure Sox10-lox-EGFP-STOP-lox-DTA (referred to below simply as Sox10-
DTA). In the presence of Cre recombinase (e.g. when crossed to a Cre-expressing 
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line), the –EGFP-STOP cassette is excised and expression of the Diphtheria toxin 
A chain (DTA) is activated, killing the cells in which it is expressed. As described 
in a later section, this has allowed me to investigate whether multiple origins of 
OLPs produce functionally different OLs. 
 
 
3.2 Results 
 
3.2.1  Mouse Sox10 cDNA probe generation and PAC library screening 
 
The expression profile of Sox10 in both the CNS and PNS is well-known, 
however regulatory sequence elements directing the expression of Sox10 in the 
CNS are yet to be defined. I have used P1-derived Phage Artifical Chromosomes 
(PACs) transgenesis to generate the Sox10 transgene. P1-derived Phage Artifical 
Chromosomes are large genomic constructs used to generate almost all the 
transgenic mouse lines used in this study. The carrying capacity of PACs is 
around 200 kilobases, therefore their size usually ensures that they contain all the 
potential regulatory elements required for authentic gene expression.  In order to 
screen a genomic PAC library for Sox10 clones, a cDNA probe specific to Sox10 
was generated. 
 
Total RNA was isolated from an E15.5 mouse brain and was used as a template 
for synthesis of the first-strand cDNA with both oligo(dT) and random hexamers 
as primers. The cDNA was then used for PCR amplification with various primers 
specific for the Sox10 gene (see Table 3.1 and Figure 3.1). 
 
A 950 bp PCR fragment was amplified, isolated, and ligated into pBluescript II 
SK+. DNA sequencing revealed that the insert cDNA corresponds to the 3’-
untranslated region (3´-UTR) of the Sox10 gene, which is found immediately 
downstream of the stop condon in exon V. 3’-UTR Sox10 cDNA template was 
subcloned into a plasmid vector which was used to generate DNA probes for 
Southern blots by PCR amplification of the insert. Mouse genomic DNA was 
digested with EcoRI, BamHI and NcoI, transferred to a membrane and hybridised 
with [α-32P]dCTP labelled insert DNA. This probe detected a single DNA 
fragment, indicating that it was specific for Sox10 and did not cross hybridise to 
other genes (Figure 3.1 C). The RPC121 Mouse PAC library (UK HGMP 
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Resources Centre) was subsequently screened using the Sox10 probe. Nine 
positive clones were identified: 427-F18, 463-K20, 487-B13, 495-L19, 495-M18, 
506-A9, 532-H19, 532-H2, and 559-I6. These clones were purchased from UK 
HGMP Resource Centre.  
 
 
 
 
 
 
 
 
Primer name Sequence 
5’   3’ 
M/RSox10F1 GTGGTGAGGATTCAGGCTCC 
M/RSox10F2 TTCCCCCAGCCTGTGTGCCC 
M/RSox10R1 CCTCTAAGGTCGGGATAGAG 
M/RSox10R2 GGGCTGGAGTAGCTAGAGGG 
 
Table 3.1 Primer sequence for PCR amplification of various regions within the 
Sox10 gene. Primer pair M/RSox10F1 and M/RSox10R1 is designed to amplify 
the ORF. Primer pair M/RSox10F1 and M/RSox10R2 is designed to amplify the 
entire gene (5’-UTR + ORF + 3’-UTR). M/RSox10F2 and M/RSox10R2 is 
designed to amplify the 3’-UTR region. 
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Figure 3.1 Generation of a Sox10 cDNA probe. (A) Total RNA was extracted 
from fresh mouse E15.5 brain tissue using the Trizol methodTM (Life 
Technologies, Inc.) Two distinct bands corresponding to the 18S and 28S 
ribosomal RNA are seen on a 1% agarose gel stained with EtBr. (B) After reverse 
transcription of total RNA, PCR with three different primer sets were used to 
amplify various regions within the Sox10 gene. Lanes 1, 3 and 5 contained cDNA 
and lanes 2, 4 and 6 contained water (negative control).  Lanes 1 and 2 contained 
a primer pair specific for the ORF, Lanes 3 and 4 contained a primer pair that 
should amplify the entire Sox10 cDNA, and Lanes 5 and 6 contained a primer pair 
specific for the 3’-UTR region. The 3’-UTR region was amplified successfully 
which generated a 940 bp fragment (red asterisk). (C) The specificity of the 3’-
UTR of Sox10 as a probe was verified by Southern blot analysis. Genomic DNA 
was isolated from mouse kidney, digested with EcoRI (lane1), BamHI (lane 2) 
and NcoI (lane 3) and hybridised to the Sox10 probe. The appearance of the 
expected size bands at ~ 5 kb in the EcoRI digest, ~ 5.2 kb in the BamHI digest 
and ~ 3.5 kb in the NcoI digest demonstrates that 3’-UTR probe is specific to the 
Sox10 gene. M is the marker lane. 
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3.2.2  Confirmation and characterization of PAC clones 
 
UK HGMP Resource Centre sent the clones as bacterial LB agar stab stocks. 
When they arrived, the cultures were streaked on LB agar plates containing 
25µg/ml kanamycin in order to get single colonies. Three single colonies were 
picked for each clone and grown in LB broth overnight. The following day, PAC 
DNA was isolated by miniprep, digested with EcoRI, electrophoresed, and 
Southern blotted. The blots were probed with the Sox10 probe to confirm the 
presence of the Sox10 gene (Figure 3.2).  The size of each PAC DNA was 
determined by NotI digestion and PFGE analysis (Figure 3.3). NotI digestion 
releases the genomic inserts from the pPAC vector. The digestion was then 
separated by PFGE to estimate the size of the inserts. 
 
The ends of two of the clones were further characterized by inverse PCR cloning 
and DNA sequencing of the PCR products (data not shown). The sequences of the 
PCR products were “blasted” against the mouse genome to determine the location 
of the PAC ends. Basically, PAC-end sequences obtained were compared 
(BLAST) against NCBI 
with internet-based facilities: BLAST, available via, 
www.ncbi.nlm.nih.gov/blast/BLAST.cgi.  PAC clone 1, designated RP21-427-
F18, was chosen for transgene generation because it contained the Sox10 gene 
relatively in the middle and the genomic insert can be easily digested with NotI 
without losing significant amounts of upstream sequences. This clone would most 
likely contain all the regulatory elements that control Sox10 expression in 
different cell types and at different developmental stages. 
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Figure 3.2 Southern blot analysis of PAC clones to confirm the presence of the 
Sox10 gene. Clones were digested with EcoRI and hybridised to the Sox10 probe. 
The expected band size is 5 kb.  
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Figure 3.3 (A) The size of the PAC genomic insert was confirmed by NotI 
digestion and PFGE analysis. The far right lane contains the lambda DNA ladder 
(marker). Other lanes contain DNA from different PAC clones. The 19.5 kb 
pPAC4 vector band is indicated (arrow). Clone 427-F18 was chosen for transgene 
generation. (B) Table listing the estimated genomic insert size of the PACs from 
the NotI digest. This was determined by the sum of the sizes of all bands 
excluding the vector band.  
PAC Clone Insert Size 
427-F18 ~120 kb 
463-K20 ~150 kb 
487-B13 ~30 kb 
495-L19 ~180 kb 
495-M18 ~170 kb 
506-A9 ~160 kb 
532-H19 ~170 kb 
532-H2 ~120 kb 
559-I6 ~145 kb 
 
A 
B 
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Figure 3.4 Diagram summarising the results from Southern Blot analysis of the 
PAC clones containing the Sox10 gene. The relative positions of the genomic 
inserts in each PAC clone are shown above. Black boxes represent the Sox10 
gene. PAC clone 487-B13 digested with NotI yielded a small fragment in size and 
therefore was not analysed further (~ 30 kb in size, figure not shown). The relative 
positions of the genomic inserts in PAC clones 427-F18 and 559-I6 are more 
accurate because they were isolated by the use of inverse PCR, sequenced, and 
sequences were “blasted” against the mouse genome database to determine the 
location of the PAC ends. Scale bar: 20 kb. 
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3.2.3  Construction of the targeting vector for homologous recombination in 
PACs 
 
The design of the targeting vector must fulfil several requirements for effective 
homologous recombination. First, it requires homologous fragments (of at least 50 
bp, generally 500 bp) flanking the transgene in the targeting construct. Second, 
the use of a positive selection marker is necessary to select candidates that have 
undergone homologous recombination. Third, this positive selection marker 
should be capable of removal afterwards. The targeting vector was designed to 
replace exons III, IV and part of V with a floxed EGFP-polyA followed by a DTA 
coding sequence (lox-EGFP-STOP-lox-DTA). The cloning strategy is 
diagrammed in Figure 3.5. Along with EGFP and DTA sequences, it also contains 
4x SV40 polyA (STOP) sequences, a chloramphenicol resistance cassette, 500 bp 
of sequence upstream including the Sox10 ATG initiation codon and 513 bp of 
Sox10 sequence downstream including the TAG stop codon. 
 
All fragments, with the exception of the selection marker (Cm), were PCR 
amplified using Expand High Fidelity Taq polymerase (1732641, Roche) 
subcloned into pCRII-Topo® vector (Invitrogen), and sequenced to confirm that 
no mutations were introduced. All PCR fragments were subcloned into Topo 
vectors because digesting PCR products directly and cloning them into the 
targeting vector was not very efficient in my hands. All primers were designed to 
contain one or more restriction enzyme sites at its 5’ end (underlined in Table 
3.2).  The assembly of the targeting vector was divided into three main parts: (i) 
5’homology; (ii) intronII/exonIII-EGFP-polyAx4; and (iii) intronII/exonIII-DTA-
frt-Cm-frt-3’ homology (Figure 3.5).  
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Primer name Sequence  
5’   3’ 
Gene 
5´mSox10fwdKpn1 GGTACCCCCGAGCTGGACCGCACACC 
 
5´mSox10revHindIII AAGCTTGAAGTGGCGACTCTCCCTGC 
5’homology 
arm 
mSox10fwdSacIIBamHI CCCCGGGGATCCGGGGCTGCACCCGCGTGCCG 
mSox10rev CCCGGGCCCGCCGCCGGGGTCCTCGTG 
 
Part of 
Intron2-Exon3 
eGFPfwd-SmaI+40bp 
Sox10 
 
CCCGGGGGAGGCGGCCGAAGCGGCGGCGGCC
GGGAGCGACATGGTGAGCAAGGGCGAGGAGCTG 
 
eGFPrevXbaI  TCTAGATTACTTGTACAGCTCGTCC 
Endogenous 
SmaI site 
found in exon 
II of Sox10 
plus 40 bp 
downstream of 
that (up to and 
including the 
ATG) 
followed by 
EGFP 
pAfwdXbaI TCTAGAGATCATAATCAGCCATACCAC 
 
pArevPstI CTCCAGTTAAGATACATTGATGAGTTTGG 
 
First SV40 
PolyA  
pAfwdPstI CTCCAGGATCATAATCAGCCATACCAC 
 
 
 
pArevHindIII  AAGCTTTTAAGATACATTGATGAGTTTGG 
 
Second SV40 
PolyA 
pAfwdHindIII AAGCTTGATCATAATCAGCCATACCAC 
 
pArevXhoI CTCGAGTTAAGATACATTGATGAGTTTGG 
Third SV40 
PolyA 
pAfwdXhoI CTCGAGGATCATAATCAGCCATACCAC 
 
pArevSpeIKpnI GGTACCACTAGTTTAAGATACATTGATGAGTTTGG 
Fourth SV40 
PolyA 
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mSox10fwdXhoINotI  CTCGAGGCGGCCGCGGGGCTGCACCCGCGTGCCG 
mSox10rev CCCGGGCCCGCCGCCGGGGTCCTCGTG 
Part of 
Intron2-Exon3  
DTAfwd-SmaI+40bp 
Sox10 
 
CCCGGGGGAGGCGGCCGAAGCGGCGGCGGCCG
GGAGCGACATGGATCCTGATGATGTTGTTG 
 
DTA-FRT-rev 
 
TCGAAGTTCCTATACTTTCTAGAGAATAGGAAC
TTCTCACAAAGATCGCCTGACACGATTTC 
 
Endogenous 
SmaI site 
found in exon 
II of Sox10 
plus 40 bp 
downstream of 
that (up to and 
including the 
ATG) 
followed by 
DTA and the 
first FRT 
3´mSox10fwdSpeI ACTAGTTAGAGGGGCCCTGTCACCACCAGTG 
3´mSox10revSacI GAGCTCAAGGATCAGAGTGTCCCACCCTGC 
 
3’homology 
arm 
 
Table 3.2 Primer sequence for PCR amplification of the genes used to make the 
targeting vector. Sequences underlined are restriction enzyme sites for digestion 
and ligation into vector. Initiation codon is shown in green, stop codon in red.  
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i) 5’ homology arm. This was generated by PCR from PAC DNA, with a KpnI 
site added to the 5’ end and a HindIII site added to the 3’ end of the fragment via 
the PCR primers. This fragment was then cloned into ploxp2-D11KS - a vector 
containing two loxP sites orientated in the same direction within the MCS. The 5’ 
homology arm was placed just before the first loxP site. This ligation yielded a 
recombinant plasmid, called ploxP-5’homol, which was confirmed by restriction 
enzyme digestion (Figure 3.5A).  
 
ii) IntronII/exonIII Sox10 (110 bp) fragment. This was PCR-amplified adding a 
SacII – BamHI site at the 5’ end. EGFP was PCR-amplified from a pBird vector 
with a forward primer that contained the endogenous SmaI site found in exon II of 
Sox10 plus 40 bp downstream of that (up to and including the ATG) and a reverse 
primer that contained an XbaI site. IntronII/exonIII Sox10 PCR fragment was 
digested with SacII and SmaI (endogenous site), and the EGFP fragment was 
digested with SmaI and Xba1. The resulting fragments were subcloned into SacI –
XbaI digested pBluescript (Figure 3.5B, Step1). Next, four polyA signals were 
PCR amplified and cloned downstream of the EGFP stop signal (Figure 3.5B, 
Step2 and 3) (see Table 3.2 for restriction enzyme sites used). Multiple SV40 
polyadenylation signals were cloned to ensure termination of transcription. The 
mechanism of polyA signalling is not well understood. Some investigators believe 
termination does not occur as soon as the RNA polymerase encounters a polyA 
sequence but rather at a distance downstream – termination is thought to be a 
gradual process.  Therefore, in the absence of Cre recombinase, it was important 
to avoid transcription of the transgene after the second loxP site because a splice 
junction is present just before the DTA and another one just before the EGFP. If 
transcription continued, there was the possibility that the EGFP-polyA could be 
spliced out which would lead to the activation of DTA in the absence of Cre. 
Splicing is a co-transcriptional event in which introns are removed and exons are 
ligated together by splicesomes. Multiple copies of polyA may also hasten the 
transport of mRNA from the nucleus to the cytoplasm and therefore decrease the 
amount of mRNA splicing at the 3’end of the transgene. IntronII/exonIII–EGFP–
polyA(x4) fragment was excised from pBluescript with BamHI and SpeI and 
cloned into BamHI–SpeI digested ploxP-5’homol plasmid. The insert was placed 
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between the loxP sites, which yielded a recombinant plasmid called ploxP-
5’homol-intronII/exonIII-EGFP-polyA(x4). 
 
iii) IntronII/exonIII fragment. This was PCR-amplified adding XhoI – NotI 
sites at the 5’-end. DTA was PCR-amplified from a pIBI30-DTAtox176 plasmid 
(donated by Marcus Fruttiger) with a forward primer that contained the 
endogenous SmaI site found in exon II of Sox10 plus 40 bp downstream of that 
(up to and including the ATG) and a reverse primer that contained HindIII. 
IntronII/exonIII Sox10 PCR fragment was digested with XhoI and SmaI 
(endogenous site), and the DTA fragment was digested with SmaI and HindIII. 
The resulting fragments were subcloned into XhoI - HindIII digested pBluescript 
(Figure 3.5C, Step1). Next, the chloramphenicol resistance selection cassette 
(Cmr) was excised from pBluescript by digesting the plasmid with NotI, blunted 
with DNA polymerase Klenow fragment, and digested with SpeI. The 3’ 
homology arm was generated by PCR from PAC DNA, with a SpeI site added to 
the 5’-end and a SacI site added to the 3’-end of the fragment. Then, the Cmr 
cassette and the 3’ homology arm were introduced into the pBluescript vector 
containing intronII/exonII Sox10 fragment and DTA by subcloning into the same 
restriction sites by via a three-way ligation (Figure 3.5C, Step2). To join the 
intron2/exon3–DTA-frt-Cmr-frt-3’homology construct in ploxp-5’homol-
intronII/exonIII-EGFP-polyA(x4), both the construct and plasmid were digested 
with NotI, blunted with Klenow polymerase, and digested with SpeI. This ligation 
yielded a recombinant plasmid called ploxp2-DIIks-Sox10-DTA targeting vector 
(Figure 3.5D). Four to six colonies selected by their Cm resistance were picked 
and checked by restriction enzyme digestion to ensure that they were properly 
constructed. All of the Cmr colonies were properly constructed. This plasmid was 
referred to as the final targeting vector vector +Cmr. Given the large number of 
cloning steps, all gene junctions in the final targeting vector were sequenced to 
ensure no unwanted inserts or deletions occurred during the assembly. Prior to 
homologous recombination, the entire construct was excised from the vector with 
SacI and KpnI, gel purified and its concentration measured.  
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3.2.4  Generation of pPAC4 Sox10-DTA by homologous recombination 
 
The first step in homologous recombination was to electroporate the desired 
pPAC4 vector containing the Sox10 gene into bacterial strain carrying the genes 
required for recombination. The recombinant strain used in this study was EL250 
E.coli. This strain contains recombination genes, such as exo, beta and gam, 
which are under the control of a temperature-sensitive lamda repressor which is 
inactive at 42oC and active at 32oC. When the recombination genes are switched 
on (at 42oC) the bacterial cells become more recombinogenic and take up linear 
DNA without degrading it. Gam inhibits E.coli exonucleases from attacking the 
linear DNA, and exo and beta are involved in the recombination event. 
 
The next step was to replace the Sox10 ORF in the pPAC4 with the targeting 
construct. The targeting fragment was excised as a 5.0 kb SacI-KpnI fragment 
from transgenic vector and purified by gel electrophoresis. 200 ng of the 
linearised targeting fragment was electroporated into 50µl of electrocompetent 
EL250. Cells were plated on Cm plates and incubated at 32oC for 12-24 hours, 
during which the lamda repressor becomes active and represses expression of the 
recombination genes.  
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Figure 3.6 Strategy for targeted PAC modification. (A) Structure of the Sox10 
gene in PAC. (B) The targeting vector was first constructed (containing a floxed 
EGFP, DTA and a floxed Cmr) and then recombined in PAC via the two regions 
of homology. (C) Sox10 gene in PAC after homologous recombination. Dashed 
lines indicate the regions of homology. Large black arrowheads, loxP sites; Cmr, 
chloroamphenical resistance gene; light blue line, homology arms; light blue 
boxes, Sox10 exons; circled “F”, frt sites. The blue arrows indicate the location of 
the PCR primer pair used for genotyping Founders and progeny. 
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When homologous recombination occurs between the endogenous locus and the 
targeting vector, crossing over can happen at multiple sites due to the presence of 
four homologous sequences in our targeting fragment. Therefore, homologous 
recombination can take place in six different ways:  
 
1. crossing over the 5’ homology and the 3’ homology resulting in a targeted 
gene containing the entire targeting construct  
2. crossing over at the 5’ homology and the first intronII/exonIII sequence  
(just before the EGFP) resulting in a targeted gene containing only one 
loxP sequence  
3. crossing over at the 5’ homology and the second intronII/exonIII 
sequence (just before the DTA) resulting in a targeted gene containing a 
floxed EGFP-polyAx4  
4. crossing over at both the intronII/exonIII sequences resulting in a 
targeting gene containing the EGFP-polyAx4 sequence and only one loxP 
site 
5. crossing over at the first intronII/exonIII sequence and the 3’ homology 
resulting in a targeted gene containing the entire construct minus the first 
loxP site 
6. crossing over at the second intronII/exonIII sequence and the 3’ 
homology resulting in a targeting gene containing DTA and FRT-flanked 
Cmr cassette 
 
Cells that have undergone the second, third and fourth type of recombination will 
not survive due to the lack of the Cmr cassette. Therefore, three types of 
homologous recombination will probably survive. This will reduce the targeting 
rate to one-third because only the first type of recombination event is needed in 
this study. Colonies were checked for correct-site insertion of the fragment by 
PCR for EGFP, DTA and polyA. To ensure the first LoxP site is present, we 
designed PCR primers that amplified the 3’end of the 5’ homology and the 5’ end 
of EGFP. The PCR product was then sequenced to ensure the recombined PAC 
contained the first LoxP site. 
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Two correct chloramphenicol resistant colonies were grown in culture overnight. 
Removal of the chloramphenicol resistant cassette from the two selected clones 
was carried out the following day by endogenous flpe activity by L-arabinose 
induction. E. coli strain, EL250, contains an arabinose-inducible Flpe gene that is 
used to direct the excision of an frt site-flanked chloramphenicol selection cassette 
after recombination (Buchholz et al., 1998, Lee et al., 2001). Endogenous flpe 
activity was induced in these colonies by the addition of L-arabinose to the 
medium to remove the floxed Cmr cassette. Colonies were screened for Cm 
sensitivity by growing them on kanamycin and chloramphenicol plates. Colonies 
that grew only on the kanamycin-containing plates were those in which removal 
of the Cmr cassette was successful. In order to confirm this, PAC DNA was 
isolated from eight clones, digested with NcoI, and Southern blotted with a Sox10 
3’-UTR probe. Removal of the Cmr cassette caused the detected band to shift 
from 3.4 kb to 11.75 kb (Figure 3.7). The integrity of one of the final modified 
PAC clones was verified by Southern blot using an EGFP probe (Figure 3.8).  
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Figure 3.7 Southern blot analysis of the restriction digest pattern of the modified 
pPAC4-Sox10DTA before and after the removal of the Cm selection cassette by 
Flpe recombinase. DNA was digested with NcoI and hybridised to a Sox10 3’-
UTR probe. The red arrow corresponds to the recombinant PAC before the 
removal of the Cm cassette (3.4 kb band). The blue arrow corresponds to the 
recombinant PACs after the removal of the Cm cassette (11.75 kb). M is the 
marker lane. All recombined PAC clones show a band shift to 11.75 kb 
corresponding to the size predicted for the Sox10 locus once recombination with 
the targeting vector and excision of the Cm selection cassette had occurred. 
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Figure 3.8 The integrity of the final modified PAC clone was confirmed by 
restriction digestion and Southern blotting. One of the modified clones in Figure 
3.6 was chosen for further analysis. The PAC clone was digested with various 
restriction enzymes, Southern blotted and probed with an EGFP probe. The 
expected band sizes were 1.3 kb for SmaI/HindIII, 5.3 kb for KpnI/SacI, 0.9 kb 
for XbaI/EcoRI, 1.7 kb for SmaI/SpeI, 2.0 kb for BamHI, 1.5 kb for PstI, 6.9 kb 
for EcoRI, 2.5 kb for AseI/EcoRV, and 4.6 kb for EcoRV/SacI. Non-specific 
bands are indicated by red arrows.  
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3.2.5  Pronuclear microinjection of the modified PAC insert 
 
As soon as the modified PAC was ready, the next step was to introduce it into 
mice by pronuclear microinjection. The modified PAC DNA was purified by 
routine alkaline lysis, followed by NotI restriction enzyme digest - to release the 
modified genomic insert from the PAC backbone. NotI digest released the 
genomic insert in two fragments; 30 kb and 130 kb, which were separated by 
pulsed-field gel electrophoresis PFGE. The 130 kb fragment was cut from the gel, 
rotated vertically relative to its original electrophoresis migration and subjected to 
electrophoresis in 4% low-melting point agarose. The concentrated PAC insert 
was excised from the gel, equilibrated with tempa buffer, melted and digested 
with agarase, and dialysed against microinjection buffer. After dialysis, the 
concentration as well as the integrity of the purified PAC insert was checked by 
PFGE (Figure 3.9). The quality of the DNA is one of the most crucial factors for 
successful generation of transgenic mice. Purified PAC insert DNA was injected 
into the pronuclei of C57BL6xCBA fertilized mouse oocytes (single cell) at a 
concentration of 1-2 ng/µl. Injected oocytes were transferred into the oviducts of 
pseudopregnant foster mice, strain CD-1, either on the same day or left to divide 
once overnight in a 37oC incubator. Multiple rounds of injection resulted in 99 
pups being born from 22 successful transfers. Pronuclear microinjections were 
performed by Ulla Dennehy and myself in the WIBR transgenic facility. 
 
3.2.6  Screening potential transgenic founder mice 
 
At three weeks of age, putative founder mice were weaned and screened for the 
presence of the transgene by PCR and Southern blot analysis of tail DNA. In 
order to detect the presence of the Sox10-DTA transgene in a mouse, various 
primer sets were designed and their ability to amplify a region within the 
transgene was tested. PCR reactions and programming needed to be optimized for 
sensitive detection. To check the specificity and sensitivity of the PCR, a positive 
control vector (modified PAC DNA) was used as a template and tested at a series 
of concentrations. The positive control vector was diluted from 1:1000 to 
1/50,000 in wild-type mouse genomic DNA.  Unmodified PAC DNA, wild type 
mouse genomic DNA, and water were used as negative controls. Of the three 
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primer sets, one set successfully amplified a region within the transgene. This 
primer set detects the presence of the 3’ end of the DTA fragment and the 5’ end 
of the 3’ Sox10 homology arm (Figure 3.6C, arrows). Putative founder mice were 
rapidly screened by PCR using this primer set. A positive control using the 
modified PAC DNA (diluted 1/50,000 in wild type mouse genomic DNA) and 
two negative controls (wild type DNA and water) were used in every PCR screen. 
Of 99 pups, 10 founders were positive for Sox10-DTA. Finally, pups were 
screened further by Southern blot to verify the transgenic status, because Southern 
blot is much less prone to false-negative or false-positive results PCR. Mouse 
genomic tail DNA was digested overnight at 37oC with EcoRI which cuts only 
once within the transgene. The digested DNA was subjected to electrophoresis in 
a 0.8% (w/v) agarose gel, transferred to a HybondTM-XL membrane, and 
hybridised with the 900 bp Sox10 3’-UTR cDNA probe. The results of the 
Southern blots completely correlated to the results from PCR. This result 
suggested that in this system, both the PCR and the Southern blot analysis are 
reliable methods for genotyping. Figure 3.10 is an example of the genotyping 
results. 
 
The ten identified founder mice were crossed with wild-type mice of the same 
strain. Founders that exhibited germ-line transmission of the transgene gave rise 
to independent transgenic mouse lines. Only three of those founders displayed 
germ-line transmission of the transgene. The remaining seven founders were 
either infertile (2), went missing (1), died (1) or lacked germ-line transmission 
(3).These seven founders were sacrificed. Analysis of transgene expression and 
the consequences of expression in the three established lines were conducted in 
the offspring. Animals from the first generation were studied for transgene 
expression. These lines were designated 1/1, 17/4, and 20/3. All three transgenic 
founders and their offspring appeared to have a normal phenotype and were 
healthy. The transgenic mice were morphologically indistinguishable from their 
wild-type littermates and reproduced normally, with a typical litter size of eight to 
twelve pups.   No obvious differences in phenotype suggest that there was no 
DTA expressed from the unrecombined transgene. These mice exhibited no 
obvious difference in life expectancy from control mice, and both male and 
female Sox10-DTA mice had normal reproductive ability. Under ultraviolet 
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illumination, transgenic offspring could be distinguished from their wt littermates 
by fluorescence in the brain and peripheral tissues. 
 
 
 
 
 
 
 
 
 
Figure 3.9 PFGE of purified NotI-digested recombinant PAC 427-F18. Lane 1 
contains 1 µl, Lane 2 contains 3 µl, and Lane 3 contains 5 µl of recombinant PAC 
427-F18. Lane 4 contains 3 µl of a previously injected PAC preparation for 
comparison. M is the marker lane. 
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Figure 3.10 Screening putative founder mice for the Sox10-DTA transgene. (A) 
PCR analysis of founder mice. Integration of the transgene is indicated by a 600 
bp band (red arrow). The negative control was wild type genomic DNA. The 
positive control was a dilution of modified PAC DNA in wild type DNA. (B) 
Southern blot with Sox10 3’-UTR probe on putative founders. Integration of the 
transgene is indicated by a 5.5 kb band (blue arrow). The endogenous band is 4.6 
kb. M is the marker lane and F is a founder. 
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3.2.7 Analysis of the EGFP expression in the CNS of Sox10-DTA transgenic 
animals 
 
The expression pattern of EGFP in the three transgenic founder lines was 
evaluated in the forebrain and spinal cord in order to assess whether it closely 
mimicked the expression of endogenous Sox10. The developmental time points 
examined were E12.5, E16.5, P0.5 and adults (P50-60). As a control, wild-type 
littermates were examined at the same time points as Sox10-DTA mice, and the 
presence of endogenous Sox10 protein and/or RNA transcripts were assessed. 
Embryos were initially screened for transgene expression under a fluorescence 
dissecting microscope. EGFP fluorescence was seen in the inner ear, the salivary 
gland, and in the sensory fibres from the DRG which are found along the entire 
length of the vertebral column. This proved to be a simple and reliable method for 
identifying Sox10-DTA embryos and newborn pups. 
 
Intrinsic EGFP fluorescence is destroyed by overnight fixation in 4% PFA. To 
circumvent this, a GFP antibody (Abcam) was used to immunolabel sections. The 
primary rabbit antiserum was used at 1:8000 dilution and was visualized with a 
fluorescein isothiocyanate (FITC)-conjugated anti-rabbit IgG. Tissue blocks were 
fixed in freshly prepared 4% PFA as described in Chapter two (section 2.11) and 
analysed using fluorescence immunohistochemistry and in situ hybridisation. 
EGFP expression was detected using fluorescence and endogenous Sox10 
expression was detected by in situ hybridisation using DIG-labelled RNA probes 
and/or by fluorescence immunohistochemistry.  
 
EGFP expression in the developing telencephalon 
 
Previous studies have indicated that during forebrain development Sox10-positive 
oligodendrocyte precursor cells first appear around E12.5. These cells arise from 
the ventral neuroepithelium of the forebrain in the VZ and SVZ between the 
anterior hypothalamus and MGE. Therefore, EGFP expression was analysed 
beginning at E12.5 in my three Sox10-DTA lines. 
 
In two of the lines (17/4 and 20/3) EGFP first appeared at E12.5 in the ventral 
telencephalon where endogenous Sox10-positive cells are normally found (Figure 
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3.11). EGFP expression in line 1/1 differed from that of endogenous Sox10, being 
expressed ectopically in the developing cortex, so line 1/1 was excluded from 
further analysis. Lines 17/4 and 20/3 were found to produce identical patterns of 
EGFP expression. Line 17/4 was chosen for further forebrain analysis. At all time 
points analysed (E16.5, P0.5 ad P10), EGFP expression closely resembled 
endogenous Sox10 expression. At E12.5, both Sox10 and EGFP expression were 
restricted to the MGE and anterior entopeduncular area (AEP) (Figure 3.11 O, P). 
By E16.5 EGFP-positive cells were scattered throughout the entire forebrain like 
the expression of endogenous Sox10 (Figure 3.12). Double immunolabelling for 
EGFP and Sox10 showed that, at E16.5, all EGFP-positive cells analysed were 
also positive for Sox10 (Figure 3.12 C1, C2, C3).  
 
At P0.5 and P10, EGFP/Sox10 double immunolabelling confirmed that EGFP and 
Sox10 were co-expressed in the same cells, indicating that transgene expression 
was restricted to the oligodendrocyte lineage (Figures 3.13 and 3.14). At P10, I 
analyzed two animals and performed counts in at least three (3-4) sections for 
each region in the telencephalon per mouse that reproduced greater than 95% of 
the cells in the brain region that co-expressed Sox10 and EGFP. In particular, I 
found only one cell that expressed EGFP but not Sox10 in one section in one 
mouse in the preoptic area (POA). In the cortex, I counted on average 185 cells 
per section where only one or two of those cells at most were Sox10+EGFP-; no 
EGFP+Sox10- cells were detected. In the CC, on average 86 cells per section were 
counted. Only 2 cells, at most, per section were Sox10+EGFP- (2.3%). In the AC, 
an average of 77 cells was counted per section, where only 1 Sox10+EGFP- cell at 
most was detected per section. The highest occurrence of Sox10+EGFP- cells was 
found in the VZ. An average of 166 cells were counted per section, where 7 cells 
(at most) were Sox10+EGFP- (4.2%). One explanation for this slightly higher 
occurrence in the VZ is that some of these Sox10-positive cells have just been 
born and have not turned on their transgene yet. Overall, the number of 
Sox10+EGFP- cells that appeared in various regions of the telencephalon was 
always less than 5%. 
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Figure 3.11 Expression of EGFP in forebrain of Sox10-DTA founder lines at 
E12.5. In situ hybridisation for Sox10 was performed on wild-type coronal 
sections (A, B, C, D, I, J, K, L) and EGFP immunohistochemistry was used to 
detect transgene expression on founder sections (E, F, G, H, M, N, O, P). In 
founder line 1-1, ectopic EGFP (but not endogenous Sox10 mRNA) was detected 
in the dorsal forebrain (E, F, G, H arrows). In founder line 17-4, the profile of 
EGFP expression corresponds closely to that of Sox10 indicating the transgene is 
regulated in the same way as the endogenous Sox10 (arrowheads). Sox10 
expression is observed in the ventral and more posterior regions of the forebrain 
(K, L); strong EGFP expression is similarly observed in this region (O, P). 
Founder line 20-3 was similar to 17-4 (data not shown). Scale bar, 1 mm. 
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Figure 3.12 In situ hybridisations and/or immunohistochemistry for PDGFRα, 
Sox10 and EGFP on serial sections of a Sox10-DTA mouse (line 17-4) at E16.5. 
Coronal sections taken at different levels along the rostrocaudal axis of the 
developing forebrain. EGFP (C, F, I) expression is observed in the forebrain in a 
pattern comparable with endogenous Sox10 (B, E, H) and PDGFRα (A, D, G).  
Co-expression of EGFP and endogenous Sox10 proteins was demonstrated by 
double-labelling (C, F, I).The area within the box in panel C is shown magnified. 
Expression of EGFP (green) and Sox10 (red) are localized in the same cells 
bodies, establishing that EGFP fluorescence accurately labels Sox10 cells (C1, 
C2, C3). Scale bars, (A-I) 1mm, (C1, C2, C3) 100 µm.   
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Figure 3.13 Transgenic expression of EGFP in the telencephalon of a Sox10-
DTA mouse (line 17-4) at P0.5. Panels A, B and C are images of serial coronal 
sections showing that EGFP (C) is expressed in a similar pattern to Sox10 (B) and 
PDGFRα (A). (A, B) are in situ hybridisations, C immunolabelling with a rabbit 
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polyclonal antibody against EGFP (green). Sections (D-W) were double 
immunolabelled with a rabbit polyclonal antibody against EGFP (green) and a 
Guinea Pig antiserum against Sox10 (red) as indicated. Co-localisation between 
EGFP and Sox10 appear as yellow in the merged images (F, J, N, R, V). Cell 
nuclei were stained with Hoescht (blue) to show tissue morphology. Note that 
Sox10 is localized in the nucleus, whereas EGFP is found to be distributed in the 
cell bodies and processes. CTX, cortex; VZ, ventricular zone; CC, corpus 
callosum; AC, anterior commissure; POA, preoptic area. Scale bars, (A, B, C) 
1mm, (D-W) 100 µm. 
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Figure 3.14 Transgenic expression of EGFP in the telencephalon of a Sox10-
DTA mouse (line 17-4) at P10. A coronal section (A, B, C) of a Sox10-DTA 
mouse immunolabelled with anti-GFP (green) and anti-Sox10 (red) antibodies. 
EGFP (A) is expressed in the same regions in which Sox10 (B) is expressed. Co-
localization between Sox10 and EGFP appears as orange/yellow in the merged 
images (C, F, J, N, R, V). Cell nuclei were stained with Hoescht (blue). CTX, 
cortex; VZ, ventricular zone; CC, corpus callosum; AC, anterior commissure; 
POA, preoptic area. Scale bars, (A,B,C) 1mm, (D-G) 100 µm, (H-W) 200 µm. 
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EGFP expression in the adult telencephalon  
 
To further characterise the EGFP expression pattern, adult Sox10-DTA mice (line 
17-4) were analysed for the presence of green fluorescence in forebrain tissue. In 
adult animals (Figure 3.15), strong EGFP expression continued in the forebrain. 
Analysis of adult brain showed vivid fluorescence in white matter tracts, such as 
corpus callosum (CC) and anterior commissure (AC). These areas are known to 
have a large proportion of fully differentiated or mature OLs.  It was expected that 
EGFP expression would continue to mimic the endogenous Sox10 expression 
profile. In the adult (P50-P60), all EGFP-positive cells were found to co-localise 
with Sox10 (Figure 3.16). EGFP expression was high in virtually every Sox10-
positive cell.  
 
I analyzed two animals and performed counts in three sections for each region in 
the telencephalon (CC, AC, and CTX) per mouse. More than 95% of the cells in 
these brain regions co-expressed Sox10 and EGFP. In the AC, an average of 609 
cells was counted per section. Out of 609 cells, 14 cells on average were 
Sox10+EGFP- and only one cell on one section in one mouse was found to be 
Sox10-EGFP+. In the AC, only 2.3% (at most) of the cells were Sox10+EGFP-.  In 
the CC, an average of 439 cells was counted per section, where an average of 20 
cells was detected to be Sox10+EGFP- (4.6%), and 2 cells were detected to be 
Sox10-EGFP+ (0.5%). In the cortex (CTX), I counted an average of 816 cells per 
section, where about 12 cells per section were Sox10+EGFP- (1.5%) and 
approximately 2 cells per section were Sox10-EGFP+ (0.2%). Overall, the number 
of Sox10+EGFP- cells that appeared in various regions of the telencephalon was 
always less than 5%.This shows that the mouse model is robust in terms of EGFP 
and Sox10 co-localization. 
 
The profile of EGFP expression is faithful to the endogenous Sox10 expression. 
EGFP expression remains strong throughout all areas of the telencephalon. EGFP 
signal was detected not only in the cell body of OLs but also in their processes.  
This may explain why white matter regions exhibited more intense labelling 
compared to gray matter regions. White matter OLs generally have more 
processes (and internodes) than grey matter OLs (Fulton et al., 1992). 
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Figure 3.15 Transgenic expression of EGFP in the telencephalon of an adult 
Sox10-DTA mouse. CTX, cortex; CC, corpus callosum; AC, anterior commissure. 
Image shown is composed of 30 higher magnification (20x objective) photos 
combined into one montage. Scale bar, 1 mm. 
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Figure 3.16 Three coronal sections (A, D, G) of an adult Sox10-DTA mouse 
immunostained with anti-GFP (green) and anti-Sox10 (red) antibodies. Sox10-
positive OLPs and OLs in the Sox10DTA mouse co-expressed EGFP, 
demonstrating the veracity of transgene expression. AC, anterior commissure; CC, 
corpus callosum; CTX, cortex. Scale bars, (A-F) 0.4 mm, (G-I) 0.5 mm. 
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EGFP expression in spinal cord 
 
The expression of EGFP was assessed at various stages in development in the 
spinal cords of all three founder Sox10-DTA lines.   
 
Transverse spinal cord sections were double-labelled with an antibody to EGFP 
and an in situ hybridisation probe to Sox10. No expression of EGFP could be 
detected in these lines at E10.5. At E11.5 EGFP protein was expressed in a 
narrow band at the border of the ventricular zone in the pMN domain of the 
ventral spinal cord, where endogenous Sox10 is normally expressed. EGFP 
expression was also detected in the dorsal half of the developing spinal cord at 
E11.5 in all three founder lines. EGFP expression was weaker in the dorsal half 
when compared to the pMN domain. At first it was thought that this was ectopic 
EGFP expression, but in situ hybridisation with Sox10 riboprobe in wild-type 
spinal cords revealed a weak dorsal expression pattern (Figure 3.17 D, arrow). 
This dorsal expression pattern was missed in the past because it required a longer 
staining time for it to appear when compared to the ventral expression pattern. For 
the dorsal expression to appear, tissue sections were kept in the staining solution 
for an extra 2-3 hours. The expression pattern shown in Figure 3.17 D is the 
endogenous pattern of Sox10. 
 
Like Sox10, EGFP was found in dispersed cells at E14.5; these cells were 
predominantly located in the ventral part of the spinal cord with a few cells 
located in the dorsal region (data not shown). Like Sox10, EGFP-expressing cells 
were uniformly distributed by E16.5 in the grey matter, with very few cells still 
present in the VZ (Figure 3.18). At around the time of birth, EGFP-positive cells 
began to accumulate in the presumptive white matter (Figure 3.19). 
 
In the adult spinal cord, a high density of EGFP-expressing cells was found in the 
white matter, whereas scattered EGFP cells were seen in gray matter (Figure 
3.20). Analysis of adult spinal cord showed vivid fluorescence in highly 
myelinated areas, such as the dorsal funiculus. 
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Double-labelling confirmed that EGFP was expressed in the same cells that were 
positive for Sox10 indicating that EGFP fluorescence was restricted to the Sox10 
lineage in the spinal cord (Figures 3.17 C3; 3.18 C3; 3.19 E, H and 3.20 C, C3). 
Therefore, EGFP faithfully recapitulates Sox10 expression through all stages of 
OL development in both the telencephalon and spinal cord. 
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Figure 3.17 Transgenic expression of EGFP in the spinal cord of a Sox10-DTA 
mouse at E12.5. In situ hybridisations for PDGFRα (A) and Sox10 (B), and 
immunohistochemistry for EGFP (C) on serial cross-sections. Double-
immunohistochemistry was performed with antibodies directed against EGFP 
(green) and Sox10 (red). Panel C is shown magnified (C1, C2, C3). Panels C1, 
C2, and C3 show a cluster of newly specified OLPs located in a restricted region 
of the ventral ventricular zone, known as the pMN domain. Coexpression of 
EGFP and endogenous Sox10 protein was demonstrated by double-labelling (C3) 
in the pMN domain. Arrows indicate a weak dorsal expression of endogenous 
Sox10 (B, black arrow) and EGFP (C, white arrow). Endogenous expression of 
Sox10 in E12.5 wild-type spinal cord (D). In situ hybridisation for Sox10 in E12.5 
wild-type spinal cord (D). Endogenous expression is seen in both in the pMN 
domain and in more dorsal regions (D, black arrow). Scale bars, (A,B,C) 200 µm, 
(C1,C2,C3) 100 µm. 
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Figure 3.18 Transgenic expression of EGFP in the spinal cord of a Sox10-DTA 
mouse at E16.5. In situ hybridisations with PDGFRα (A) and Sox10 (B) specific 
probes were performed on serial cross-sections. Immunohistochemistry for EGFP 
(C1, green) and Sox10 (C2, red) were also carried out. Coexpression of EGFP and 
Sox10 is visible as a yellow signal in panel C3. There is strong overlap between 
EGFP and Sox10, verifying the authenticity of transgene expression. Counts on 
two animals; four sections per mouse were performed. An average of  440 cells 
were counted per section, where 438 were Sox10+EGFP+ (99.5%), 2 were 
Sox10+EGFP- (0.5%), and no Sox10-EGFP+ were found.  
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Figure 3.19 Transgene expression of the EGFP marker in the spinal cord of a 
Sox10-DTA mouse at birth. Distribution of Sox10 mRNA transcript (A) and GFP 
protein (B) in a serial cross-section. Grey and white matter regions were 
immunolabelled with anti-GFP (C, F) and anti-Sox10 (D, G) antibodies. 
GFP/Sox10-positive cells are distributed throughout the spinal cord (E, H). EGFP 
(green) is detected in all the cells that are Sox10-positive (red). Counts on two 
animals; four sections per mouse were performed. An average of  904 cells were 
counted per section, where 893 were Sox10+EGFP+ (99%), 11 were Sox10+EGFP- 
(1%), and no Sox10-EGFP+ were found. Scale bars, (A,B) 0.5 mm, (C-H) 250 µm. 
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Figure 3.20 Cross-section of an adult Sox10-DTA spinal cord showing vivid 
EGFP fluorescence in both the grey and white matter regions. Sox10 
immunolabelling of the spinal cord shows that most EGFP-postitive cells (green) 
also express Sox10 (red). The area within the box in panel C is shown magnified 
(C1, C2, C3). Counts on two animals; three sections per mouse were performed. 
An average of 1200 cells were counted per section, where 1177 (98%) were 
Sox10+EGFP+, 18 (1.5%) were Sox10+EGFP-, and 5 (0.5%) were Sox10-EGFP+.  
Scale bars, (A,B,C) 1 mm, (C1,C2,C3) 0.5 mm. 
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3.2.8 Functional analysis of the Sox10-DTA strain 
 
The next important question to answer was whether or not the DTA transgene 
could be successfully activated in the OL lineage. In order to test the functionality 
of the Sox10-DTA strain and whether ablation is specific to OLPs, we took 
advantage of an available Olig2-Cre knock-in mouse line and crossed it to our 
Sox10-DTA line. As mentioned previously, Olig2 is a transcription factor that is 
required for the generation of motor neurons and OLs in mice (Lu et al., 2002). In 
the Olig2-Cre mouse, Cre recombinase expression is controlled by endogenous 
Olig2 promoter and its regulatory sequences in a BAC. In our double-transgenic 
offspring (Sox10-DTA/Olig2-Cre), Cre recombinase is expressed in neuronal 
precursors and throughout the OL lineage, where it has the ability to remove the 
floxed EGFP thus activating transcription of DTA. DTA will only be activated in 
cells that express Sox10, therefore only cells that express (or have expressed) Cre 
recombinase and Sox10 will express and be killed by DTA. 
 
In one of the lines (founder line1/1), double-transgenic (dTg) offspring (Sox10-
DTA/Olig2-Cre) developed normally till P16-18, but after that they showed a 
slight tremor and weakness of the tail when attempting movement. These pups 
also exhibited recurrent seizures and died around P18-21.  
 
In contrast to Line 1/1, dTg offspring (Sox10-DTA/Olig2-Cre) from lines 17/4 
and 20/3 unexpectedly died at P1. These pups were easily distinguished from their 
wild-type or single-transgenic littermates several hours after birth by the lack of 
milk in their stomachs. Postnatal death was probably due to starvation since unfed 
wild-type newborns typically died at this age. Mutants did not survive longer 
when their normal wild-type littermates were removed, therefore death was not a 
result of the inability of these mutants to compete with more fit littermates. These 
mutant pups were never abandoned because they were always found intermixed 
with their littermates under the mother. Manual stimulation of the mouth region 
evoked jaw movements in these mutants and suckling noises could be heard when 
these pups were placed close to the ear, but I could not determine whether the 
pups were able to suckle properly. Mutant pups typically had a flexed posture of 
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the forelimbs at all times. This probably made it difficult for these pups to move 
toward or grasp the mother’s nipple for milk. Further analysis carried out on these 
pups revealed a decrease in the number of motor neurons in the spinal cord when 
compared to control littermates (Figure 3.21).  It is believed that the transgene in 
lines 17/4 and 20/3 may have been turned on slightly sooner than in line 1/1, 
therefore, some motor neurons were ablated. EGFP was not observed at E9.5 or 
E10.5 (data not shown), however the transgene might have been turned on just 
before motor neuron production ceased around E12. Founder lines 17/4 and 20/3 
were not used further for spinal cord studies. 
 
To verify the expected ablation pattern, I analysed the presence of OLPs and OLs 
in the developing spinal cord and forebrain in Sox10-DTA/Olig2-Cre mice by 
immunohistochemistry and in situ hybridisation. Sox10-DTA/Olig2-Cre double-
transgenic mice were first analysed at birth. These pups were identified by 
dissecting out their brains and spinal cords and examining them under a 
fluorescence microscope. Pups positive for both transgenes were identified as 
having green fluorescence in the DRGs and no fluorescence in the CNS. The 
genotypes of these pups were confirmed by PCR analysis. The effectiveness of 
the DTA transgene was evaluated in the spinal cord by immunohistochemistry 
and in situ hybridisation. Founder line 1/1 is a good model for spinal cord studies. 
 
In sharp contrast to Sox10-DTA controls, no cells positive for Sox10 or EGFP 
could be detected in spinal cords of double-transgenic pups (Figure 3.22). At birth 
and at P13, in situ hybridisation revealed no signals for PDGFRα or PLP (Figures 
3.23C, D and 3.24F) indicating the absence of both OLPs and differentiated OLs. 
Immunohistochemistry using antibodies against CC1 (mature OL marker), NeuN 
(neuronal marker) and GFAP (a generic astrocyte marker) revealed a complete 
lack of CC1 labelling in the double-transgenics, however NeuN and GFAP 
immunolabelling were comparable to controls (Figure 3.25). Therefore, 
oligodendrogenesis but not neuron or astrocyte generation is affected in Sox10-
DTA/Olig2-Cre mice. 
 
The effectiveness of the DTA transgene was also evaluated in the forebrain by 
immunohistochemistry and in situ hybridisation. Founder line 17/4 was used in all 
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forebrain experiments in this Thesis. Double-transgenic mice, Sox10-DT/Olig2-
Cre, were assessed for the presence of EGFP and Sox10 protein in the 
telencephalon (Figure 3.26). These mutant mice had no EGFP or Sox10-positive 
cells detected in various regions of the telencephalon, including the lateral cortex, 
motor cortex, corpus callosum, anterior commissure, and preoptic area at birth. In 
situ hybridisation was performed with a PDGFRα riboprobe to ensure that all 
OLPs were ablated (Figure 3.27). Double-transgenic mice were completely 
devoid of PDGFRα transcripts in the CNS, demonstrating that they had undergone 
complete ablation of these cells. There were, however, a few Sox10-expressing 
cells found only within the subventricular zone. These cells were weakly labelled 
with Sox10 and were smaller in size when compared to control tissue. These cells 
are thought to be newly generated OLPs whose DTA transgene has just been 
activated because no Sox10-positive cells were found beyond the subventricular 
zone (Figure 3.27B). 
 
Efficiency of OLP ablation was revealed by in situ hybridisation and 
immunohistochemistry with OL lineage markers, such as Sox10, PDGFRα, PLP, 
and CC1.  Analysis on brain and spinal cord sections revealed complete absence 
of these markers in the CNS of dTg (Olig2-Cre/Sox10-DTA) mice when 
compared with that of controls (Sox10-DTA). This shows that recombination is 
occurring correctly and efficiently and it also shows DTA is functional. 
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Figure 3.21 Reduction of motor neurons in Olig2-Cre/Sox10-DTA.  Spinal cord 
sections from control Sox10-DTA (A, B) and Olig2-Cre/Sox10-DTA (C, D) in 
Founder line 17/4 at E10.5. The sections were taken at the same A-P level. Motor 
neurons are immunolabelled with an antibody against MNR2 (red). EGFP is 
shown as green and Hoescht nuclear staining is shown as blue. 
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Table 3.3 Quantification of MNR2-positive cells in the spinal cord of Sox10-DTA 
(control) and Sox10-DTA/Olig2-Cre embryos at E10.5 in Founder line 17/4. The 
number of MNR2 cells was quantified by counting the total number of MNR2 
cells in each spinal cord slice. Counts from six sections per embryo; n=2 controls 
and 2 Sox10-DTA / Olig2-Cre mice; mean ± SD. 
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Figure 3.22 Absence of EGFP (green) and Sox10 (red) positive cells in Olig2-
Cre/Sox10-DTA mutant mice. Matching spinal cord sections from control Sox10-
DTA (A, C, E) and Olig2-Cre/Sox10-DTA (B, D, F) in Founder line 1/1 at birth. 
Scale bar, 0.5 mm. 
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Figure 3.23 Lack of OLPs and mature OLs in Olig2-Cre/Sox10-DTA mice (line 
1-1) at birth. In situ hybridisation was performed with antisense riboprobes 
directed against PDGFRα (A, C) and PLP (B, D) on spinal cord tissues from 
control (A, B) and Olig2-Cre/Sox10-DTA (C, D). OLPs expressing PDGFRα (A) 
and mature oligodendrocytes expressing PLP (B) are missing in Olig2-Cre/Sox10-
DTA pups (C, D). Scale bar, 0.5 mm. 
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Figure 3.24 Lack of OLs in Olig2-Cre/Sox10-DTA mice at P13. 
Immunohistochemistry with antibodies specific for EGFP (A, B), Sox10 (C, D), 
and in situ hybridisation with a PLP-specific probe (E, F) were performed on 
spinal cord cross-sections obtained from control (A, C, E) and Olig2-Cre/Sox10-
DTA  (B, D, F). Scale bar, 0.5 mm. 
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Figure 3.25 Olig2-Cre/Sox10-DTA -mediated cell ablation is specific to OLs (B). 
Expression of NeuN and GFAP (D, F) is unchanged in Olig2-Cre/Sox10-DTA 
mice at P13. Neurons expressing NeuN and astrocytes expressing GFAP are 
visible both in control (C, E) and in Olig2-Cre/Sox10-DTA (D, F) animals. No 
signal for CC1 (which marks mature OLs) is present in the double transgenic (B). 
Scale bar, 0.5 mm. 
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Figure 3.26 Absence of Sox10-positive cells in Olig2-Cre/Sox10-DTA pups at 
birth. Immunohistochemistry with antibodies against EGFP (green) and Sox10 
(red) was used to analyse cross sections of telencephalon from control and Olig2-
Cre/Sox10-DTA pups. All cell nuclei were stained with Hoechst dye. LAT CTX, 
lateral cortex; MC, motor cortex; CC, corpus callosum; AC, anterior commissure; 
POA, preoptic area. Scale bar, 200 µm. 
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Figure 3.27 Ablation of OLPs in the telencephalon at birth. In situ hybridisation 
analysis of coronal sections from P1 control (Sox10-DTA) and mutant (Olig2-
Cre/Sox10-DTA) animals using Sox10 (A, B) and PDGFRα (C) mRNA specific 
probes. Note the complete absence of specific signals for PDGFRα and the nearly 
complete lack of Sox10-positive cells in mutant animals versus controls. SVZ, 
subventricular zone; CC, corpus callosum; MC, motor cortex; POA, preoptic area. 
Scale bars, (A, C) 1 mm, (B) 200 µm. 
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Figure 3.28 Ablation of OLPs in more posterior regions of the forebrain. In situ 
hybridisation analysis of coronal sections from P1 control (Sox10-DTA) and 
mutant (Olig2-Cre/Sox10-DTA) animals using Sox10 (A, B) and PDGFRα (C, D) 
mRNA specific probes. Note the complete absence of specific signals for 
PDGFRα and the nearly complete lack of Sox10 signal in mutant animals versus 
controls. Scale bar, 1 mm. 
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3.3 Discussion 
 
The aim of the work described in this chapter was to generate a tool for the 
analysis of population dynamics of OLs in the developing forebrain and spinal 
cord. I sought to establish a transgenic mouse line in which OLPs can be readily 
identified with a fluorescent marker and can be specifically ablated when crossed 
to a Cre-expressing mouse line. This mouse line, called Sox10-DTA, was 
generated by introducing an EGFP-DTA transgene into a PAC containing the 
Sox10 locus by homologous recombination, then microinjected into the 
pronucleus of single-cell fertilized oocytes where the recombined PAC integrated 
randomly into the mouse genome. PAC technology was employed since the 
regulatory sequences that control the expression of Sox10 are not fully known. 
PACs have a high probability of carrying all the regulatory elements required for 
correct expression of the gene of interest because of their large size. A total of ten 
founder mice were identified by PCR genotyping of tail DNA, and verified by 
Southern blot analysis of tail DNA. Independent breeding lines were established 
from only three of those founders (named 1/1, 17/4, 20/3) since they were the only 
founders that exhibited germ-line transmission of the transgene. Line 1/1 
exhibited ectopic expression in the dorsal forebrain at a very early stage. To 
determine whether these ectopic EGFP-expressing cells die when crossed with a 
mouse line that expresses Cre recombinase in the cortex (Emx1-iCre) I attempted 
to detect cell death using both an apoptosis detection kit or antibodies against the 
cleaved form of Caspase-3. In all attempts, cell death was never detected in this 
region.  Line 1/1 was nevertheless excluded from subsequent forebrain analysis.  
 
EGFP expression was found to be expressed in a restricted region within the 
ventral telencephalon and spinal cord corresponding to known regions of OL 
specification. These fluorescent cells were found to be dispersed uniformly in the 
CNS by E16.5 and began to accumulate in white matter regions postnatally. These 
results are consistent with studies that described the neuroepithelial origins of 
oligodendrocytes (Pringle et al., 1993; Noll and Miller, 1993). 
 
EGFP/Sox10 double immunostaining was performed to determine the extent of 
co-localisation between the two. Results indicate that EGFP and Sox10 were 
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nearly co-localised in all regions of the forebrain and spinal cord throughout 
development. 
 
The presence of weak fluorescence in the dorsal spinal cords in all three founder 
lines at E12.5 was initially concerning because it was thought that this was ectopic 
expression of the transgene. However, closer analysis revealed that these EGFP-
positive cells most likely express endogenous Sox10 transcripts. In situ 
hybridisation with Sox10 riboprobe in wild-type spinal sections revealed a weak 
dorsal expression pattern. This dorsal expression pattern was missed in the past 
because it required a longer development time for it to appear when compared to 
the ventral expression pattern. For the dorsal expression to appear, tissue sections 
must be kept in the staining solution for an extra 2-3 hours. In both wild-type and 
transgenic spinal cords, Sox10 mRNA transcript is present in the dorsal spinal 
cord at E12.5 but the protein is not. Sox10 mRNA levels of the transcript is not 
translated into the protein, or not detectable amounts of protein. Double labelled 
in situ hybridisation to detect mRNA for EGFP and Sox10 would confirm that 
these EGFP-positive cells express Sox10. However, this could not be confirmed 
since numerous attempts to generate an EGFP riboprobe were unsuccessful. This 
expression of Sox10 mRNA in the dorsal spinal cord likely precedes 
oligodendrogenesis from dorsal region of the NE. Recent studies have shown that 
at least three NE domains in the dorsal spinal cord (dp3-dp5) generate OLPs at 
late embryonic stages (Cai et al., 2005; Vallstedt et al., 2005; Fogarty et al., 
2005). The early activation of the Sox10 and PDGFRα genes may be demarcating 
the NE domains with oligodendrogenic potential. 
 
To test the activity of DTA, the Sox10-DTA mouse line was crossed with Olig2-
Cre line. As mentioned previously, Olig2 has a crucial role in in vivo 
oligodendrogenesis (Grinspan et al., 2002; Lu et al., 2000; Lu et al., 2002). In 
addition, Olig2 is expressed by all OLs regardless of their site of origin. Sox10-
DTA/Olig2-Cre pups showed a nearly complete lack of Sox10-positive cells. In 
situ hybridisation revealed only a few faintly labelled Sox10-expressing cells in 
the subventricular zone. These cells are likely to reflect the continuous generation 
of OLPs. These cells are probably newly born OLPs whose DTA transgene have 
just been activated because no Sox10-positive cells were found beyond the 
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subventricular zone. In addition, analysis of the expression of other OLP and OL 
makers, such as PDGFRα, PLP, and CC1, confirmed the absence of OLPs and 
OLs in Olig2-Cre/Sox10-DTA mice since none of these markers were expressed 
in Olig2-Cre/Sox10-DTA mice. These results confirm that the EGFP coding 
sequence can be efficiently removed and DTA can be activated. This system 
appears to be very efficient in its elimination of OLP cells. It is well known that 
Jimpy-4J mutant mice (also known as PLPJp-4j) lack myelin in the CNS because 
their OLs fail to produce myelin protein. Founder line 1/1 Sox10-DTA/Olig2-Cre 
animals share similar neurological abnormalities with Jimpy-4J mice and also 
with mice lacking PDGF-A. These mice developed tremors, seizures, and died 
within 3-4 weeks after birth (Billings-Gagliardi et al., 1995; Fruttiger et al., 1999). 
Similarities between these mutants suggest that Sox10DTA/Olig2Cre animals, 
from line 1/1, die because myelin is completely absent in the CNS. 
 
Intracellular production of DTA inhibits protein synthesis which leads to cell 
death through programmed cell death (apoptosis) (Epinat et al., 1999). The 
toxicity of wild-type DTA is extremely high so that even one molecule of DTA 
introduced into a cell might be sufficient to kill the cell (Yamaizumi et al., 1978). 
An attenuated version of DTA, called Tox17, was used in this mouse line since 
the toxicity is estimated to be 30-fold less than the wild-type version of DTA. The 
potential advantage of using the attenuated form is that it is less likely to cause 
undesirable non-specific cell lethality. Cells that might express very low transient 
levels of Sox10 are unlikely to die since much more of the attenuated DTA 
protein is needed to accumulate before it can inhibit protein synthesis and cause 
cell death. The Sox10-DTA mouse line can efficiently ablate OLs since OLPs and 
OLs were not dectected in the Olig2-Cre/Sox10-DTA embryos and pups. 
However, assays for apoptosis in Olig2-Cre/Sox10-DTA CNS were unsuccessful 
(data not shown). Positive and negative controls were included in those 
experiements. Positive controls were forelimb buds of E13.5 wild-type mouse 
embryos, since massive cell death occurs in this region as a means of digit 
separation. Negative controls were age-matched wild-type littermates. Positive 
controls always gave beautiful capase-3 staining and no staining was seen in the 
negative controls. Tunnel and active caspase-3 staining were performed on tissues 
aged E12.5, E14.5, E18.5 and birth.  No apoptotic cells were detected at all the 
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stages analysed. It is likely that freshly generated apoptotic cells are rapidly 
recognized, engulfed and cleared from tissue. The rapid clearance of apoptotic 
cells has been suggested to prevent the release of potentially harmful materials 
from dead cells (Gaipl et al., 2005). 
 
It is expected that this mouse model will be a useful tool for researchers interested 
in studies relating to Sox10 gene expression and/or glia development in the CNS 
and PNS. The EGFP fluorescence and Sox10 expression are well linked, 
providing a convenient in vivo marker for Sox10-positive cells. EGFP-labelled 
cells can also be isolated from embryos or adult mice by fluorescence activated 
cell sorting (FACS) and used for in vitro studies of isolated glial cells or for 
transplantation studies. 
 
In conclusion, the immunohistochemical characterisation of EGFP-positive cells 
in Sox10-DTA mouse CNS indicated that transgene expression was exclusive to 
Sox10-positive cells and was maintained from embryonic to adult developmental 
stages. This mouse model allows excellent visualisation of all OLPs and OLs. In 
addition, DTA expression is activated following Cre-mediated excision of the 
floxed EGFP sequences, resulting in the specific ablation of Cre and Sox10 
expressing cells. Founder 17/4 was used in all forebrain experiments (Chapter 4). 
Founder 1/1 can be used for future spinal cord studies. This decision was based on 
the fact that Line 1/1 had ectopic expression in the cortex and Line 17/4 had a 
slight early activation in the spinal cord NE resulting in loss of MNs and early 
death of pups when crossed to an Olig2-Cre mouse.  
  133 
Chapter 4 
 
 
Population Dynamics of OLs in the Developing 
Telencephalon 
 
 
 
4.1 Introduction: Origin of OLs in the Developing Telencephalon 
 
The telencephalon arises from the most anterior part of the neural tube, and can be 
broadly divided into two main regions, dorsal and ventral. The main structure of 
the dorsal telencephalon is the cortex, whereas the ganglionic eminences and 
anterior entopeduncular area (AEP) comprise the ventral region (Figure 4.1). 
Forebrain patterning occurs before neuronal and glial specification and migration 
because the specification of these cell types requires the formation of distinct 
progenitor domains along the anterior-posterior and dorsal-ventral axes. These 
progenitor domains are established by gradients of morphogens. 
 
A number of studies in the past decade or two have focused on tracing the sites of 
origin and migration routes of OLPs in the spinal cord during development. 
Considerably less attention has been given to understanding the origins of 
embryonic OLPs in the telencephalon. OLs were initially presumed to originate 
throughout the neuroepithelium of the neural tube, because mature myelin-
forming OLs are distributed ubiquitously throughout the dorsal and ventral CNS. 
The lack of reliable molecular markers for early stages of OL cell development 
made it difficult to determine unambiguously the origin of OLs. One of the first 
OL markers to be identified was galactocerebroside (GC, a myelin glycolipid) 
(Raff et al., 1978). Unfortunately, this marker identifies differentiated OLs in 
rodents, so could not label the earliest stages of the lineage.  
 
The identification of the platelet-derived growth factor receptor alpha-subunit 
(PDGFRα) as a very early OL lineage marker was particularly useful for studying 
the earlier development of the OL lineage (Pringle et al., 1993). Later, the 
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discovery of other early OL lineage makers such as, Sox10, Olig1 and Olig2 have 
allowed rapid progress in the study of OL lineage development. To date, Olig1 
and Olig2 are the earliest known specific markers for the OL lineage.  
 
Using antibodies or in situ hybridisation probes against these markers has shown 
that embryonic OLPs first originate from the ventral region of the telencephalon, 
specifically in the anterior entopeduncular area (AEP) and medial ganglionic 
eminence (MGE), beginning at E12.5 (Tekki-Kessaris et al., 2001). These cells 
proliferate, migrate and populate the entire developing telencephalon, including 
the cortex. It was initially unclear whether all OLPs originate in ventral territories. 
For example, chick-quail and chick-mouse chimera experiments (Spassky et al., 
1998; Olivier et al., 2001) suggested that OLPs in the cerebral cortex originated in 
the ventral forebrain (AEP), whereas studies of cortical stem cells in culture (He 
et al., 2001; Qian et al., 2000) showed that cortical precursors have the potential to 
generate OLPs and OLs even in the absence of SHH. Another study showed that 
PLP, believed to be a specific marker of OL lineage cells, was expressed at the 
lateral edges of the early postnatal cortex (Ivanova et al., 2003). Therefore, there 
was controversy over the ventral or dorsal origins of forebrain OLPs. While at the 
same time, Dr. Temple’s group followed cells from the ventral telencephalon 
using the expression of ventral telencephalic genes, the Dlx homeobox genes. 
They showed Dlx-positive OLPs in the dorsal forebrain region (He et al., 2001). 
However, Qian et al. (2000) showed that stem cells isolated very early on (E10) 
from the dorsal telencephalon can make OLs even without the presence of SHH. 
A recent report from Dr. Ikenaka’s group showed that OLPs found in the postnatal 
subventricular zone (SVZ) are unlikely to come from the ventral telencephalon 
because OLP processes were not orientated toward the SVZ (Ivanova et al., 
2003).  
 
Using in vivo genetic fate-mapping strategy in mice, Kessaris et al. (2006) 
reinvestigated the question of the origins of OL lineage cells in the cortex. 
Kessaris et al. made use of Cre recombinase and the restricted expression patterns 
of Nkx2.1, Gsh2, and Emx1 in order to fate map the cells derived from the 
AEP/MGE, MGE/LGE, and cortex respectively (Figure 4.1).  
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They found that oligodendrogenesis in the telencephalon occurs in three distinct 
phases or waves. Their analysis revealed that the first wave of oligodendrogenesis 
begins at E12.5 in the Nkx2.1-expressing region, mainly from the AEP. These 
OLPs migrated throughout the embryonic telencephalon including the cerebral 
cortex. The second wave of OLP production begins in the MGE/LGE (Gsh2-
expressing region) at about E14.5. These OLPs also migrate throughout the 
telencephalon. The last wave of OLP production occurs after birth, from the 
cortical VZ (Emx1-expressing region). These dorsally-derived OLPs remained 
within the cortex and did not migrate into the ventral forebrain. 
 
Although originally described in terms of three successive waves of OLP genesis, 
it is perhaps more likely that OLP genesis proceeds in a single progressive 
“mexican wave” from ventral to dorsal. Surprisingly, the first wave of OLP 
production (from Nkx2.1-expressing region) disappears about a week after birth 
(P10); however, the remaining two waves of OLPs are present in the adult 
telencephalon: Gsh2-derived OLs are found throughout the entire telencephalon 
and Emx1-derived OLs are restricted within the cortex (Kessaris et. al., 2006). 
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Figure 4.1 The origin of OLPs and their migration through the developing 
telencephalon. During development, telencephalic OLs arise from three 
successive migratory waves of oligodendrogenesis. The first wave arises from the 
Nkx2.1-expressing region beginning at E12.5, the second from the Gsh2-
expressing region beginning at E14.5 and the third wave begins around birth from 
the Emx1-expressing region. Figure taken from Kessaris et al., (2006). 
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Objective   
 
It appears that OLs do not arise exclusively from the ventral neuroepithelium. 
Both dorsal and ventral neural tube gives rise to OLPs. It is well known that Shh 
is required for the specification of OLs in the ventral neuroepithelium, because 
disruption of Shh signalling prevent OLPs from being generated in this region. 
However, Shh has never been detected in the dorsal region of the telencephalon. 
This would suggest that dorsally-derived OLPs are generated using a different 
signalling pathway. In addition, different morphological types of mature OLs have 
been described. Type I/II OLs have small cell bodies with multiple thin processes 
that myelinate numerous small diameter axons. Type III/IV OLs, however, have 
larger cell bodies with only a few processes which myelinate axons that are larger 
in diameter (Butt et. al., 1998). Do multiple origins of OLPs produce functionally 
different OLs? Are these differences due to different sites of origin of OLPs? To 
address these questions we decided to ablate OLPs from different parts of the 
forebrain VZ, to determine whether 1) this would give rise to permanent deficits 
of OLs in particular forebrain territories or 2) whether loss of a specific ventral or 
dorsal source of OLPs would result in specific neural phenotypes that might 
suggest that different functional sub-types of OLs originate in different parts of 
the VZ. 
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4.2 Results 
 
4.2.1 Deleting Single OL Precursor Populations in the Developing 
Telencephalon 
 
Three different transgenic mouse lines, Nkx2.1-iCre, Gsh2-iCre and Emx1-iCre 
were generated in the Richardson laboratory using the PAC modification 
technique. In each of the PAC transgenic vectors, endogenous protein coding 
sequence was replaced by sequences encoding iCre. The modified PAC inserts 
were purified and microinjected separately into the pronucleus of fertilized mouse 
oocytes. Three independent transgenic lines were generated, all of which the iCre 
recombinase was faithfully expressed in all regions where the endogenous gene 
(Nkx, Gsh2, or Emx1) is normally expressed. In the Nkx2.1-iCre line, the iCre is 
expressed in the same pattern as the Nkx2.1 gene in the forebrain, including in the 
septum, pre-optic area and medial ganglionic eminence (MGE). In the Gsh2-iCre 
line, the iCre is expressed in the same areas as the Gsh2 gene, including the lateral 
ganglionic eminence (LGE), caudual ganglionic eminence (CGE) and part of the 
MGE. In the Emx1-iCre mouse line, the iCre is expressed in the dorsal cortex. N. 
Kessaris and M. Grist generated the Nkx2.1-iCre and Gsh2-iCre constructs and 
M. Fogarty generated the Emx1-iCre construct. Ulla Dennehy and myself carried 
out all the pronuclear microinjections. 
 
In order to investigate whether the three spatially distinct OL lineages in the 
telencephalon are functionally different, we first genetically ablated each lineage 
individually in the developing telencephalon. The Nkx2.1-iCre, Gsh2-iCre and 
Emx1-iCre transgenic lines were individually crossed to my Sox10-DTA line and 
the offspring examined at various stages. I was mostly interested in the Sox10-
DTA/Gsh2-iCre and Sox10-DTA/Emx1-iCre offspring, since Gsh2- and Emx1-
derived OLPs represent the major sources of OLPs and OLs in the postnatal 
forebrain (Kessaris et al., 2006).  
As a first step, I generated a series of transgenic mice by crossing the Sox10-DTA 
line to either the Gsh2-iCre or Emx1-iCre line and examined the double-
transgenic offspring for EGFP expression in the forebrain. One of the first time 
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points analyzed was P12, chosen because the Emx1-derived OLP population is 
normally generated after birth. At P12, in Sox10-DTA/Emx1-iCre pups, 
EGFP/Sox10 double positive oligodendroglial cells were seen throughout the 
developing telencephalon. Direct examination of the stained tissues did not show 
any apparent differences in the distribution of EGFP or Sox10 positive cells when 
compared to its Sox10-DTA littermates (Figure 4.2 A-D). This result prompted us 
to investigate whether DTA-mediated ablation had been effective in the Sox10-
DTA/Emx1-iCre pups. To do this, we generated double-transgenic mice 
containing the Emx1-iCre transgene and a Cre-dependent LacZ reporter (Rosa26-
LacZ), and triple-transgenic mice containing the Emx1-iCre transgene, Rosa26-
LacZ and the Sox10-DTA transgene. In the presence of Emx1-iCre and Rosa26-
LacZ, LacZ positive cells (blue stained cell bodies) were found to be densely 
distributed throughout the developing cortex at P12, indicating that cortically 
derived cells had undergone Cre-mediated recombination (Figure 4.2 G). These 
LacZ positive cells represent neurons, astrocytes and oligodendrocytes as 
described by Iwasato et al. (2004) and Kessaris et al. (2006). Cortical tissues from 
P12 triple transgenic mice (Emx1-iCre/Rosa26-LacZ/Sox10-DTA) stained with 
X-gal were also populated with LacZ positive cells (Figure 4.2 H). It is believed 
that these blue cells are neurons and astrocytes but not oligodendrocytes. 
Unfortunately, the conditions for X-gal staining, which involves a blue precipitate 
formed by the reaction between β-gal and X-gal, was incompatible with NeuN, 
GFAP, and Sox10 immunolabelling so the identity of the X-gal positive cells 
could not be confirmed by double-immunolabeling. However, loss of 
oligodendrocytes was dramatically illustrated in the corpus callosum because this 
tract contains the cell bodies of oligodendrocyte lineage cells and astrocytes but 
no neuronal cell bodies (only their axons). The corpus callosum contained no 
LacZ positive cells, which confirms Emx1-derived OLs and OLPs were 
effectively ablated by DTA (Figure 4.2 H). Despite the death of Emx1-derived 
OLs, EGFP and Sox10 positive cells were found throughout the corpus callosum 
in Emx1-iCre/Sox10-DTA mice at P12 (Figure 4.2 B, D). This prompted us to see 
whether there was significant difference between Emx1-iCre/Sox10DTA and its 
Sox10-DTA aged-matched littermates with regards to the number of OL cells. To 
investigate this, OL-cell numbers were determined in P12 telencephalic corpus 
callosum by manually counting the number of Sox10-postive cells per unit area of 
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corpus callosum tissue in micrographs (see Materials and Methods 2.11.7). The 
analysis revealed no statistically significant difference in the number of Sox10-
positive cells in the telencephalic corpus callosum between Emx1-iCre/Sox10-
DTA mice and Sox10-DTA aged-matched (control) littermates at P12. 
Next, we investigated whether the amount of myelin was affected by the loss of 
Emx1-derived OLPs and OLs. Coronally-sectioned telencephalic adult brains 
from Emx1-iCre/Sox10-DTA mice and Sox10-DTA controls were stained using 
the histological myelin stain Sudan black. There was no observable differences 
between the amounts of myelin in the corpus callosum of these animals (Figure 
4.2 E, F). The extent of myelin stain along the corpus callosum was identical in 
both the Emx1-iCre/Sox10-DTA and Sox10-DTA control animals; both groups of 
animals had dense staining for myelin. Emx1-iCre/Sox10-DTA mice survived for 
more than two years, behaved normally, and reproduced normally, with normal 
size and frequency of litters. The lack of difference between Emx1-iCre/Sox10-
DTA and Sox10-DTA mice shows that the loss of Emx1-derived OLs can be 
compensated for by one or more alternative OL lineages. 
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Figure 4.2 Genetic ablation of Emx1-derived OLPs reveals functional redundancy 
at P12 in the corpus callosum. Immunohistochemistry and myelin analysis of 
coronal CC sections from P12 control (Sox10-DTA: A, C, E) and Emx1-
iCre/Sox10-DTA (B, D, F) animals using EGFP (A, B), Sox10 (C, D), and Sudan 
Black (E, F). Emx1-derived OLPs have been effectively ablated by DTA (G, H). 
LacZ positive cells are present in the CC of Emx1-iCre/R26R-LacZ (G) but 
absent from the CC of Emx1-iCre/R26R-LacZ/Sox10-DTA (H).  Scale bar, 0.5 
mm. 
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I also conditionally killed Gsh2-derived OL lineage cells, by crossing Gsh2-iCre 
mice with Sox10-DTA mice. At P12 EGFP/Sox10 double positive 
oligodendroglial cells were seen throughout the developing telencephalon in 
Gsh2i-Cre/Sox10-DTA pups. EGFP and Sox10 immunolabeling were 
indistinguishable between Gsh2i-Cre/Sox10-DTA and their control littermates 
(Figure 4.3 A, B, D, E). To ensure that region-specific ablation had occurred in 
the Gsh2-Cre/Sox10-DTA pups, we generated double-transgenic mice containing 
the Gsh2-iCre transgene and the Rosa26-LacZ reporter, and triple-transgenic mice 
containing in addition the Sox10-DTA transgene. In the presence of Gsh2-iCre 
and Rosa26-LacZ, LacZ positive cells were densely distributed throughout the 
developing telencephalon (Figure 4.4 A, C). In keeping with previous fate-
mapping studies which had shown that the majority of OLs in the anterior 
commissure and approximately 50% of OLs found in the corpus callosum at P10 
are derived from the Gsh2-expressing region of the telencephalon (Kessaris et al., 
2006). However, in the triple transgenic mice (i.e. in the presence of Sox10-DTA) 
the corpus callosum and anterior commissure contained no LacZ positive cells, 
confirming that Gsh2-derived OLs were effectively ablated by DTA (Figure 4.4 
B, D). Despite the death of Gsh2-derived OLs, EGFP and Sox10 positive cells 
were found throughout the corpus callosum and anterior commissure in Gsh2-
iCre/Sox10-DTA mice at P12 (Figure 4.3 D, E, J, K). Cell counts revealed that 
there was no decrease in the number of Sox10-positive cells in the corpus 
callosum and anterior commissure of Gsh2-iCre/Sox10-DTA compared with 
Sox10-DTA control mice. Therefore, despite the loss of all Gsh2-derived OLPs in 
Gsh2-iCre/Sox10-DTA mice, there is efficient compensation by OLPs derived 
from other regions of the telencephalon.  
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Figure 4.3 Genetic ablation of Gsh2-derived OLPs reveals functional redundancy 
at P12 in the corpus callosum and in the anterior commissure. 
Immunohistochemistry and myelin analysis of coronal corpus callosum sections 
(A through F) and anterior commissure (G through L) from P12 control (Sox10-
DTA: A, B, C, G, H, I) and Gsh2-iCre/Sox10-DTA (D, E, F, J, K, L) animals 
using EGFP (A, D, G, J), Sox10 (B, E, H, K), and Sudan Black (C, F, I, L). Scale 
bar, 0.5 mm. 
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Figure 4.4 Gsh2-derived OLPs are effectively ablated by DTA. LacZ positive 
cells are present in the CC (A) and AC (C) of Gsh2-iCre/R26R-LacZ (arrows) but 
absent in the CC (B) and AC (D) of Gsh2-iCre/R26R-LacZ/Sox10-DTA 
(arrowheads). CC, corpus callosum; AC, anterior commissure. Scale bar, 0.5 mm. 
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Moreover, there was no observable reduction in the amount of myelin in corpus 
callosum and in the anterior commissure in Gsh2-iCre/Sox10-DTA mice (Figure 
4.3 C, F, I, L). The fertility and lifespan of Gsh2-iCre/Sox10-DTA mice were 
similar to Sox10-DTA and wild-type mice. The lack of difference between Gsh2-
iCre/Sox10-DTA and Sox10-DTA mice indicates that the loss of Gsh2-derived 
OLs can be compensated for by one or more alternative OL lineages, just as for 
loss of Emx1-derived OLs. 
To determine whether there is a delay in OL development in these double 
transgenic mice we examined EGFP expression in the telencephalon at an earlier 
stage. EGFP-expressing cells represent OLPs derived from Cre non-expressing 
regions (Cre-negative neuroepithelium). At P3, Gsh2-iCre/Sox10-DTA mice 
showed a slight delay in the accumulation of EGFP-positive cells in the motor 
cortex (Figure 4.5 B).  This delay was only detected in the posterior dorsomedial 
cortex at P3. The delay in the accumulation of EGFP-positive cells is transient, 
because the distribution of EGFP in this region is normalized by P15 (Figure 4.5 
D). When we examined EGFP expression in the telencephalon at P1, we saw a 
delay in the accumulation of EGFP-positive cells in both the anterior and posterior 
regions of the motor cortex (Figure 4.6). To confirm that this represented a delay 
in inward migration of OLPs, we examined the expression of PDGFRα. A delay 
in the accumulation of PDGFRα-positive cells in the anterior and posterior 
regions of the motor cortex was observed (Figure 4.7). We also looked at Nkx2.1-
iCre/Sox10-DTA mice at P1 for a delay in OLP accumulation. We found no 
observable deficit in these mice at P1 (Figure 4.8).  
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Figure 4.5 A brief delay in the accumulation of OLPs in the posterior 
dorsomedial cortex after genetic ablation of Gsh2-derived OLPs (arrow). 
Immunohistochemical analysis of coronal sections from P3 (A, B) and P15 (C, D) 
mice. Scale bar, 0.4 mm. 
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Figure 4.6 A brief delay at P1 in the accumulation of OLPs in the outer anterior 
and posterior dorsomedial cortex after genetic ablation of Gsh2-derived OLPs 
(arrows). Anti-GFP immunolabelling of coronal sections from control (Sox10-
DTA: A, B) and Gsh2-iCre/Sox10-DTA (C, D) mice. Cell nuclei were labelled 
with Hoechst dye (blue). Scale bar, 1 mm. 
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Figure 4.7 In situ hybridisation analysis of coronal sections from P1 control 
(Sox10DTA) and Gsh2-iCre/Sox10-DTA animals using a PDGFRα mRNA 
specific probe. Note the delay in the accumulation of specific signals for PDGFRα 
in the dorso-medial tips of the cortex in Gsh2-iCre/Sox10-DTA animals (black 
arrows) versus controls. Scale bars, 0.5 mm (A, C) and 1 mm (B, D). 
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Figure 4.8 No observable delay at P1 in the accumulation of OLPs in the outer 
posterior dorsomedial cortex after genetic ablation of Nkx2.1-derived OLPs. Anti-
GFP immunolabelling of coronal sections from P1 mice. Cell nuclei were labelled 
with Hoechst dye (blue). Scale bar, 1 mm. 
 
4.2.2 Deleting both Nkx2.1- and Gsh2-derived OLP Populations in the 
Developing Telencephalon 
 
Given the plasticity of OLP development observed above - i.e. ablation of Gsh2-
derived OLPs can be compensated for by inward migration of OLPs from other 
regions of the telencephalon or possibly beyond - I wanted to determine the limits 
of this plasticity by ablating OLPs from all parts of the ventral neuroepithelium 
(Gsh2 and Nkx2.1). I generated triple-transgenic mice that carried Sox10-DTA, 
Nkx2.1-iCre and Gsh2-iCre transgenes in their genome. Nkx2.1-iCre and Gsh2-
iCre mice were crossed separately with Sox10-DTA mice to generate double-
transgenic offspring. Subsequently, the double-transgenics were intercrossed 
(Nkx2.1-iCre/Sox10-DTA X Gsh2-iCre/Sox10-DTA) to generate triple-transgenic 
mice (Nkx2.1-iCre/Sox10-DTA/Gsh2-iCre). 
I obtained triple Nkx2.1-iCre/Sox10-DTA/Gsh2-iCre transgenics, which I 
examined for EGFP expression. At P1, the earliest time point examined, EGFP-
positive cells were distributed throughout the ventral region of the telencephalon. 
  150 
Very few EGFP-positive cells were found in the motor cortex at birth (Figure 
4.9); however, by P5 EGFP-positive cells were found throughout this region 
(Figure 4.10). Therefore, there is a short delay in accumulation of EGFP-positive 
OLPs in the dorsal cortex of mice in which all ventrally-derived OLPs have been 
ablated. 
 
 
 
 
 
 
 
Figure 4.9 A delay in the accumulation of OLPs in the dorsal cortex at P1 after 
genetic ablation of Nkx2.1 and Gsh2-derived OLPs. Immunohistochemical 
analysis of coronal sections from Sox10-DTA (A) and triple-transgenic (B) mice 
using anti-EGFP antibodies. Cell nuclei were labelled with Hoechst dye (A, B). 
Scale bar, 0.7 mm. 
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Figure 4.10 No observable deficit at P5 in the accumulation of OLPs in the 
telencephalon after genetic ablation of Nkx2.1 and Gsh2-derived OLPs. 
Immunohistochemical analysis of coronal sections from P5 mice using EGFP. All 
cell nuclei were labelled with Hoechst dye. Scale bar, 1 mm. 
 
 
 
 
  152 
It remained possible that there was a long-term reduction in the number of OLPs 
in Nkx2.1-iCre/Gsh2-iCre/Sox10-DTA cortex relative to controls; to test this I 
counted OLPs in the motor cortex, corpus callosum and anterior commissure and 
present the data as number of cells per surface unit in Figure 4.11. 
 
Around birth, Sox10- and EGFP-positive cells are abundant and evenly 
distributed throughout the telencephalon of control mice. However, in newborn 
triple-transgenic (Nkx2.1-iCre/Gsh2-iCre/Sox10-DTA) mice the number of these 
cells was much reduced in these areas. A reduction in Sox10 positive cells is also 
detected at P8 in all regions analysed. However, some time between P8 and P10 
the number of Sox10 positive cells in the triple-transgenic mice catches up with 
the control mice (Figure 4.11).  
 
Despite the loss of both Nkx2.1-derived and Gsh2-derived OLPs, OL-lineage cells 
(Sox10-postive) distributed uniformly throughout the developing telencephalon in 
normal or near-normal numbers after P10, indicating that loss of ventrally-derived 
OLPs can be compensated for by OLPs from other sources. 
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Figure 4.11 Quantification of Sox10-positive cells in the motor cortex, corpus 
callosum, and anterior commissure in Sox10-DTA (control) and Nkx2-iCre/Gsh2-
iCre/Sox10-DTA mice at selected time points. Solid and dashed lines correspond 
to control and Nkx2-iCre/Gsh2-iCre/Sox10-DTA mice, respectively. Counts from 
four to six sections per mouse. n=2 animals/group. Number of sox10+ cells per 
2.25 mm2 (A) and per 0.04 mm2 (B, C). MC, motor cortex; CC, corpus callosum; 
AC, anterior commissure. P-values are for each time-point are shown. 
MC 
CC 
AC 
A 
B 
C 
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4.2.3 Timing of Myelination 
 
Next, I wanted to see whether a delay in the accumulation of OLPs had an effect 
on the timing of myelination. First, we needed to find out when myelination 
begins in a normal developing mouse telencephalon. To do this we evaluated the 
expression of mRNA for myelin proteolipid protein (PLP) – the most abundant 
myelin protein found in the mature CNS. The time of onset of PLP expression 
was first evaluated in wild-type C57BL6xCBA mice and Sox10-DTA control 
mice. In situ hybridisation analysis showed that mature PLP-expressing OLs first 
appear before P2 in the developing telencephalon in both the Sox10-DTA control 
and wild-type mice (Figure 4.12 and not shown).  
 
When I examined triple-transgenic mice (Nkx2.1-iCre/Gsh2-iCre/Sox10-DTA), 
PLP-expressing cells did not appear in the forebrain until about P8-P9 (Figures 
4.13, 4.14 & 4.15). There were noticeably less PLP-expressing cells at P9 in the 
triple transgenic mice, but a few days later, numbers appeared to have normalised 
in the triple-transgenics (Figure 4.16). Surprisingly, there was a difference in the 
number of PLP-expressing cells at P10 in the MC. What was more surprising was 
that the number of PLP-expressing cells in the MC of triple-transgenic mice was 
higher than its age-matched controls (Figure 4.17 A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  155 
 
 
 
 
 
Figure 4.12 The time of onset of PLP expression in the developing forebrain in 
Sox10-DTA mice is around P2-P3. Coronal sections of Sox10-DTA mice 
forebrain were subjected to in situ hybridisation with a DIG-labelled probe against 
PLP. Scale bar, 1 mm. 
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Figure 4.13 PLP expression in Sox10-DTA (control) (A) and Nkx2-iCre/Gsh2-
iCre/Sox10-DTA (B) mice at P5. There is a complete absence of PLP positive 
cells in the triple-transgenic. Scale bar, 1 mm. 
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Figure 4.14 PLP expression in Sox10-DTA (control) (A) and Nkx2.1-iCre/Gsh2-
iCre/Sox10-DTA (B) mice at P8. There is a near-absence of PLP positive cells in 
the triple-transgenic. Scale bar, 1 mm. 
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Figure 4.15 PLP expression in Sox10-DTA (control) (A) and Nkx2.1-iCre/Gsh2-
iCre/Sox10-DTA (B) mice at P9. PLP positive cells begin to appear in the triple-
transgenic. Scale bar, 1 mm. 
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Figure 4.16 PLP expression in Sox10-DTA (control) (A) and Nkx2.1-iCre/Gsh2-
iCre/Sox10-DTA (B) mice at P10. PLP expression in triple-transgenic mice (B) 
was indistinguishable from controls (A) by P10. Scale bar, 1 mm. 
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Figure 4.17 Quantification of PLP-positive cells in the motor cortex, corpus 
callosum, and anterior commissure in Sox10-DTA (control) and Nkx2.1-
iCre/Gsh2-iCre/Sox10-DTA mice at selected time points. Solid and dashed lines 
correspond to control and Nkx2.1-iCre/Gsh2-iCre/Sox10-DTA mice, respectively. 
Counts from four to six sections per mouse. Number of PLP+ cells per 2.25 mm2 
(A) and per 0.08 mm2 (B, C). n=2 animals/group. MC, motor cortex; CC, corpus 
callosum; AC, anterior commissure. P-values for each time-point are shown. 
 
MC 
CC 
AC 
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C 
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4.2.4 Deleting All Telencephalon-Derived OLPs in the Developing Forebrain 
 
It was surprising to see many EGFP-positive cells in the ventral region of the 
telencephalon in triple-transgenic mice (Sox10-DTA/Nkx2.1-iCre/Gsh2-iCre) at 
P1 since Emx1-derived OLPs are only just beginning to appear at this age and 
would not be expected to have migrated to the ventral forebrain yet, if indeed they 
can migrate at all. This raised the possibility that ablation of ventrally-derived 
OLPs in the telencephalon results in migration of OLPs derived from more 
posterior regions, i.e. diencephalon. Another possibility is that the Emx1-
expressing region, which normally generates OLPs at birth, may be induced to 
generate OLPs earlier because of the lack of ventrally-derived OLPs. In order to 
test these ideas, we generated mice in which all telencephalon derived-OLPs were 
ablated. Many mating pairs were set up to give us ‘quadruple-transgenic’ mice 
(Sox10-DTA/Nkx2.1-iCre/Gsh2-iCre/Emx1-iCre). Although time-consuming, I 
was able to obtain several offspring with this genotype for analysis. 
 
The first time point analyzed was P1. At this stage, EGFP positive cells were 
uniformly distributed in the ventral telencephalon. There was a near-absence of 
EGFP-positive cells in the dorsal half of the telencephalon (Figure 4.18 D). In the 
controls, EGFP-positive cells are abundant and evenly distributed throughout the 
telencephalon (Figure 4.18 B). To further confirm that the dorsal half of the 
telencephalon did not contain OLPs, we examined the expression of PDGFRα 
(Figure 4.18 A, C). The expression of PDGFRα matched that of EGFP.  
 
The next time point examined was P15. At this time point, EGFP-positive cells 
were distributed uniformly throughout the telencephalon, however there was still 
a small region, at the medial tips of the motor cortex, that was devoid of EGFP-
positive cells (Figure 4.19 B). An absence of PLP mRNA-positive cells in the 
same area was also detected (Figure 4.19 D). In addition, the PLP staining was 
considerably less intense in quadruple-transgenics when compared to controls 
(Figure 4.19 C, D). Quantification of OLPs and/or OLs was not attempted at this 
time point because the number of transgenic mice needed for statistical analysis 
was not available. The generation of quadruple transgenic mice containing the 
four transgenes was extremely time-consuming; therefore, I generated enough 
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quadruple transgenic mice to determine if OLs in these mice fully recovered by 
adulthood. Quantification of Sox10 positive cells was carried out in three 
telencephalic regions: motor cortex, corpus callosum, and the anterior commissure 
at 20 weeks of age. As shown in Figure 4.20, the numbers of Sox10-positive cells 
between the Sox10-DTA (controls) and quadruple-transgenic mice were not 
significantly different in the motor cortex and anterior commissure (Figure 4.20 
A, C). However, the number of Sox10 positive cells in the corpus callosum of 
quadruple mice was statistically different from the Sox10-DTA mice (controls). 
The mean (±SD) was 66.3 ±2.6 in controls and 59.2 ±4.1 in quadruple transgenic 
mice, so it was evident that the number of Sox10 positive cells was statistically 
different from each other (p=0.014) (Figure 4.20 B). Quantification of 
differentiated OLs was also carried out in the same telencephalic regions: motor 
cortex, corpus callosum, and anterior commissure. As shown in Figure 4.21, the 
number of PLP-expressing cells in each region examined was not statistically 
different between the Sox10-DTA (controls) and the quadruple-transgenic mice. 
Therefore, there was no difference in mature OL numbers across the three regions 
examined, between Sox10-DTA (controls) and quadruple transgenic mice. 
 
Despite the loss of all telencephalic derived OLs, there was no apparent reduction 
in the number of OLs in the three telencephalic regions analyzed as visualised by 
EGFP, PLP, and Sudan black staining (Figures 4.22, 4.23, 4.24). Although there 
was a significant difference in the number of Sox10-positive cells in the corpus 
callosum, there was no observable difference as visualized by EGFP staining 
(Figure 4.23 A, D). There were also no observable differences in the amount of 
myelin in the corpus callosum and anterior commissure Figures 4.23 C, F; 4.24 C, 
F). The extent of myelin stain in these areas was similar in both the control and 
quadruple-transgenic mice. 
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Figure 4.18 Delay in the accumulation of OLPs in the dorsal and lateral cortex at 
P1 after genetic ablation of all telencephalic-derived OLPs. In situ hybridisation 
and immunohistochemical analysis of coronal sections from Sox10-DTA (A, B) 
and quadruple transgenic (C, D) mice using PDGFRα mRNA (A, C) and EGFP 
antibodies (B, D). Cell nuclei were labelled with Hoechst dye (blue) (B, D). Scale 
bar, 1 mm.  
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Figure 4.19 Slight delay in the accumulation of OLPs in the dorsal cortex at P15 
after genetic ablation of all telencephalic-derived OLPs (arrows). In situ 
hybridisation and immunohistochemistry analysis of coronal sections from Sox10-
DTA (A, C) and quadruple transgenic (B, D) mice using EGFP antibodies (A, B) 
and PDGFRα mRNA (C, D). Cell nuclei were labelled with Hoechst dye (blue) 
(A, B). Scale bar, 1 mm. 
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Figure 4.20 Quantification of Sox10-positive cells in the motor cortex, corpus 
callosum, and anterior commissure in Sox10-DTA (control) and Nkx2.1-
iCre/Gsh2-iCre/Emx1-iCre/Sox10-DTA mice at 20 weeks. Similar numbers of 
Sox10 cells are present at this time point. Counts from four to six sections per 
mouse; mean ± SD. Number of sox10+ cells per 2.25 mm2 (A) and per 0.08 mm2 
(B, C). n=2 animals/group. MC, motor cortex; CC, corpus callosum; AC, anterior 
commissure. P-values are shown above the bar graphs. 
A 
B 
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Figure 4.21 Quantification of PLP-positive cells in the motor cortex, 
corpus callosum, and anterior commissure in Sox10-DTA (control) and 
Nkx2.1-iCre/Gsh2-iCre/Emx1-iCre/Sox10-DTA mice at 20 weeks. Similar 
numbers of PLP cells are present at this time point. Counts from four to 
six sections per mouse; mean ± SD. Number of PLP+ cells per 2.25 mm2 
(A) and per 0.08 mm2 (B, C). n=2 animals/group. MC, motor cortex; CC, 
corpus callosum; AC, anterior commissure. P-values are shown above the 
bar graphs. 
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Figure 4.22 Genetic ablation of all telencephalic-derived OLPs reveals functional 
redundancy at the adult stage in the frontal mortor cortex. Immunohistochemistry 
and in situ hybridisation of coronal sections from adult control (Sox10-DTA: A, 
B) and Nkx2.1-iCre/Gsh2-iCre/Emx1-iCre/Sox10-DTA (C, D) animals using 
EGFP (A, C) and PLP (B, D). Scale bar, 0.5 mm. 
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Figure 4.23 Genetic ablation of all telencephalic-derived OLPs reveals functional 
redundancy at the adult stage in the corpus callosum. Immunohistochemistry, in 
situ hybridisation and myelin analysis of coronal sections from adult control 
(Sox10-DTA: A, B, C) and Nkx2.1-iCre/Gsh2-iCre/Emx1-iCre/Sox10-DTA (D, 
E, F) animals using EGFP (A, D), PLP (B, E), and Sudan Black (C, F). Scale bar, 
0.5 mm. 
 
 
Figure 4.24 Genetic ablation of all telencephalic-derived OLPs reveals functional 
redundancy at the adult stage in the anterior commissure. Immunohistochemistry, 
in situ hybridisation and myelin analysis of coronal sections from adult control 
(Sox10-DTA: A, B, C) and Nkx2.1-iCre/Gsh2-iCre/Emx1-iCre/Sox10-DTA (D, 
E, F) animals using EGFP (A, D), PLP (B, E), and Sudan Black (C, F). Scale bar, 
0.5 mm. 
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4.3 Discussion 
 
The aim of this chapter was to investigate whether or not the three regionally 
distinct OL lineages in the forebrain are functionally distinct. It is extremely 
important to know if functionally different OLs subtypes exist because this may 
aid in the study of a variety of OL diseases like multiple sclerosis (MS), 
leukodystrophies, and glial cancers; and may also have an impact on the 
development of therapies for myelin repair. This study will also give us a better 
understanding of OLP behaviour during normal development. One of the most 
straightforward endeavours to reveal the in vivo function of a specific OL 
lineage/population or any cell type is to remove the lineage/population and 
observe the consequences in vivo. This approach was mediated by generating a 
binary transgenic system that enabled us to selectively eliminate an OLP 
population according to their site of origin, by targeted expression of the highly 
toxic diphtheria A chain (DTA). DTA was placed under the control of an OL 
gene, Sox10. DTA expression was further controlled by placing a floxed EGFP 
just before the DTA gene, ensuring that DTA expression is limited to OLs derived 
from specific Cre-expressing regions. We successfully eliminated one or more 
OLP lineages at their site of origin using the Sox10-DTA mouse line by 
combining it with one or more telencephalic iCre-expressing mouse lines 
(Nkx2.1-iCre, Gsh2-iCre, or Emx1-iCre).  
 
Surprisingly, we found that the ablation of one OL lineage has no lasting effect on 
the numbers or distribution of OLPs or mature OLs in the forebrain. The region 
where OLPs were ablated was fully recovered by P12. This recovery is quite fast,  
suggesting the other two neighbouring OL lineages quickly expanded to fill in the 
available space. Moreover, the loss of an OL lineage did not seem to affect the 
overall health and survival of the mice, which were raised into adulthood. The 
lack of difference between the ablated mice and the controls show that the loss of 
an OL lineage, at the site of origin, can be compensated for by neighbouring OL 
populations. 
 
Surprisingly, when all ventrally-derived OLs (Nkx2.1 and Gsh2-derived OLs) 
were ablated, at the site of origin, the observed reduction in the number of OLPs 
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at birth was not followed by a long-term reduction in the number of OLs and the 
amount of myelin that formed postnatally. Quantitative analysis showed that OLs 
fully recovered by two weeks after birth. These mice appeared and behaved 
normally, were viable and fertile, but were a little smaller in size compared to 
their control littermates. The difference in brain size and body is as yet unknown. 
The delay in the accumulation of OLs caused by the ablation could have caused 
some neurons to die, which might account for their slightly smaller brain size. It is 
known that OLs influence neuron survival and death (Wilkins et al., 2001; 
Wilkins et al., 2003). They do this by providing neurons with secreted 
neurotrophins including Nerve Growth Factor (NGF), Brain-derived neurotrophic 
factor (BDNF), and neurotrophin-3 (Dai et al., 2003). Colello et al. (1994) have 
shown that the elimination of OLPs in the optic nerve at birth by x-irradiation 
results in reduced axon diameters. Perhaps the presence of OLPs to support 
neurons is required in a critical developmental time window; this may be why a 
normal CNS produces OLPs rapidly and in excess. Counting of neuronal cell 
numbers, axons and measurement of axonal diameter in controls and triple-
transgenic mice might help to unravel this.   
 
Remarkably, we found that when all telencephalic-derived OLPs were ablated, the 
telencephalon was able to recover the loss of OLs. At P1 the dorsal half of the 
telencephalon was nearly devoid of OLPs. However, this delay in accumulation of 
OLPs was transient. A quantitative analysis in the adult stage showed that the 
motor cortex and anterior commissure had a complete recovery of Sox10-positive 
cells; and the corpus callosum had a recovery of Sox10-positive cells to levels 
close to controls. All three regions had a complete recovery of PLP-expressing 
cells.  
 
Sox10-DTA and quadruple transgenics are phenotypically distinguishable for 
body size. They were often slightly smaller than their Sox10-DTA (control) and 
wild-type littermates. This helped facilitate the identification of the quadruple 
transgenic from the controls; however, all mice used in this study were genotyped 
from tail biopsy specimen DNA, via PCR analyses. The quadruple transgenic 
animals appeared healthy and active with normal behaviour. 
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It is amazing how OLPs from outside the telencephalon integrate seamlessly into 
the telencephalon; they can populate and myelinate the telencephalon. This result 
is surprising, as the forebrain is large when compared to other brain regions. The 
observation that OL cell numbers recover implies the existence of a mechanism 
for sensing and maintaining OL cell numbers. Perhaps the loss and/or decrease in 
OLP number may cause an increase in a recruitment signal that is detected by 
neighbouring OLPs. One mechanism by which non-ablated OLPs might sense the 
need to proliferate and replace ablated OLPs is via the available supply of growth 
factors such as the Platelet Derived Growth Factor A (PDGF-A). Numerous 
studies have shown that PDGF-A and one of its receptors, PDGFRα, plays an 
important role in cellular proliferation in OLs. Several studies have shown that 
PDGF-A is mitogenic for OLPs in vitro and in vivo (Richardson et al., 1988; Raff 
et al., 1988; Noble et al., 1988).  PDGF-A is made by and secreted by neuronal 
cell bodies and by astrocytes in the CNS. Mice lacking PDGF-A have a major 
reduction in the number of OLs and suffer from tremors, whereas over-expression 
of PDGF-A leads to an increase in the number of OLPs (Fruttiger et al., 1999; 
Calver et al., 1998; van Hexnigen et al., 2001) however, the final number of 
mature OLs is the same as in the wild-type littermates (Calver et al., 1998). It is 
likely that as long as excess PDGF-A is available in the developing telencephalon, 
OLPs from more distant regions will proliferate and move into PDGF-rich 
territory. If so, one might predict that OLPs at the migration front might be 
dividing more rapidly than those behind the leading edge. I tried to test this by 
administering BrdU to quadruple-transgenic mice; I was unable to detect any 
obvious increase in the frequency of BrdU+ OLPs in these mice relative to 
controls, although this was not quantified because I did not have enough 
quadruple transgenics for statistical analysis. Perhaps, major observable 
differences in the number of Brdu+/PDGFRα+ cells between the control and 
quadruple transgenic mice would have been apparent at a different time point or 
perhaps cell proliferation was altered in another brain region (the source that 
replenished the ablated OLPs). It is also possible that OLPs cease dividing while 
they are migrating so BrdU incorporation might not be an appropriate indication 
of PDGF-driven responses. 
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Why should there be multiple OL lineages? It has been suggested that as the brain 
evolved and increased in volume  ̶  particularly with the expansion of the cerebral 
cortex  ̶  the region of VZ that is able to generate OLPs expanded in parallel in 
order to increase the OL supply. According to this idea the ventral OLP origins 
(e.g. MGE) would be evolutionarily “primitive” and the more dorsal OLP origins 
would be later additions.  However, my finding shows that it is possible for the 
mouse telencephalon to be populated by OLPs from outside the forebrain, this 
tends to undermine the idea that expansion of the telencephalon required an 
expanded telencephalic source of OLPs.  
 
Another question that was raised by the existence of multiple OLP sources was, 
are OL lineage cells from different VZ territories, which express different 
cocktails of transcription factors and other proteins, functionally identical or 
distinct? If they are different  ̶  for example, if they are specialized for myelinating 
different axon tracts, different classes of neurons (e.g. different neurotransmitter 
subtypes)  ̶  then we might expect that ablating one source of OLPs could not be 
compensated for by OLPs from other sources. However, since there appears to be 
a great deal of flexibility in that OL lineage cells from even outside the 
telencephalon can substitute for telencephalon-derived cells, it seems unlikely that 
there are specialised, dedicated subtypes of OLPs or OLs. 
 
Since these experiments were completed further work from the Richardson lab 
tended to support the idea that there are not different subtypes of OL lineage cells 
based on their embryonic sites of origin. Tripathi et. al. (2011) made a two-colour 
reporter mouse line Sox10-lox-EGFP-Stop-lox-tdTomato, designed to label OL-
lineage cells green (EGFP) in the absence of Cre and red (tdTomato) in the 
presence of Cre. Crossing these reporter mice with Gsh2-Cre or Emx1-Cre 
resulted in labelling of LGE- or cortex-derived OLPs and OLs in the corpus 
callosum, allowing the cells to be distinguished in slice cultures and their 
electrophysiological properties examined separately. Tripathi et. al. (2011) were, 
however, unable to find any differences between dorsally- and ventrally-derived 
cells by patch-clamp studies. Likewise, they could find no electrical differences 
between dorsally- and ventrally-derived OL lineage cells in the spinal cord. 
However, dorsally-derived cells in the spinal cord seemed to displace ventrally-
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derived cells in dorsal axon tracts (e.g. cortico-spinal tract) and these tracts ended 
up being myelinated almost exclusively by dorsally-derived OLs. Thus, there 
might be functional differences between OLs from different sources but these are 
not critical differences. 
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Chapter 5 
 
 
Summary and discussion 
 
 
 
5.1 Summary of data 
We currently have a good understanding of the developmental origin of OLPs in 
the telencephalon and the spinal cord. In the telencephalon, OLPs are generated in 
a wave from ventral to dorsal (Kessaris et al., 2006).  In the spinal cord, OLPs are 
specified from both the ventral and dorsal halves (Cai et al., 2005; Vallstedt et al., 
2005; Fogarty et al., 2005). These findings have prompted me to explore whether 
or not these OL lineages are functionally equivalent and can substitute for one 
another if either ventrally or dorsally-derived OLPs are ablated in vivo. This study 
provides direct evidence that ventral and dorsal OLPs and the OLs that derive 
from them are functionally equivalent from a developmental perspective. 
I have described the generation and characterization of the Sox10-DTA transgenic 
mouse line. PAC transgenic approach was used to generate the line. A mouse 
PAC clone containing the Sox10 coding region along with additional upstream 
and downstream sequences was identified. These flanking sequences are likely to 
contain regulatory elements necessary for faithful gene expression. To generate 
the Sox10-DTA mouse line, a loxP-flanked EGFP-polyA-STOP cassette followed 
by a DTA sequence was inserted into the Sox10 PAC. The modified PAC insert 
was then introduced into the germ line of mice by pronuclear DNA injection into 
fertilized mouse eggs at the one-cell stage.  
Founder Sox10-DTA transgenic mice were characterized for authentic expression 
in OL lineage cells, and mated to Olig2-Cre to activate the DTA transgene in 
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OLPs during development. Activation of DTA in Olig2-Cre expressing cells 
erased all OLP and OLs in the brain and spinal cord. These mice developed 
seizures and tremors, and died soon after birth, reminiscent of severely 
dysmyelinated mutants (e.g. Jimpy) and PDGF-A knockouts (Knapp et al., 1986; 
Skoff, 1995; Fruttiger et al., 1999). This Sox10-DTA mouse line is an efficient 
model system to ablate OLPs and OLs during early development. 
Crossing the Sox10-DTA to a set of Cre-expressing lines that delineate different 
regions of the forebrain VZ eliminated OL lineage cells arising in these distinct 
forebrain territories and allowed me to determine whether neighbouring territories 
could compensate for their loss. 
I found that removing one OL “lineage” in the forebrain, either the Gsh2 or the 
Emx1-derived lineage, had no long-lasting impact on the number and overall 
distribution of OLs. At P12, the number of OLs in regions that normally contained 
a high number of OLs derived from the ablated lineage was the same as in the 
control mice. The loss of one OL population did not affect the overall health and 
longevity of the animals. 
When both Nkx2.1 and Gsh2-derived OLPs were ablated at their site of origin in 
the telencephalon, there was a reduction in the number and distribution of OLPs 
and OLs during early postnatal life. However, between 8 and 10 days of age, the 
number of OLPs caught up with control animals. In addition, my experiments 
showed that a lack of Nkx2.1 and Gsh2-derived OLPs results in an approximately 
one-week delay in the appearance of mature OLs. However, at about P10, there is 
no longer any apparent difference between transgenic and control mice. 
Strikingly, when all telencephalic OLPs are ablated - that is Nkx2.1, Gsh2, and 
Emx1-derived OLPs - the telencephalon is still able to recover from the loss of all 
these cells. At birth, a delay in the accumulation of OLPs is seen in the dorsal 
region of the telencephalon, i.e. motor cortex, but this delay is short lived. By 20 
weeks, OL cell numbers are comparable to control animals. Despite the absence 
of telencephalic lineages, there is no obvious impact on the overall health and 
lifespan of the animals. 
 
! 176!
5.2 Comparison with findings from other studies 
The results of this study are in contrast with the findings of Yue et al. (2006) who 
showed that ventrally-derived OLPs could not compensate for myelination 
deficits in the dorsal telencephalon during development. In their study, Yue el al. 
used mice that were genetically engineered to have the Olig2 gene conditionally 
knocked out in the dorsal telencephalon when crossed to an Emx1-Cre deleter 
line. They generated transgenic mice that are null for Olig2 in dorsally-derived 
OLPs but wild-type in all other areas. They showed Olig2 ablation does not affect 
the specification and proliferation of OLPs in the dorsal telencephalon; however, 
it does affect the appearance of mature OLs markers such as MBP and PLP. 
Despite the deficit of mature OLs in the dorsal telencephalon, these mice had 
normal numbers of mature OLs in the ventral telencephalon. Mice that were null 
for Olig2 in the dorsal telecephalon developed tremor that began to manifest 
around two weeks of age. 
Even though we both used a conditional Cre-loxP approach, the strategies were 
different; our study used conditional cell ablation whereas Yue et al. (2006) used 
conditional gene deletion. I sought to kill OL lineage cells, whereas Yue et al. 
(2006) deleted Olig2 but did not kill the cells.  In the Yue et al. study, the targeted 
cells were viable or, at the very least, still generating Olig2-negative OLPs, 
because normal numbers of PDGFRα and NG2-positive cells were present in the 
cortex even though there were essentially no Olig2-positive cells. These Olig2-
negative OLPs are presumably dysfunctional because they fail to differentiate into 
mature OLs. A possible explanation for the in vivo difference observed in my 
experiments with theirs is that the dysfunctional OLP population (Olig2-negative 
cells) may inhibit unaffected Olig2-positive OLPs from migrating to the dorsal 
telencephalon, possibly because the Olig2-negative OLPs occupy the available 
space in the cortex. More recently, Zhu et al. (2012) have shown that deleting 
Olig2 from developing OLPs (i.e. NG2+ cells) in the dorsal forebrain causes a 
fate switch so that the OLPs generate protoplasmic astrocytes rather than 
myelinating OLs. Perhaps these additional astrocytes in the cortex may inhibit the 
inward migration of Olig2-positive OLPs from the ventral telencephalon (e.g. 
LGE). 
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Our results show that proves the telencephalon is capable of recovery after all 
telencephalic-derived OLPs are ablated during development. This is a striking 
finding. What drives OLPs to a specific region in the brain? One possibility is that 
the ablated region is abundant in OLP mitogens and/or other factors because the 
ablated cells did not utilise the available mitogen. It is well established that 
environmental cues, a major player being PDGF, play a critical role in the 
motility, proliferation, and survival of OLPs (van Heyningen et al., 2001). In vitro 
studies, using chemotaxis chambers, have shown that OLPs migrate towards 
higher concentrations of PDGF (Armstrong et al., 1990). In vivo studies, using 
transgenic mice, have shown that PDGF is the main mitogen for OLPs in same 
CNS regions because overexpression of this growth factor results ectopic 
production of OLPs and PDGF knockouts have dramatically reduced numbers of 
OLPs (Calver et al., 1998; Fruttiger et al., 1999). It is probable that, as long as 
PDGF is available, neighbouring OLP populations are attracted to the PDGF and 
migrate into the OLP-depleted region. It also seems reasonable to speculate that 
OLPs in the forebrain are all guided in the same way, through the same 
environmental cues, regardless of their site of origin. 
The issue of whether all OLs are the same still remains to be determined. It seems 
reasonable to believe that embryonic forebrain OLPs are all guided in the same 
way, however, do they become different once they begin to mature, perhaps by 
signals in the local microenvironment? Differences among OLs have been 
reported. Pio del Rio-Hortega (1928) was the first to support the idea of different 
subtypes of OLs. Bakiri et al. (2011) showed that OLs in the rat corpus callosum 
and cerebellum white matter regions have differences in the number of axons they 
myelinate and the length of their internodes. Callosal OLs myelinate more axons 
and have shorter internodes than OLs in the cerebellum. There is evidence that 
shows a difference between adult OLPs in grey and white matter regions in terms 
of differentiating into mature OLs (Dimou et al., 2008; Viganò et al., 2013). OLPs 
from grey matter mature into OLs with a lower efficiency when compared to 
OLPs located in white matter. Work from Karadottir et al. (2008) showed, via 
patch-clamp studies, that OLPs have two electrically distinct classes: one that 
expresses voltage-gated Na+ channels and the other that does not. However, it has 
also been suggested by others that all OLPs express voltage-gated Na+ channels, 
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which are then down-regulated when OLPs differentiate into OLs (Clarke et al., 
2012). Tripathi et al. (2011) generated a dual reporter mouse line to colour code 
ventrally and dorsally-derived OLPs for functional studies. They found that 
heterogenous expression of voltage-gated Na+ channels was not related to 
developmental origin, therefore ventrally and dorsally-derived OLPs are 
electrically similar. They did, however, discover that dorsally-derived OLs 
gradually over time displace ventrally-derived OLs in dorsal axon tracts. This 
suggests that dorsally-derived OLs may have a selective advantage over ventrally-
derived OLs in dorsal white matter regions at a later developmental stage.  
5.3 Future directions and applications 
Conditional targeted ablation of specific cell lineages in transgenic animals is a 
very powerful strategy to determine the function of the cell lineage in vivo. This 
strategy has allowed us to study whether OLs lineages are functionally equivalent. 
This study is the first to show that OL lineages are functionally equivalent in the 
CNS. A number of questions remain open for further investigation. 
Animals that had one or more OL-populations ablated at the point of origin, 
appeared healthy and fertile.  Even though these mice did not display obvious 
defects, we cannot rule out the possibility that they might have a subtle underlying 
defect in cognitive or motor behaviours.  It would be interesting to learn if there is 
a difference in the ultrastructure of the myelin in ablated mice compared to 
controls.  This could be determined by an electron microscope (EM) study of 
myelin thickness (number of wraps) and myelin compaction.  Potential 
differences in the number or lengths of internodes per OL could be explored by 
labelling a subset of OLs with a membrane-associated reporter transgene such as 
Tau-mGFP (Young et al., 2013).  This approach reveals the full morphology of 
the cell including the processes and myelin sheaths. 
Although investigation into the source of OL lineage(s) that replenishes the 
genetic ablation of all telencephalic–derived OLPs have not been analysed, it is 
likely that they come from neighbouring sources, such as the diencephalon. More 
elaborate transgenic mouse lines would be needed to determine where the cells 
come from. The simultaneous use of both the existing Cres (Nkx2.1-iCre/Gsh2-
iCre/Emx1-iCre) and new FLP deleters, along with Sox10-DTA, can allow 
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lineage ablation and lineage tracing simultaneously. This raises the question of 
how far can they possibly migrate? Do they need to be close by? A possible 
approach to answer this question would be to use the Olig2Cre/Sox10-DTA 
transgenic mice and transplant embryonic OLPs into specific locations in the CNS 
and observing the distance these cells can migrate in vivo.  
It is well documented that spinal cord OLs arise from both the dorsal and the 
ventral halves of the spinal cord.  It is known that approximately 80% of OLs 
found in the adult spinal cord arise from OLPs generated in the ventral spinal 
cord, specifically the progenitor domain known as pMN (Fogarty, 2005; Tripathi 
et. al., 2011). It would be intriguing to know if the spinal cord could recover from 
a loss of ventrally-derived OLPs. In order to determine this, one would need to 
cross the Sox10-DTA mouse line to an Nkx6.1-Cre mouse line (where Cre is 
expressed in the ventral spinal cord). Based on this study, we could hypothesize 
that dorsally-derived OLPs may compensate for the loss, however, whether there 
is enough time to make up for the loss would be a matter of future investigation. 
Dorsally-derived OLPs appear several days after ventrally-derived OLPs are 
generated and only make up a small population of the total number of OLs in the 
spinal cord. It is proposed that these mice can gradually recover the loss of 
ventrally-derived OLPs by the proliferation, migration and differentiation of 
dorsally-derived OLPs. This might even reveal if dorsally-derived embryonic 
OLPs are more migratory than currently thought. It is possible that these cells can 
migrate long distances if given the opportunity, i.e. not being hampered by the 
high abundance ventrally-derived OLP population.  
It would be instructive to identify the signals that induce OLPs to migrate to areas 
where they are needed and to generate myelin. What is their surveillance 
mechanism? One could use live imaging, e.g two-photon fluorescence imaging 
through a cranial window, to observe OLP mobility directly in vivo.  An imaging 
study of this sort in the adult mouse cortical grey matter has been reported 
recently from the Bergles lab (Hughes et al., 2013).  They revealed that adult 
OLPs are highly dynamic, continuously extending and retracting their processes 
when migrating and avoiding contact with other OLPs (self-repulsion).  When one 
OLP was removed by laser ablation the neighbouring OLPs grew into the space 
thus created and one of them underwent cell division to replace the missing cell. It 
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could be that loss of one cell reduces local demand for PDGF and allows nearby 
cells to compete for the additional PDGF that becomes available.  Alternatively, 
contact-mediated molecules and receptors (e.g. Semphorins and Netrins) could 
play a role in inhibiting cell division and this inhibition might be relieved locally 
when a cell is ablated.  Probably both secreted factors (e.g. PDGF) and contact-
mediated mechanisms serve to create an even distribution of embryonic OLPs 
(Valentino et al., 2011).  
It would also be interesting to compare the expression profiles of dorsally- and 
ventrally-derived OLs and OLPs, as well as adult white matter versus grey matter 
OLPs. DNA microarray analysis can help reveal similarities as well as differences 
between them.  It would also be intriguing to test whether dorsally- or ventrally-
derived adult OLPs have different abilities to remyelinate experimentally induced 
demyelinated lesions.  
OLs have been characterized into four distinct morphologies, types I-IV, that 
myelinate axons with different diameters.  In addition, there is evidence that small 
and large diameter myelin sheaths have different compositions (Hartman et al., 
1982). This raises the possibility that phenotypic divergence might be regulated 
by axon-derived factors, as is true of Schwann cells (the myelinating glia of the 
PNS) (Roberts and Lloyd, 2012).  The main player that controls differentiation 
and sheath thickness in the PNS is axonal membrane-bound Neuregulin1-Type III 
(NRG1 Type III), which activates the ErbB2/3 receptor complex on Schwann 
cells (Nave and Salzer, 2006). It would be interesting to know whether a similar 
signalling system is used in the CNS? If so, what is the neuron to OLP dialogue? 
NRG1/ErbB signalling is not essential in the CNS because mice that lack one or 
more of these ErbB receptors still myelinate normally (Brinkmann et al., 2008). 
On the other hand, over-expressing NRG1 in neurons can increase myelin sheath 
thickness in the CNS (Brinkmann et al., 2008).  Recently, evidence was presented 
that central myelination has a default, constitutive pathway that can be switched 
by Neuregulin or Brain-derived neurotrophic factor (BDNF) to an NMDA-
dependent myelination pathway (Lundgaard et al., 2013).  It appears that the 
control of myelination in the CNS is more complex than in the PNS. 
Understanding these complexities is likely to provide clues to how to stimulate 
remyelination during demyelinating diseases. 
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White matter diseases of the CNS, such as leukodystrophies and multiple 
sclerosis, remain difficult to treat because of the great cellular complexity of the 
brain and spinal cord. Recent investigation raised the question whether embryonic 
stem cells or skin-derived human induced pluripotent stem cells (hiPSCs) are the 
most effective cell source to treat myelin disorders. Data from Dr. Steve 
Goldman’s lab shows that human skin cells reprogrammed to become OLPs are 
an effective cell source to treat myelin disorders - potentially quicker and more 
efficiently than embryonic stem cells (Wang et al., 2013). Nevertheless, it is 
important to ascertain whether there are different subsets of OLPs and OLs, which 
may inform the development of more specific treatments for white matter diseases 
by identifying the best cell source for treating dysmyelination. My study, for the 
first time, provides direct evidence revealing that OLPs can alter their migration 
routes and final resting sites when the environment changes, and appear to be 
functionally equivalent from a developmental perspective.  
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Annex 
 
 
Generation and Characterization of a Gsh2-iCre mouse line for 
spinal cord studies 
 
 
A new Gsh2-iCre mouse line was generated specifically for spinal cord studies 
because the Gsh2-iCre line used previously for forebrain studies (Chapter 4) did 
not express iCre correctly in the spinal cord.  
 
Gsh2 (genomic screened homeobox-2) was identified and cloned as a 
homeodomain transcription factor on the basis of sequence homology to the most 
conserved region of the Drosophila Hox homeobox domain (Singh et al., 1991). 
The mouse Gsh2 coding sequence resembles that of Gsh1, with only two amino 
acid mis-matches (Hsieh-Li et al., 1995). Mouse Gsh2 is located on chromosome 
5 and consists of two exons and a 915 bp open reading frame which encodes a 
protein of 305 amino acids (Dauwerse et al., 2002). The gene itself is 2.29 kb in 
length. Gsh2 has a highly restricted expression pattern in the embryonic CNS, 
being expressed in the ganglionic eminences of the developing forebrain and in 
restricted domains of the developing hindbrain and dorsal spinal cord. The 
introduction to Gsh2 in this chapter focuses only the developing spinal cord. 
 
Both Gsh1 and Gsh2 are first expressed beginning at E9.5-E10.5. Gsh1 is 
expressed in progenitor domains dP3 and dP4. Gsh2 is initially expressed in dP3 
progenitor domain, but by E11.5 its expression extends ventrally into progenitor 
domains dP4 and dP5 (Kriks et al., 2005) (Figure A1). Cells that express Gsh2 
have been shown to give rise to various dorsal interneuron subtypes. A loss of 
Gsh2 expression leads to a loss of dP3 interneurons and an increase in dP2 
interneurons, whereas dP4 and dP5 interneurons develop normally (Kriks et al., 
2005). This increase in dP2 neurons is at the expense of dP3 neurons. Moreover, 
loss of Gsh2 leads to a down-regulation of Mash1, which leads to a loss of dP3 
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interneurons. Mash1 mutant spinal cords exhibit the same phenotype; namely a 
marked reduction in dP3 interneurons. Conversely, over-expression of Gsh2 or 
Mash1 leads to ectopic production of dP3 interneurons. Mash1 is expressesd in 
progenitor domains dP5-dP3 in wild-type spinal cords (Gowan, K. et al., 2001) 
 
 
 
 
 
 
Figure A1 Diagram showing the distinct progenitor domains in the embryonic 
mouse spinal cord. Expression domains of Msx3 (dP1-dP5), Gsh2 (dP3-dP5), 
Dbx1/2 (dP6-p1), and Nkx6.1 (p2-p3) are shown. Abbreviations: RP, roof plate; 
FP, floor plate. The black dashed line separates the dorsal and ventral halves of 
the spinal cord. 
 
 
Ventral 
 
 
FP 
RP 
Dorsal  
Domain 
P3 
pMN 
p2 
p1 
p0 
dP6 
dP5 
dP4 
dP3 
dP1 
dP2 
Gsh2 
Dbx
1/2 
Nkx6.
1 
Msx3 
! 195!
Medial and dorsal neuroepithelium is responsible for a second phase of 
oligodendrogenesis 
 
As stated in the introduction of this thesis (Chapter 1), it was initially believed by 
some workers (Richardson et al., 2000) that OLs were generated exclusively in 
the ventral part of the spinal cord. However, three recent publications revealed 
that regions in the medial and dorsal spinal cord are also responsible for a second 
phase of oligodendrocyte production that begins around E14.5. (Cai et al, 2005, 
Vallstedt et al., 2005, Fogarty et al., 2005). Cai et al. and Vallstedt et al. examined 
mouse embryos lacking Nkx6.1 and Nkx6.2 genes. In these double mutant lines 
(Nkx6 null), the ventral spinal cord fails to generate OLs. However, this uncovers 
another source of OLPs in the dorsal cord. Fogarty et al. showed, using Cre-lox 
fate-mapping that intermediate/dorsal neuroepithelium can generate OLPs and 
that these OLPs can mature into OLs.  
 
Subsequent work from the Richardson lab revealed that the dorsal half of the 
neural tube (dP1-dP5) can generate OLPs and that these OLPs go on to mature 
into myelin producing OLs (Fogarty, 2005; Tripathi et al., 2011). They showed 
that the dorsal half of the neuroepithelium generates 15-20% of all spinal cord 
OLs, and that many of these come to rest in the dorsal funiculus (DF).  
 
 
PAC library screening, confirmation and characterization of PAC clones for 
Gsh2 
 
Screening of the Mouse RPC121 PAC library and the analysis of Gsh2 containing 
PAC clones were done by Matthew Grist and Nicoletta Kessaris, prior to the 
generation of the Gsh2-iCre mouse line used in forebrain experiments. Therefore, 
I did not need to re-screen the library. To generate a new Gsh2-iCre mouse line, I 
used a different Gsh2-containing PAC clone, PAC clone 4 (Figure A2).  
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Figure A2 A schematic diagram showing Gsh2 containing PAC clones identified 
in our original screen. At the top of the diagram is a 300 kb portion of 
chromosome 5 centred on the Gsh2 locus (black box) including nearby genes 
(stippled boxes). The relative positions and sizes of the genomic inserts in each 
PAC clone are shown below. PAC clone 4 (PAC4) was used to generate the new 
Gsh2-iCre mouse line. Scale bar, 20 kb. 
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Construction of the targeting vector for homologous recombination in PACs 
     
The targeting vector was generated by Matthew Grist and Nicoletta Kessaris. It 
was designed to recombine with and replace the PAC clone 4 Gsh2 ORF with 
Cre-polyA followed by a chloramphenicol resistance cassette (Cmr), flanked by 
recombinogenic FRT sites as shown in Figure A3. This was mediated via a 500 bp 
region of homology located immediately upstream of and including the Gsh2 
ATG and a 550 bp region of homology located immediately downstream of the 
Gsh2 translation stop codon. The SV40 polyadenylation (pA) signal was inserted 
immediately downstream of the Cre gene to ensure correct termination of 
transcription. Positive selection for recombinant PAC clones was mediated by 
chloramphenicol resistance.  
 
 
 
Figure A3 Homologous recombination between targeting vector and Gsh2 
genomic DNA. CmR, chloroamphenicol resistance gene; pA, polyA sequences; 
circled “F”, frt sites; dashed lines, regions of homology; light blue lines and 
boxes, Gsh2 sequences; grey arrows, location of primers for genotyping. 
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Generation of PAC Gsh2-iCre by homologous recombination  
 
Gsh2 PAC clone 4 was modified in bacteria by homologous recombination 
according to the method of Lee et al. (Lee et al., 2001) and the protocol 
summarised in Chapter 2. To begin with, the PAC clone 4 was electroporated into 
EL250 bacteria. Next, two rounds of homologous recombination were carried out. 
Homologous recombination was first employed to replace unwanted sequences 
(i.e. SV40-promoter, SV40-pA, HCMV-promoter, and loxG) in the PAC vector 
backbone with an ampicillin resistant cassette (Figure A4). These unwanted 
sequences might otherwise interfere with the expression of the transgene in mice. 
Ampicillin resistant colonies were identified on ampicillin-containing plates and 
confirmed by PCR, using primers that amplified the junction region between 
AmpR and PAC backbone (Figure A5). 
 
 
 
 
 
 
 
Figure A4 Homologous recombination between the ampicillin cassette and PAC 
clone 4 backbone. BLS, Blasticidin-S-Methylase; AmpR, ampicillin resistance 
gene; dashed lines, regions of homology; blue lines, PAC vector sequences. 
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Figure A5 Homologous recombination of the AmpR cassette into PAC was 
confirmed by PCR. The positive control used was a previously modified PAC 
DNA. The negative controls were the AmpR cassette (-ve1) and water (-ve2). The 
positive control was a PAC that had been identified positive for AmpR by 
Southern blot from previous work. M is the marker lane. Lanes 1-10 contains the 
AmpR colonies.  
 
 
 
Next, PAC clone 4 Gsh2 ORF was replaced with the iCre-pA-frt-Cmr-frt cassette 
(Figure A6), by a second round of homologous recombination via the designed 5’ 
and 3’ homology regions. The targeting fragment was excised as a 3.75 kb 
AscI/PacI fragment and purified by gel electrophoresis. 200 ng of the linearised 
targeting fragment was electroporated into 50µl of PAC clone 4-containing 
electrocompetent EL250 bacteria. Cells were plated on Cm plates and incubated at 
32oC for 12-25 hours; recombinant clones were identified by Cm selection. 
Removal of the Cmr cassette from recombined clones was subsequently carried 
out by flpe activity induced by arabinose induction of the host EL250 cells. 
Removal of the resistance cassette was confirmed by Southern blot analysis, 
which indicated all clones tested had undergone successful recombination (Figure 
A7). 
 
 
 
!
M!
1!M! 2! 3! 4! 5! 6! 7! 8! 9! 10! @ve! +ve! @ve!
! 200!
 
 
 
Figure A6 The structure of the targeting vector for Gsh2-iCre. Diagram of the 
engineered targeting construct that was used to replace the wild-type Gsh2 gene in 
PAC clone 4. Insert size is 3.75 kb. Restriction enzyme digestion sites are shown. 
Arm, region of homology to Gsh2 gene; pA, polyA sequences; CmR, 
chloroamphenicol resistance gene; circled “F”, frt sites. 
 
 
 
 
 
 
 
Figure A7 Southern blot analysis of the restriction digest pattern of the modified 
PAC clone 4 before and after the removal of the Cm selection cassette by Flpe 
recombinase. DNA was digested with BglII/KpnI and hybridised to a 3’-iCre 
probe. The red arrow corresponds to the recombinant PAC before the removal of 
the Cm cassette (2.530 kb band). The blue arrow corresponds to the recombinant 
PACs after the removal of the Cm cassette (1.030 kb).  
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Generation of PAC-transgenic mice 
 
Transgenic mice were generated from pronuclear injection of linear PAC DNA 
into mouse oocytes. Modified PAC DNA was purified by routine alkaline lysis, 
followed by AscI restriction enzyme digest - to linearize the modified PAC clone 
4 plasmid. The digest was separated by PFGE. The 150 kb fragment was cut from 
the gel, rotated vertically relative to its original electrophoresis migration and 
purified by electrophoresis in low-melting point agarose. After dialysis into 
microinjection buffer, the concentration as well as the integrity of the purified 
PAC insert was checked by PFGE. Purified PAC insert DNA was injected into the 
pronuclei of C57BL6xCBA fertilized mouse oocytes at a concentration of about 
1-2 ng/µl. Injected oocytes were transferred into the oviducts of pseudopregnant 
foster mice, strain CD-1, either on the same day or left to divide once overnight in 
a 37oC incubator. Pronuclear microinjections were performed by Ulla Dennehy 
and myself in the WIBR transgenic facility. 
 
 
Screening founder mice for the presence of the Gsh2-iCre transgene 
 
Mice carrying the PAC transgene were genotyped by PCR using tail DNA and 
primers designed to amplify sequences spanning the iCre and Gsh2 region in the 
iCre transgene and Gsh2 (forward primer, located in Gsh2 5′-
GCAAGTTTTATGGTGCTGTTTTGG-3′; reverse primer, located in iCre, 5′-
CCTTGAAGAAGATGGTGCG-3′; the PCR product is 752 bp) (Figure A8). Nine 
pups derived from pronuclear injection harboured the PAC transgene. F1 founders 
were generated by crossing founder males (4/2, 4/3, 5/6, 6/2, 8/6, 9/1) or founder 
females (2/6, 6/4, 8/2) to Rosa26-GFP reporter mice. 
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Figure A8 Screening putative founder mice for the Gsh2-iCre transgene. 
Integration of the transgene is indicated by a 752 bp band (red arrow). The 
negative controls were wild type genomic DNA (-ve 1) and water (-ve 2). The 
positive control (+ve) was DNA from a mouse that had been identified positive 
for Gsh2-iCre from previous work (Chapter 4).  M indicates the marker lane and 
F1-3 are founders. 
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Analysis of transgene expression in embryonic mouse spinal cords 
 
Transgene expression was analyzed in embryos obtained by timed matings of 
transgenic animals with floxed Rosa26-GFP reporter mice. The genotype of each 
embryo was determined by PCR, using tail. 
 
Figure A9 shows the activation of the transgene when Gsh2-iCre mice were 
crossed to the Rosa26-GFP reporter mice. In addition, it reveals that transgene 
expression is occurring in the same pattern as Gsh2 expression; therefore, the 
transgene is regulated in the same way as that of the endogenous Gsh2 gene. 
Serial sections were further analysed for Olig3 and Dbx1 expression in order to 
define the ventral and dorsal limits GFP expression (Figure A10). The results 
show the Olig3-expressing domain lies dorsally to the GFP-expressing domain 
with a slight overlap and the Dbx1-expressing domain lies immediately ventral to 
the GFP-expressing domain. There is no overlap between Dbx1 and GFP but a 
slight overlap between Olig3 and GFP expression. Figures A10 and A11 show 
that the Gsh2-iCre transgenic line expresses iCre in a population of 
oligodendrocytes. 
 
 
 
 
 
Figure A9 In situ hybridisation and immunohistochemistry on consecutive 
sections from an E12.5 Gsh2-iCre/Rosa26-GFP embryo. The expression of GFP 
(B) is found in the same limits of the endogenous Gsh2 (A) expression domain 
indicating that regulation is occurring as expected. Scale bar, 0.5 mm. 
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Figure A10 Defining the limits of GFP expression in Gsh2iCre/Rosa26-GFP pup. 
In situ hybridisation of Dbx1 and Olig3 and immunohistochemistry of GFP on 
serial sections of E11.5 upper (A, B, C) and lumbar (D, E, F) Gsh2-iCre/Rosa26-
GFP spinal cord. GFP (B, E) expression is found to be immediately dorsal to 
Dbx1 (A, D) and ventral with slight overlap (red arrow) to Olig3 (C, F). Scale bar, 
0.25 mm. 
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Figure A11 Oligodendrocytes in a P10 Gsh2-iCre/Rosa26-GFP animal. Labelling 
for GFP (A, C) and Sox10 (B, D) shows the presence of GFP/Sox10-positive 
oligodendrocytes (arrowheads) in the dorsal (A, B) and lateral funiculus (C, D) of 
the spinal cord. Arrows show non-localisation. DF, dorsal funiculus; LF, lateral 
funiculus. Scale bar, 0.3 mm. 
 
